Back to GetFilings.com



Table of Contents



UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


FORM 10-K

(Mark One)

  þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2002

OR

  o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from            to                 .

Commission File Number 333-62989


CDRJ Investments (Lux) S.A.

(Exact name of Registrant as specified in its charter)


     
Luxembourg   98-0185444
(State or other jurisdiction of
Incorporation or organization)
  (I.R.S. Employer
Identification Number)
174 Route de Longwy
L-1941 Luxembourg
Luxembourg
(352) 226027
(Address, including zip code, and telephone number, including area code, of
registrant’s principal executive offices)

Securities registered pursuant to Section 12(b) of the Act:

None

Securities registered pursuant to Section 12(g) of the Act:

None

      Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes o          No þ

      Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.     þ

      Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Act). Yes o          No þ

      The registrant does not have a class of equity securities registered pursuant to Section 12 of the Securities Exchange Act of 1934 and there is no public market for voting stock of the registrant.

      As of March 7, 2003, the registrant had outstanding 831,888 shares of common stock, par value $2.00 per share.

Documents incorporated by reference

None




TABLE OF CONTENTS

PART I
Item 1.Business
Item 2.Properties
Item 3.Legal Proceedings
Item 4.Submission of Matters to a Vote of Security Holders
PART II
Item 5.Market for Registrant’s Common Equity and Related Stockholder Matters
Item 6.Selected Financial Data
Item 7.Management’s Discussion and Analysis of Financial Condition and Results of Operations
Item 7A. Quantitative and Qualitative Disclosures About Market Risk
Item 8.Financial Statements and Supplementary Data
Item 9.Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
PART III
Item 10.Directors, Executive Officers and Significant Employees of the Company
Item 11.Executive Compensation
Item 12.Security Ownership of Certain Beneficial Owners and Management
Item 13.Certain Relationships and Related Transactions
Item 14.Controls and Procedures
PART IV
Item 15.Exhibits, Financial Statement Schedules and Reports on Form 8-K
SIGNATURES
CERTIFICATIONS
EXHIBIT INDEX
EXHIBIT 21.1


Table of Contents

CDRJ INVESTMENTS (LUX) S.A. AND SUBSIDIARIES

TABLE OF CONTENTS

                 
Item

Description

Page

PART I
   1.     Business     1  
   2.     Properties     8  
   3.     Legal Proceedings     8  
   4.     Submission of Matters to a Vote of Security Holders     8  
 
PART II
   5.     Market for Registrant’s Common Equity and Related Stockholder Matters     9  
   6.     Selected Financial Data     10  
   7.     Management’s Discussion and Analysis of Financial Condition and Results of Operations     12  
   7A.     Quantitative and Qualitative Disclosures About Market Risk     29  
   8.     Financial Statements and Supplementary Data     34  
   9.     Changes in and Disagreements with Accountants on Accounting and Financial Disclosure     108  
 
PART III
  10.     Directors, Executive Officers and Significant Employees of the Company     109  
  11.     Executive Compensation     112  
  12.     Security Ownership of Certain Beneficial Owners and Management     114  
  13.     Certain Relationships and Related Transactions     116  
  14.     Controls and Procedures     117  
 
PART IV
  15.     Exhibits, Financial Statement Schedules and Reports on Form 8-K     118  
        Signatures     125  
        Certifications     126  

i


Table of Contents

PART I

Item 1. Business

General

      CDRJ Investments (Lux) S.A., a Luxembourg société anonyme (“Parent”) is a holding company that conducts all of its operations through its subsidiaries. Prior to the consummation of the acquisition (the “Acquisition”) by the Parent of the Jafra Business (as defined) from The Gillette Company (“Gillette”) in 1998, the terms “Company” and “Jafra” refer to the various subsidiaries and divisions of Gillette conducting the worldwide Jafra cosmetics business (the “Jafra Business”), and, following the consummation of the Acquisition, collectively to the Parent and its subsidiaries.

      The Company is a manufacturer and marketer of premium skin and body care products, color cosmetics, fragrances, and other personal care products. The Company markets its products through a direct selling, multilevel distribution system comprised of self-employed consultants (who perform the duties of sales representatives). The Company’s business is comprised of one industry segment, direct selling, with worldwide operations. Financial information relating to geographic areas is incorporated by reference to the analysis of net sales and operating income by geographic area in Note 11 to the consolidated financial statements included in Item 8. “Financial Statements and Supplementary Data.”

      The Jafra Business was started in 1956, as a California corporation, by Jan and Frank Day and was purchased by Gillette in 1973. The Company expanded into Latin America in 1977 and into Europe in 1978. On April 30, 1998, the Parent completed the Acquisition of the Company from Gillette. The Parent was organized to effect the Acquisition. The Acquisition was sponsored by Clayton, Dubilier & Rice Fund V Limited Partnership (“CD&R Fund V”), a Cayman Islands exempted limited partnership managed by Clayton, Dubilier & Rice, Inc. (“CD&R”), a private investment firm specializing in acquisitions that involve management participation.

Strategy

      The Company’s strategy consists primarily of the following key initiatives:

      Continue to Grow Consultant Base and Sales in Core Markets. The Company’s market position and distribution network of approximately 269,000 consultants in Mexico positions the Company to continue to grow the business by capturing additional market share. The Company intends to continue to pursue the divisional strategy initiated in late 2000 in which operations in the United States were bifurcated to focus on the Hispanic population and the non-Hispanic population. The establishment of two distinct divisions (the Hispanic Division and the General Division) in the United States has allowed the Company to tailor distinct marketing strategies for those demographics as well as provide U.S. Spanish and non-Spanish speaking consultants with specialized recruiting programs, training, and product offerings tailored to the specific demographic. In the General Division the Company will continue to leverage e-commerce capabilities. In the Hispanic Division the Company will continue to leverage its market position in Mexico in areas of training, recruitment and marketing.

      Continue to Provide Support to Consultants. The Company will continue its operational and cultural focus on providing consultants with superior customer service and effective marketing tools, including catalogues, sales brochures, new product demonstrations and training sessions, to grow their businesses. Additionally, the Company intends to continue to stimulate sales and new consultant recruitment efforts through recognition events, incentives, gifts and free travel for consultants.

      Develop New and Enhanced Products. The Company intends to focus on the development of new and innovative products that capitalize on the face-to-face interaction between consultants and their clients. New product introductions are fundamental to the Company’s direct selling business model in that they serve to motivate consultants and give them new and exciting products to demonstrate and market to their clients. The Company employs a “fast follower” product development strategy that minimizes research costs and focuses development efforts on products that have proven successful in the marketplace.

1


Table of Contents

      Leverage Economies of Scale. Since the acquisition in 1998, the Company increased gross profit and reduced selling, general and administrative expenses, primarily by reducing manufacturing and overhead costs, streamlining marketing efforts and improving inventory and working capital management. The Company believes that its direct selling business model will continue to generate significant organic growth and that the resulting scale will afford it increasing opportunities to leverage its fixed cost base and increase efficiencies in its purchasing, manufacturing, marketing, training and technology functions.

      Exit Secondary Markets. Due to the challenging macroeconomic environment that has affected results in the non-core markets in which the Company currently operates, it has adopted a strategic plan to focus on the strengths of the core U.S. and Mexican markets. The Company may consider plans to exit certain non-core markets in some or all of South America, Thailand and Europe through either a sale or discontinuation of their operations.

Products

      The Company continuously introduces new and revitalized products based on changes in consumer demand and technological advances in order to enhance the quality, image and price positioning of its products. During 2002, the Company launched 29 new products, excluding limited life products. In connection with the new color line, the Company launched 289 new products during 2001 and 2002. Research and development is conducted at the Jafra Skin, Body and Color Laboratory, located in the Westlake Village, California facility. Amounts incurred on research activities relating to the development of new products and improvement of existing products were $ 1.5 million in 2002, $1.8 million in 2001 and $1.9 million in 2000.

      Employees in the Research and Development Department formulate products and analyze them for chemical purity and microbial integrity. A separate small scale pilot batch is always produced and tested prior to full scale manufacture. The Company continues to invest in upgrading of its product lines by adding new formulations and contemporary fragrances. Through product development, manufacturing and packaging, the Company believes that it has enhanced the consistency and quality of its products.

      The following table sets forth the sales of the Company’s principal product lines for the three years ended December 31, 2002, 2001 and 2000:

                                                     
2002 2001 2000



Sales by Percentage Sales by Percentage Sales by Percentage
Product Line of Total Product Line of Total Product Line of Total
($ in millions) Sales ($ in millions) Sales ($ in millions) Sales






Skin care
  $ 68.8       18.2 %   $ 69.4       19.0 %   $ 65.8       21.0 %
Color cosmetics
    99.5       26.2       94.3       25.8       82.4       26.2  
Fragrances
    126.6       33.4       125.4       34.3       103.7       33.0  
Body care and personal care
    42.1       11.1       37.0       10.1       29.6       9.4  
Other(1)
    42.0       11.1       39.3       10.8       32.6       10.4  
     
     
     
     
     
     
 
 
Subtotal before shipping and other fees less commissions
    379.0       100.0 %     365.4       100.0 %     314.1       100.0 %
             
             
             
 
Shipping and other fees less commissions
    12.0               10.8               7.1          
     
             
             
         
   
Total
  $ 391.0             $ 376.2             $ 321.2          
     
             
             
         

(1)  Includes sales aids (e.g., party hostess gifts, demonstration products, etc.) and promotional materials, which typically do not qualify for commissions or overrides.

      Skin Care. The Company sells personalized skin programs in a free matrix skincare system that allows individuals to select a regiment to meet individual needs. Skin care products include cleansers, masks, skin fresheners and moisturizers for day and night. In addition to basic skin care products, The Company offers specialty products to enhance skin texture and encourage cell revitalization, including its premier product, Royal Jelly Milk Balm Moisture Lotion, and products for maturing skin (Time Protector and Time

2


Table of Contents

Corrector), eye care (Optimeyes) and elasticity (Elasticity Recovery Hydrogel). The Company seeks to use the most recent advances in ingredient technology. The Company is committed to maintaining contemporary formulas and routinely evaluating and updating its product offerings. During 2002, the Company continued to promote the skin care line and added a new staple skin care product, Makeup Remover for Eyes and Lips. Royal Jelly Vitamins were re-launched to promote health and beauty through internal wellness. Also, the Company had continued success with Intensive Retinol Treatment, capsules that release measured doses of retinol into the skin. In 2003, the Company plans to launch new products that address skin pigmentation problems.

      Color. The Company’s range of color cosmetics for the face, eyes, lips, cheeks and nails contribute significantly to its results. The Company internally develops lipstick formulas, foundations and mascaras. In 1999, the Company implemented a new color palette strategy by introducing seasonal color products, through innovative fashion color statements in the spring and fall shade product offerings. This has been a consistent strategy for 2000, 2001 and 2002, and has continued to drive the sales of color products. In 2001, the Company undertook a major restage of its entire color line. The new line consists of 31 new products, including 13 new formulas. In total, the restage involved the repackaging of approximately 280 items. The new color line was launched in Mexico during the fourth quarter of 2001 and globally in the second quarter of 2002.

      Fragrance. In 1996, the Company introduced Adorisse, a contemporary women’s fragrance, and Fm Force Magnetique, a prestige men’s fragrance. The Company further extended its fragrance line in 1997 with Le Moiré for women and Legend for Men. In 1998, the Company launched the following fragrances for women: Sensations, a youthful fragrance, Joie de Vivre, a lifestyle fragrance, and Reflections, a signature fragrance. The following fragrances were also launched for men in 1998, Epic, an aspirational fragrance, and JF9 Green, a sub-brand of the existing JF9. In 1999, The Company introduced Chosen, a prestige fragrance for women, as well as a special 20th anniversary fragrance for the Mexico market. The fragrance category includes line extensions such as body lotions, shower gels, deodorants, after-shave lotions and shave creams for some of the most popular fragrances. The Company has a continued strategy of introducing new fragrances each year. In 2001, Sphera was introduced for women and Victus was introduced for men. In 2002, multiple new fragrances were launched. Navigo was launched as a master brand and two fragrances were launched simultaneously for men and women. JF9 Black, a sub brand of JF9 was launched for a limited time.

      Body Care and Personal Care. The Company markets a broad selection of body, bath, sun and personal care products, including deodorants and shampoos. The Company’s premier body care product, Royal Jelly Body Complex, contains “royal jelly” (a substance produced by queen bees) in an oil-free deep moisturizing formula with natural botanical extracts and vitamins. Other offerings in the body care line include sunscreens, hand care lotions, revitalizing sprays, and bath products. While the Company varies its product offerings and continues to develop new products, Royal Almond and Precious Protein products remain popular sellers. In 2002, the Company leveraged the success of the Royal Almond brand by introducing Royal Ginger, a scent extension to the body care family. Also, the Company launched the Define Your Body line of four products, a complete line of technologically advanced body treatment products. The Company continued to build on the success of the Jafra Spa line with the launches of the Spa fragrances and the Scalp Massage and Hair Treatment. The Tender Moments Baby line was enhanced with the launch of pediatrician-tested Baby Bottom Balm, formulated with soothing ingredients. In a collaborative effort with Kevin Charles, founder of the Kevin Charles Salon Spa, the Company launched a new hair care line of salon quality products. Developed by the Company, tested by Kevin Charles in his salon, these products cleanse, nourish, protect and style hair. In 2003, the Company will continue to promote body and personal care products with fragrance-driven line extensions.

      Other Products. The Company is considering expanding its product line to include nutritional and wellness products. Any decision to offer such products will include consideration of the attendant risks, including potential product liability.

3


Table of Contents

Marketing

      Strategy and Product Positioning. The Company positions its products to appeal to a relatively wide range of market categories, demographic groups and lifestyles. The Company products generally price at the higher end of the mass market category, but slightly below prestige brands.

      Product Strategy. The Company’s product strategy is to provide customers with exciting and prestige quality product lines that fit into the Company’s value-added demonstration sales techniques and promote the sale of multiple products per home visit. To that end, the Company develops integrated products and actively promotes cross-selling among categories, thus encouraging multi-product sales and repeat purchases. Product variety and modernization are keys to the Company’s success. The Company continues to look for ways to expand product offerings and broaden its appeal in the marketplace. This led to the development of the Retinol capsules and the new color line.

      Marketing Material & Corporate Image. The company supports its identity and corporate image through its energetic network of consultants and word-of-mouth. The Company uses a sophisticated and integrated promotional approach that includes meetings, marketing literature, and the Internet to create strong corporate imagery and support corporate identity.

Independent Sales Force

      Jafra’s self-employed sales force is composed of approximately 416,000 consultants worldwide as of December 31, 2002. Approximately 80,000 of these consultants are in the United States and the Dominican Republic, 269,000 are in Mexico and 67,000 are in other markets. These consultants are not agents or employees of the Company; they are independent contractors or dealers. They purchase products directly from the Company and sell them directly to their customers.

      More seasoned senior consultants, who have experience managing their own consultant networks, recruit and train the Company’s field level organization. The Company sells substantially all of its products directly to its consultants. Each consultant conducts her Jafra sales operations as a stand-alone business, purchasing Jafra goods and reselling them to customers, as well as offering free personal care consultations. The Company’s independent sales force constitutes its primary marketing contact with the general public.

      Selling. The primary role of a Jafra consultant is to sell Jafra products. Although sales occur as a result of person-to-person sales, the Company also encourages its consultants to arrange sales parties at customers’ homes. Sales parties permit a more efficient use of a consultant’s time, allowing the consultant to offer products and cosmetic advice to multiple potential customers at the same time, and provide a comfortable selling environment in which clients can learn about skin care and sample the Jafra product line. Such parties also provide an introduction to potential recruits and the opportunity for referrals to other potential clients, party hostesses and recruits.

      The Company does not require consultants to maintain any inventory. Instead, Jafra consultants can wait to purchase products from the Company until they have a firm customer order to fill. Consultants generally personally deliver orders to their customers within one week of placement of an order. By delivering products directly to the customer, the Jafra consultant creates an additional sales opportunity. The short-term delivery requirements and the nature of the Company’s business preclude any significant backlog.

      Recruiting. The Company believes that the lower start-up costs and policy of providing retail discounts to consultants even on small orders helps recruit consultants. Other major attractions to prospective recruits include flexible hours, increased disposable income, an attractive incentive program (including international travel, national and regional meetings, awards and free products), personal and professional recognition, social interaction, product discounts and career development opportunities.

      The Company also emphasizes a commitment to consultants’ personal and professional training, thereby building consultants’ management and entrepreneurial skills.

      Consultant Management and Training. To become a manager, a consultant must sponsor a specified number of recruits and meet certain minimum sales levels. Once a consultant becomes a manager, she is

4


Table of Contents

eligible to earn commissions on her personal sales plus overrides on the sales of her downline consultants. A manager continues to gain seniority in the Jafra sales force by meeting the prescribed recruitment and sales requirements at each level of management. At more senior levels, managers may have several junior managers who in turn sponsor and manage other managers and consultants. The most successful managers have many such downline managers and consultants, and earn commissions on their personal sales plus overrides on their downline group’s sales.

      Training for new consultants focuses first on the personalized selling of the Jafra product line, beginning with skin care and the administration of a Jafra business. Training is conducted primarily by the Company’s consultant managers. Managers train their downline consultants at monthly meetings using materials prepared by the Company. In training managers, the Company seeks to improve leadership and management skills, while teaching managers to motivate downline consultants to higher sales levels.

      Income Opportunities and Recognition. Consultants earn income by purchasing products from the Company at retail discounts and selling to consumers at suggested retail prices. Once a consultant becomes a manager, her compensation also includes overrides on the wholesale value of paid sales made by herself and her recruits. The overrides are paid to motivate and compensate the managers to train, recruit and develop downline consultants. Additionally, managers often perform collection efforts on the Company’s behalf as the overrides paid on a consultant’s downline productivity are paid only upon the collection of payment for the underlying product sale.

      The Company believes that public recognition of sales accomplishments serves the dual purpose of identifying successful role models and boosting consultant morale. Each year the Company sponsors major events in most geographic markets to recognize and reward sales and recruiting achievements and strengthen the bond between the independent sales force and the Company. Consultants and managers must meet certain qualification levels to receive invitation to attend these events.

International Operations

      The Company’s international operations are subject to certain customary risks inherent in carrying on business abroad, including the risk of adverse currency fluctuations, the effect of regulatory and legal restrictions imposed by foreign governments, and unfavorable economic and political conditions.

      Due to the challenging macroeconomic environment that has effected the Company’s results in the non-core markets in which the Company operates, the Company recently adopted a strategic plan to focus on the strengths of the core U.S. and Mexican markets. The Company may consider plans to exit certain non-core markets, including some or all of South America, Thailand and Europe through either a sale or discontinuation of their operations.

      The most important markets to date are Mexico and the United States, which represented approximately 64% and 24%, respectively, of total 2002 consolidated sales. See Note 11 of the consolidated financial statements appearing in Item 8. “Financial Statements and Supplementary Date.” The Company has entered into foreign currency contracts to help mitigate the risk that a potential currency devaluation in Mexico would have on operations and liquidity. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Quantitative and Qualitative Disclosures About Market Risk — Foreign Currency Risk.”

Manufacturing

      The Company has a manufacturing facility in Naucalpan, Mexico, which is near Mexico City. This facility produces color cosmetics and most of the Company’s fragrances. Until June of 1999, the Company produced skin care and personal use products at the Westlake Village, California manufacturing facility. In June of 1999, the Company outsourced the U.S. product manufacturing functions to a third-party contractor.

      The Company and the third-party contractor (the “contractor”) entered into a manufacturing agreement, dated as of June 10, 1999. Subject to the terms and conditions of the manufacturing agreement, the contractor has agreed to manufacture all of the Company’s requirements for certain cosmetic and skin care products for

5


Table of Contents

an initial term of five years expiring in 2004. Following the expiration of the initial five-year term, the manufacturing agreement will be automatically extended for additional one-year terms unless terminated by six months’ prior written notice by either party. The manufacturing agreement provides for price renegotiations by the contractor if the Company’s quarterly or annual purchase volume falls below specified minimums. The manufacturing agreement requires the contractor to maintain insurance to cover costs associated with any product liability or product recall caused by the acts or omissions of the contractor. In addition, the Company is obligated to purchase materials acquired by the contractor based upon product forecasts provided by the Company if the contractor is unable to sell such materials to a third-party. The contractor is solely responsible for obtaining the inventories, manufacturing the inventories at its current location in Chino, California, complying with applicable laws and regulations, and performing quality assurance functions.

      Beginning in 2001, the Company began manufacturing, through a third-party, a limited number of items in Brazil, for sale in South America.

      The Company purchases from other third-party suppliers certain finished goods and raw materials for use in its manufacturing operations. In general, the Company does not have written contracts with other suppliers. Finished goods and raw materials used in the Company’s products, such as glass, plastics, and chemicals, generally are available stock items or can be obtained to the Company’s specifications from more than one potential supplier.

Distribution

      As of December 31, 2002, the Company uses three distribution centers in the United States and Mexico and various other distribution centers globally. The U.S. warehouses in Bridgeport, New Jersey and Westlake Village, California currently stock the entire Jafra product line. In Mexico, the Company has historically outsourced virtually all of its distribution to third-parties. However, in January 2002, the Company opened a distribution center in Mexico and terminated the third-party distribution function. This distribution center services all consultants in Mexico. Management believes that its facilities are adequate to meet demand in its existing markets for the foreseeable future.

      Typically, owned or leased distribution centers are located in an area that allows for direct delivery to consultants by either post or carrier. Maintaining a short delivery cycle in direct selling is an important competitive advantage.

Competition

      The Company sells all of its products in highly competitive markets. The principal bases of competition in the cosmetics direct selling industry are price, quality and range of product offerings. Several direct sales companies compete with the Company in sales of cosmetic products, and at least two such competitors, Mary Kay and Avon, are substantially larger than the Company in terms of total independent salespersons, sales volume and resources. In addition, the Company’s products compete with cosmetics and toiletry items manufactured by cosmetic companies that sell their products in retail or department stores. Several of such competitors are substantially larger than the Company in terms of sales and have substantially more resources. The Company also faces competition in recruiting independent salespersons from other direct selling organizations whose product lines may or may not compete with the Company’s products.

      The Company believes that its senior management team with a strong direct selling track record, motivated direct sales force, prestige quality product lines, product development capabilities, geographic diversification, short delivery cycle, and manufacturing technology are significant factors in establishing and maintaining its competitive position.

Patents and Trademarks

      The Company’s operations do not depend to any significant extent upon any single trademark other than the Jafra trademark and one of its most significant line of products, Royal Jelly, is not protected by any registered trademark. Some of the trademarks Jafra uses, however, are identified with and important to the

6


Table of Contents

sale of its products. Some of the more important trademarks are: Adorisse (a contemporary women’s fragrance), Eau D’Aromes (revitalizing fragrance spray), JF9 (a men’s prestige fragrance), Legend for Men (a men’s premium fragrance), Le Moiré (a contemporary women’s fragrance), and Optimeyes (eye treatment lotion). The Company’s operations do not depend to any significant extent on any single or related group of patents, although the Company has have applied for or received patent protection in its major markets for certain skin creams, dispensers and product containers, nor does it rely upon any single or related group of licenses, franchises or concessions. The Company has in the past licensed know-how from Gillette relating to the design, development and manufacture of its products and is permitted to continue to use such know-how in connection with its products.

      In 1998, a former employee of Gillette filed applications to register the Jafra trademark in Algeria, Bangladesh, China, Cyprus, Egypt, Gambia, Ghana, Guyana, India, Kenya, Malawi, Morocco, Nigeria, OAPI, Pakistan, Sierra Leone, Syria, Sudan, Surinam, Tanzania, Tunisia, Zambia, and Zimbabwe, jurisdictions in which the Company does not currently operate. In 1998, Gillette obtained a court order prohibiting this employee from transferring or licensing such trademark applications and registrations and requiring that the trademark applications and registrations be assigned to Gillette. The relevant documentation relating to the transfer of these trademarks to the Company has been completed. The Company has filed the documents obtained from this former employee in those jurisdictions in which the documentation will be accepted in order to secure the abandonment and cancellation of this employee’s applications and registrations. If the Company is not able to secure cancellation or abandonment of the applications and registrations in these jurisdictions, it may be prohibited from distributing its products in these jurisdictions.

Management Information Systems

      During 2001, the Company redefined its Internet strategy and continued to develop and implement an expanded e-commerce system. The expanded e-commerce platform became operational in the United States during June 2001, with the consultant adoption rate averaging 24% of order volume by year end 2002. In Mexico, an e-commerce platform was launched during the second half of 2001. The Company also selected a new platform to run its core operations in the United States. The U.S. business will replace the order entry, fulfillment, commission and override processing and financial system software with Enterprise Resource Planning (ERP) software from JD Edwards. Wave one of this implementation of the financial systems was implemented in April of 2002. Waves two and three, which relate to the order entry and remaining commercial systems, will be implemented in the second quarter of 2003. The Company anticipates that this new system may be leveraged to improve computer operations in Mexico, Puerto Rico and the Dominican Republic during 2004.

Seasonality

      The Company’s net sales, as measured in local currencies, during the fourth quarter of the year are typically slightly higher than in the other three quarters of the year due to seasonal holiday purchases.

Environmental Matters

      The Company’s operations are subject to various federal, state, local and foreign laws or regulations governing environmental, health and safety matters. Some of its operations require environmental permits and controls and these permits are subject to modification, renewal and revocation by issuing authorities. Violations of or liabilities under environmental laws could result in fines or penalties, obligations to clean up contaminated properties or claims for property damage or personal injury. The Company believes that it is in material compliance with all such laws, regulations and permits, and under present conditions, it does not foresee that such laws and regulations will have a material adverse effect on its capital expenditures, earnings or competitive position.

7


Table of Contents

Employees

      As of December 31, 2002, the Company had 1,016 full-time employees, of which 267 were employed in the United States and 749 in other countries. The Company also had 427 outside contract employees.

Item 2. Properties

      The Company is headquartered and maintains a warehouse and distribution facility in Westlake Village, California, 40 miles north of Los Angeles. Manufacturing is done on a global basis for the color and fragrance product lines at the Company’s facility in Naucalpan, Mexico. The Westlake Village, California and Naucalpan, Mexico facilities are owned by the Company, except for a small portion of the Naucalpan facility that is leased. In addition, the Company leases certain distribution facilities, sales offices and service centers to facilitate its operations globally. As of January 1, 2002, the Company began utilizing a leased distribution center in Lerma, Mexico. The Company’s properties are suitable and adequate to meet its current and anticipated requirements.

Item 3. Legal Proceedings

      The Company is subject from time to time to various litigation and claims arising in the ordinary course of its business. The Company does not believe that any known litigation or claims pending against it would, if determined in a manner adverse to it, have a material adverse effect on its business, financial condition or results of operations.

Item 4. Submission of Matters to a Vote of Security Holders

      No matters were submitted to a vote of the security holders of the Company during the fourth quarter of 2002.

8


Table of Contents

PART II

Item 5. Market for Registrant’s Common Equity and Related Stockholder Matters

      There is no established public trading market for Parent common stock (the “Common Stock”). The number of holders of record of the Company’s Common Stock on March 7, 2003 was 32. On July 11, 2000, a member of management purchased 316 shares of Common Stock for a purchase price of $150 per share, or a total of $47,400; on July 27, 2000, a former member of management exercised options to purchase 158 shares of Common Stock for a purchase price of $100 per share, or a total of $15,800, and then sold a total of 632 shares of Common Stock back to the Company at $210 per share, or a total of $132,720; on August 9, 2000, certain members of management purchased an aggregate of 4,108 shares of Common Stock for a purchase price of $210 per share, or a total of $862,860; on November 6, 2000, a former member of management sold 316 shares of Common Stock back to the Company at $210 per share, or a total of $66,360; on February 10, 2001, certain members of management purchased an aggregate of 474 shares of Common Stock for a purchase price of $210 per share, or a total of $99,540; on June 14, 2001, a former member of management and a former director, sold an aggregate total of 2,563 shares of Common Stock back to the Company at $250 per share, or a total of $640,750; on September 19, 2001, a former member of management exercised options to purchase 210 shares of Common Stock for a purchase price of $150 per share, or a total of $31,500, and then sold a total of 526 shares of Common Stock back to the Company at $250 per share, or a total of $131,500. All of these transactions were exempt from the registration requirements of the Securities Act of 1933, as amended, as either offerings to accredited investors under Regulation D or offerings to employees under Rule 701. See Item 12. “Security Ownership of Certain Beneficial Owners and Management.” The parent has not paid in the past, and does not expect to pay for the foreseeable future, regular dividends on shares of its Common Stock. The declaration and payment of future dividends, if any, will be at the sole discretion of the Board of Directors of the Parent, subject to the restrictions set forth in the senior credit agreement and the Indenture for its senior subordinated notes (the “Indenture”), which currently restrict the payment of cash dividends to stockholders, and restrictions, if any, imposed by other indebtedness outstanding from time to time. See Item 7. “Management’s Discussion and Analysis of Financial Conditions and Results of Operations — Liquidity and Capital Resources.”

9


Table of Contents

Item 6. Selected Financial Data

      The following is a summary of selected financial data of the Company (amounts in millions except for consultant and consultant productivity data). The selected financial data as of December 31, 2002 and 2001 and for the years ended December 31, 2002, 2001 and 2000 are derived from the audited financial statements which appear in Item 8. “Financial Statements and Supplementary Data.” The related selected financial data should be read in conjunction with such financial statements and notes thereto and Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” All other financial data presented has been derived from audited financial statements of the Company which are not included herein. The financial data for the four months ended April 30, 1998 reflects the Jafra Business prior to the Acquisition and are referred to as the “Predecessor” operations.

                                                   
Predecessor

Four
Eight Months Months
Years Ended December 31, Ended Ended

December 31, April 30,
2002 2001 2000 1999 1998 1998






Statement of Operations Data:
                                               
Net sales(a)
  $ 391.0     $ 376.2     $ 321.2     $ 296.4     $ 174.5     $ 79.2  
Cost of sales(b)
    92.4       87.0       79.5       82.3       56.3       22.7  
     
     
     
     
     
     
 
Gross profit
    298.6       289.2       241.7       214.1       118.2       56.5  
Selling, general and administrative expenses(a)
    240.9       232.9       196.6       180.7       110.9       51.1  
Restructuring and impairment charges(c)
                2.6       4.8              
Loss (gain) on sale of assets
    (0.1 )     0.1       0.1       (1.0 )     0.2        
     
     
     
     
     
     
 
Income from operations
    57.8       56.2       42.4       29.6       7.1       5.4  
Other income (expense):
                                               
 
Exchange (loss) gain, net
    (11.2 )     (9.7 )     (11.7 )     3.3       (1.8 )     1.4  
 
Interest (expense) income, net
    (11.4 )     (13.3 )     (15.7 )     (16.9 )     (11.5 )     0.1  
 
Other income (expense), net
    0.1       (0.1 )     1.6       0.1       (0.1 )     0.1  
     
     
     
     
     
     
 
Income (loss) before income taxes, extraordinary item and cumulative effect of accounting change
    35.3       33.1       16.6       16.1       (6.3 )     7.0  
Income tax expense
    16.3       17.4       10.0       10.9       1.7       2.9  
     
     
     
     
     
     
 
Income (loss) before extraordinary item and cumulative effect of accounting change
    19.0       15.7       6.6       5.2       (8.0 )     4.1  
Extraordinary loss on early extinguishment of debt, net of income tax benefit of $0.2 in 2000 and $0.2 in 1999.
                0.3       0.6              
     
     
     
     
     
     
 
Income (loss) before cumulative effect of accounting change
    19.0       15.7       6.3       4.6       (8.0 )     4.1  
Cumulative effect of accounting change, net of income tax expense of $0 in 2002 and $0.1 in 2001(e)
    (0.2 )     0.1                          
     
     
     
     
     
     
 
Net income (loss)
  $ 18.8     $ 15.8     $ 6.3     $ 4.6     $ (8.0 )   $ 4.1  
     
     
     
     
     
     
 
Balance Sheet Data (at end of period):
                                               
Cash and cash equivalents
  $ 27.2     $ 6.7     $ 5.8     $ 4.9     $ 18.4          
Working capital
    31.9       14.2       19.2       34.2       22.9          
Property and equipment, net
    60.7       59.6       51.4       50.6       56.2          
Total assets
    288.3       291.1       276.9       278.4       288.6          
Total debt(d)
    84.4       93.1       109.0       133.5       141.5          
Stockholders’ equity
  $ 108.5     $ 96.0     $ 81.2     $ 75.8     $ 75.4          

10


Table of Contents

                                                 
Predecessor

Four
Eight Months Months
Years Ended December 31, Ended Ended

December 31, April 30,
2002 2001 2000 1999 1998 1998






Other Financial Data:
                                               
Net cash provided by (used in) operating activities
    43.1       30.1       32.5       (1.6 )     18.1       (8.0 )
Net cash provided by (used in) investing activities
    (11.3 )     (11.7 )     (7.2 )     (3.1 )     (211.1 )     2.6  
Net cash provided by (used in) financing activities
    (8.7 )     (16.6 )     (23.5 )     (7.4 )     211.7       (8.8 )
Depreciation and amortization
    5.6       7.7       7.6       7.1       5.1       1.4  
Amortization of deferred financing fees
    1.4       1.4       1.4       1.8       1.4        
Capital expenditures
  $ 11.0     $ 11.4     $ 7.1     $ 5.8     $ 6.4     $ 6.1  
Total ending consultants
    416,000       369,000       310,000       292,000       247,600       220,000  
Average ending consultants(f)
    394,000       362,000       307,000       275,000       238,000       215,000  
Consultant productivity(f)
  $ 992     $ 1,039     $ 1,046     $ 1,078     $ 1,103     $ 1,103  

(a)  In connection with the adoption of Emerging Issues Task Force Issue No. 01-9, “Accounting for Consideration Given by a Vendor to a Customer or a Reseller of the Vendor’s Products,” on January 1, 2002, reclassifications have been made to all periods ending prior to that date to reflect commissions on personal sales paid to consultants, previously reported as selling, general and administrative expenses, as a reduction of net sales and selling, general and administrative expenses. The amounts that have been reclassified as a reduction to net sales and selling, general and administrative expenses are $3.9 million, $3.4 million, $3.2 million, $1.9 million and $0.8 million for the years ended December 31, 2001, 2000 and 1999, the eight- months ended December 31, 1998, the four-months ended April 30, 1998, respectively.
 
(b)  Cost of sales for the eight months ended December 31, 1998 includes a $2.7 million charge relating to the sale of certain inventories that were revalued to fair value in conjunction with the Acquisition.
 
(c)  Restructuring and impairment charges include the following: for 2000, approximately $1.6 million of restructuring charges and approximately $1.0 million of asset impairment charges and for 1999, approximately $3.7 million of restructuring charges and approximately $1.1 million of asset impairment charges.
 
(d)  Total debt consists of borrowings under the subordinated notes, term loan, revolving loan and unsecured foreign bank loan.
 
(e)  In connection with the adoption of Statement of Financial Accounting Standards (“SFAS”) No. 142, “Goodwill and other Intangible Assets,” on January 1, 2002, the Company recorded a net loss of $0.2 million (net of a tax effect of $0) as a cumulative transition adjustment to earnings. In connection with the adoption of SFAS No. 133, “Accounting for Derivative Instruments and Hedging Activities,” on January 1, 2001, the Company recorded a net gain of $0.1 million (net of a tax effect of $0.1 million) as a cumulative transition adjustment to earnings.

(f)  The average consultant base is calculated based on the total ending consultant base for each of the prior twelve months. A consultant is included in the total ending consultant base if she places an order within the past four months. Consultant productivity is defined as net sales in U.S. dollars divided by the annual average number of consultants. Full year 1998 consultant productivity is shown for comparability.

11


Table of Contents

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

      The following discussion of the results of operations, financial condition and liquidity of the Company should be read in conjunction with the information contained in the consolidated financial statements and notes thereto included in Item 8. “Financial Statements and Supplementary Data” in this Form 10-K. These statements have been prepared in conformity with accounting principles generally accepted in the United States of America and require management to make estimates and assumptions that affect amounts reported and disclosed in the financial statements and related notes. Actual results could differ from these estimates.

Results of Operations

      The following table represents selected components of the Company’s results of operations, in millions of dollars and as percentages of net sales. The table reflects the operations of the Company for the years ended December 31, 2002, 2001 and 2000.

                                                 
Years Ended December 31,

2002 2001 2000



($ in millions)
Net sales(1)
  $ 391.0       100.0 %   $ 376.2       100.0 %   $ 321.2       100.0 %
Cost of sales
    92.4       23.6       87.0       23.1       79.5       24.8  
     
     
     
     
     
     
 
Gross profit
    298.6       76.4       289.2       76.9       241.7       75.2  
Selling, general and administrative expenses(1)
    240.9       61.6       232.9       62.0       196.6       61.2  
Restructuring and impairment charges
                            2.6       0.8  
Loss (gain) on sale of assets
    (0.1 )     0.0       0.1       0.0       0.1       0.0  
     
     
     
     
     
     
 
Income from operations
    57.8       14.8       56.2       14.9       42.4       13.2  
Exchange loss, net
    (11.2 )     (2.9 )     (9.7 )     (2.6 )     (11.7 )     (3.6 )
Interest expense, net
    (11.4 )     (2.9 )     (13.3 )     (3.5 )     (15.7 )     (4.9 )
Other income (expense), net
    0.1       0.0       (0.1 )     0.0       1.6       0.5  
     
     
     
     
     
     
 
Income before income taxes, extraordinary item and cumulative effect of accounting change
    35.3       9.0       33.1       8.8       16.6       5.2  
Income tax expense
    16.3       4.1       17.4       4.6       10.0       3.1  
     
     
     
     
     
     
 
Income before extraordinary item and cumulative effect of accounting change
    19.0       4.9       15.7       4.2       6.6       2.1  
Extraordinary loss on early extinguishment of debt, net of income tax benefit of $0.2 million
                            0.3       0.1  
     
     
     
     
     
     
 
Income before cumulative effect of accounting change
    19.0       4.9       15.7       4.2       6.3       2.0  
Cumulative effect of accounting change, net of income tax expense of $0 in 2002 and $0.1 million in 2001.
    (0.2 )     (0.1 )     0.1       0.0              
     
     
     
     
     
     
 
Net income
  $ 18.8       4.8 %   $ 15.8       4.2 %   $ 6.3       2.0 %
     
     
     
     
     
     
 

(1)  In connection with the adoption of Emerging Issues Task Force Issue No. 01-9, “Accounting for Consideration Given by a Vendor to a Customer or a Reseller of the Vendor’s Products,” on January 1, 2002, reclassifications have been made to periods ending prior to that date to reflect commissions on personal sales paid to consultants, previously reported as selling, general and administrative expenses, as a reduction of net sales and selling, general and administrative expenses. The amounts that have been reclassified as a reduction of net sales and selling, general and administrative expenses are $3.9 million and $3.4 million, for the years ended December 31, 2001 and 2000, respectively.

12


Table of Contents

      The following tables represent selected components of the consolidated results of operations by market. Management evaluates market performance based on segment operating income, excluding reorganization and restructuring charges, unusual gains and losses, and amortization of goodwill and other intangible assets. Results for subsidiaries in South America, the Dominican Republic, and Thailand are combined and included in the following tables under the caption “All Others.” Corporate expenses, reorganization and restructuring charges, unusual gains and losses and amortization of goodwill and other intangible assets are included under the caption “Corporate, Unallocated and Other.”

                                                         
Corporate,
United Total Unallocated Consolidated
Mexico States Europe All Others Segments and Other Total







(Dollars in millions)
Year Ended December 31, 2002
                                                       
Net sales
  $ 251.6     $ 92.1     $ 26.9     $ 20.4     $ 391.0     $     $ 391.0  
Cost of sales
    60.6       21.2       6.3       6.2       94.3       (1.9 )     92.4  
     
     
     
     
     
     
     
 
Gross profit
    191.0       70.9       20.6       14.2       296.7       1.9       298.6  
Selling, general and administrative expenses
    124.8       55.3       19.4       20.3       219.8       21.1       240.9  
Gain on sale of assets
    (0.1 )                       (0.1 )           (0.1 )
     
     
     
     
     
     
     
 
Income (loss) from operations
  $ 66.3     $ 15.6     $ 1.2     $ (6.1 )   $ 77.0     $ (19.2 )   $ 57.8  
     
     
     
     
     
     
     
 
Year Ended December 31, 2001
                                                       
Net sales
  $ 247.5     $ 79.6     $ 26.4     $ 22.7     $ 376.2     $     $ 376.2  
Cost of sales
    59.4       18.3       5.5       6.4       89.6       (2.6 )     87.0  
     
     
     
     
     
     
     
 
Gross profit
    188.1       61.3       20.9       16.3       286.6       2.6       289.2  
Selling, general and administrative expenses
    116.8       49.7       19.1       22.2       207.8       25.1       232.9  
Loss on sale of assets
          0.1                   0.1             0.1  
     
     
     
     
     
     
     
 
Income (loss) from operations
  $ 71.3     $ 11.5     $ 1.8     $ (5.9 )   $ 78.7     $ (22.5 )   $ 56.2  
     
     
     
     
     
     
     
 
Year Ended December 31, 2000
                                                       
Net sales
  $ 199.8     $ 74.1     $ 26.9     $ 20.4     $ 321.2     $     $ 321.2  
Cost of sales
    48.8       16.5       6.3       6.9       78.5       1.0       79.5  
     
     
     
     
     
     
     
 
Gross profit
    151.0       57.6       20.6       13.5       242.7       (1.0 )     241.7  
Selling, general and administrative expenses
    86.6       46.9       20.3       19.5       173.3       23.3       196.6  
Restructuring and impairment charges
                                  2.6       2.6  
Loss on sale of assets
                0.1             0.1             0.1  
     
     
     
     
     
     
     
 
Income (loss) from operations
  $ 64.4     $ 10.7     $ 0.2     $ (6.0 )   $ 69.3     $ (26.9 )   $ 42.4  
     
     
     
     
     
     
     
 

Year Ended December 31, 2002 Compared to Year Ended December 31, 2001

      Net Sales. Net sales for 2002 increased to $391.0 million from $376.2 million in 2001, an increase of $14.8 million, or 3.9%. In local currencies, net sales increased 7.6% in 2002 compared to 2001. The average number of ending consultants worldwide increased 8.8% to approximately 394,000 consultants in 2002, an increase of 32,000 consultants over the 2001 average number of consultants. A consultant is included in the total ending consultant base if she places an order within the four months immediately preceding the period end date. The average consultant base is calculated based on the total ending number of consultants for each of the prior twelve months. Consultant activity decreased approximately 1.6%, with 49.0% of all consultants considered active in 2002, compared to 49.7% in 2001. In general, consultants are considered to be active ordering consultants if they place an order within the month. Consultant productivity decreased 4.5% in 2002 compared to 2001, due primarily to weaker local currencies, partially offset by increased productivity in the

13


Table of Contents

United States subsidiary due to planned program changes. The Company defines consultant productivity as net sales in U.S. dollars divided by the annual average number of consultants.

      In Mexico, net sales, excluding intersegment sales, for 2002 increased to $251.6 million from $247.5 million in 2001, an increase of $4.1 million, or 1.7%. In local currency, net sales in Mexico increased 5.5% over net sales during 2001. The year-to-year increase was due to an increase in the average number of consultants, partially offset by reduced productivity. The reduction in productivity was partially due to weaker average exchange rates of the Mexican peso. In Mexico, the average number of consultants in 2002 increased to approximately 252,000, 9.9% over the 2001 average number of consultants. Consultant productivity decreased 7.5% in 2002 compared to 2001.

      In the United States, net sales, excluding intersegment sales, for 2002 increased to $92.1 million from $79.6 million in 2001, an increase of $12.5 million, or 15.7%. The U.S. selling market has established two distinct selling divisions to focus on the individual characteristics of the Hispanic Division and the General Division. The establishment of two distinct selling divisions allows the Company to focus on independent marketing strategies and to provide specialized recruiting, training and product offerings, which has contributed to the increased net sales. Sales in the Hispanic Division increased 19.7% to $61.2 million and sales in the General Division increased 8.6% to $30.9 million during 2002 compared to net sales in 2001. In the Hispanic Division, the year-to-year increase was driven by increases in the number of consultants, the number of active consultants and consultant productivity. In the General Division, the year-to-year increase was driven by an increase in consultant productivity, partially offset by a smaller consultant base. In the United States, the increased productivity was due to certain productivity-related changes in the program during the second quarter of 2002. In the Hispanic Division, the average number of consultants increased 12.1% to 39,000 compared to the 2001 average. Hispanic Division consultant productivity increased 6.8% in 2002 compared to 2001 productivity. Additionally, in 2002, consultant activity increased 6.3% in the Hispanic Division compared to 2001, with 60.7% of all consultants considered to be active in 2002. The Hispanic Division also reported increases in the number of leaders. A leader is defined as a consultant who sponsors a specified number of recruits and meets certain minimum sales levels. In the General Division, consultant productivity increased 16.5% and the average number of consultants decreased 6.8% to approximately 29,000 consultants in 2002.

      In Europe, net sales, excluding intersegment sales, for 2002 increased to $26.9 million from $26.4 million in 2001, an increase of $0.5 million, or 1.9%. Measured in local currencies, net sales in 2002 decreased 3.6% compared to net sales in 2001. The increase in net sales measured in U.S. dollars was the result of the strengthening of the euro and Swiss Franc compared to the U.S. dollar, partially offset by a decrease in the average number of consultants, and reduced consultant productivity in local currencies. In Europe, the average number consultants decreased 2.6% to approximately 16,000 consultants. Consultant productivity increased 5.0% in 2002, compared to 2001, due to the strengthening of local currencies compared to the U.S. dollar. Measured in local currencies, consultant productivity decreased 1.1% in 2002 compared to 2001 productivity.

      Gross Profit. Gross profit in 2002 increased to $298.6 million from $289.2 million in 2001, an increase of $9.4 million, or 3.3%. Gross profit as a percentage of net sales (gross margin) decreased to 76.4% from 76.9%.

      In Mexico, gross margin decreased nominally to 75.9% in 2002 compared to 76.0% in 2001 due primarily to incrementally greater charges related to the reserve for slow moving inventory in 2002 (excluding Mexico manufacturing operations), the weakening of the peso compared to the U.S. dollar, partially offset by a more favorable product mix. Excluding charges for the reserve for slow moving inventory in 2002, gross margin would have been approximately 76.3% in 2002, compared to 76.1% in 2001. The percentage of resale sales compared to total sales remained constant at 91.2%.

      In the United States, gross margin remained constant at 77.0% between 2002 and 2001. In 2002, sales of new products contributed a greater gross margin compared to 2001. This was offset by a lower gross margin contribution from non-resale sale products. Charges for the reserve for slow moving inventory were relatively constant between 2002 and 2001.

14


Table of Contents

      In Europe, gross margin in 2002 decreased to approximately 76.6% compared to 79.2% in 2001 primarily due to a more aggressive product mix implemented in an effort to generate sales.

      Selling, General and Administrative Expenses. SG&A expenses in 2002 increased to $240.9 million from $232.9 million in 2001, an increase of $8.0 million, or 3.4%. SG&A expenses, as a percentage of net sales, decreased to 61.6% in 2002 from 62.0% in 2001, primarily due to the discontinuation of amortization of goodwill and trademarks pursuant to SFAS No. 142 (See “New Accounting Pronouncements”). In 2001, the Company recorded $3.5 million of charges related to amortization of intangible assets.

      In Mexico, SG&A expenses increased to $124.8 million in 2002, from $116.8 million in 2001. As a percentage of net sales, SG&A expenses increased to 49.6% in 2002 compared to 47.2% in 2001. The primary factors for the increase in SG&A expenses as a percentage of net sales were selling expenses, variable freight expenses and administrative expenses. Selling expenses increased due primarily to an increase in the number of regional sales managers. As a percentage of sales, variable freight expenses increased 1.1% due to increased orders and higher average packaging costs. Administrative expenses increased primarily due an additional $3.4 million of bad debt expense in 2002, compared to 2001, due to declining consultant liquidity as a result of the general economic condition. Excluding the charges for bad debt expense, administrative expense was relatively constant as a percentage of sales in 2002 and 2001.

      In the United States, SG&A expenses increased to $55.3 million in 2002 from $49.7 million in 2001, an increase of $5.6 million, or 11.3%. However, as a percentage of net sales, SG&A expenses decreased to 60.0% from 62.4% primarily due to decreases in sales promotional expenses and administrative expenses. Sales promotional expenses decreased as a percentage of net sales due to the mix of events. Administrative expenses decreased as a percentage of net sales due to an increase in net sales as most of these expenses are fixed in nature. However, administrative expenses were relatively constant in total. Certain other variable expenses, such as period distribution and freight out, increased in total, but were relatively constant as a percentage of net sales.

      In Europe, SG&A expenses increased to $19.4 million in 2002 from $19.1 million in 2001, an increase of $0.3 million. As a percentage of net sales, SG&A expenses decreased to 72.1% in 2002 from 72.3% in 2001. Administrative expenses increased as a percentage of net sales and in total due to larger charges related to the reserve for uncollectible accounts in Italy and incrementally higher information technology expenses in Germany in 2002 compared to 2001. The increase in administrative expenses, as a percentage of net sales, was offset by reduced sales promotional and override expenses, in 2002 compared to 2001.

      SG&A expenses in the other selling markets (South America, Dominican Republic and Thailand) decreased to $20.3 million in 2002, compared to $22.2 million in 2001, primarily due to the favorable impact on expenses of currency devaluation of the South American currencies compared to the U.S. dollar, and decreased incremental charges related to the reserve for uncollectible accounts in the Company’s Brazilian subsidiary in 2002 compared to 2001. SG&A expenses in the corporate, unallocated and other categories decreased $4.0 million in 2002, compared to 2001, primarily due to the discontinuation of intangible amortization pursuant to SFAS No. 142 and administrative cost savings in the Company’s corporate headquarters.

      Exchange Loss. The Company’s net foreign exchange loss in 2002 was $11.2 million compared to $9.7 million in 2001, an increase in exchange losses of $1.5 million, or 15.5%. The Company’s foreign exchange gains and losses primarily result from the Company’s operations in Mexico and South America. The net exchange loss has three primary elements: gains or losses on forward currency and option contracts, unrealized and realized gains or losses on the remeasurement of U.S. dollar-denominated debt, and gains or losses on transactions denominated in foreign currencies.

      In 2002, the Company continued to use forward contracts to protect against potential devaluation of the Mexican peso by selling Mexican pesos and buying U.S. dollars. Additionally, during 2002, the Company modified its hedging program to include the use of foreign currency option contracts (“option contracts” or “options”) to hedge foreign currency exposures to the Mexican peso. In order to execute the option contracts and to offset the current outstanding forward contracts to sell Mexican pesos, the Company entered into

15


Table of Contents

forward contracts to buy Mexican pesos. The Company purchases exchange rate put options which gives it the right, but not the obligation, to sell Mexican pesos at a specified U.S. dollar exchange rate (“strike rate”). The option contracts provide protection in the event the Mexican peso weakens beyond the option strike rate. In conjunction with the put options, and as part of a zero-cost option collar structure, the Company sold Mexican peso call options, which give the courterparty the right, but not the obligation, to buy Mexican pesos from the Company at a specified strike rate. The effect of these contracts would be to limit the benefit the Company would otherwise derive from the strengthening of the Mexican peso beyond the strike rate.

      During the year ended December 31, 2002, the Company recognized $2.6 million of exchange losses related to forward contracts and $0.9 million of exchange gains related to option contracts (including the reclassification of other comprehensive loss into exchange loss). As the Company utilizes hedge accounting pursuant to SFAS No. 133 for forward and option contracts to hedge certain forecasted transactions, certain losses and gains are deferred as a separate component of other comprehensive loss and are recognized in income at the same time that the underlying hedged exposure is recognized in income. As of December 31, 2001, the Company had deferred losses of $3.7 million as a component of other comprehensive loss. During 2002, the Company deferred an additional $1.8 million of losses on forward exchange contracts and $1.3 million of exchange gains on option contracts as a component of other comprehensive loss. During the year ended December 31, 2002, the Company reclassified $1.6 million of losses on forward contracts and $0.5 million of exchange gains on option contracts from other comprehensive loss into exchange loss on the consolidated statement of income. Additionally, during the year ended December 31, 2002, the Company reclassified $3.1 million of losses on forward contracts and $0.4 million of exchange gains on option contracts from other comprehensive loss into cost of sales in the consolidated statements of income.

      During the year ended December 31, 2002, the Mexican peso devalued 13.5%, which resulted in a $5.2 million loss on the remeasurement of U.S. dollar-denominated debt, most of which was unrealized. The Company recognized $4.3 million of other exchange losses on other foreign currency transactions, most of which was unrealized, primarily due to the weakening of the South American currencies.

      During 2001, the Company recognized a total of $12.2 million of exchange losses related to forward contracts (including the reclassification of other comprehensive loss into exchange loss). During 2001, the Company deferred $5.5 million of losses as a component of other comprehensive loss, pursuant to SFAS No. 133. Of this $5.5 million, $0.8 million was recognized as a component of exchange loss and $1.0 million was recognized as cost of sales, in the consolidated statements of income, resulting in $3.7 million of exchange losses deferred as a component of other comprehensive loss at December 31, 2001. As the Mexican peso strengthened in 2001, the Company recognized $2.8 million of exchange gains on the remeasurement of U.S. dollar-denominated debt in 2001. Additionally, the Company recognized $0.3 million of net exchange losses on other transactions denominated in foreign currencies.

      Interest Expense. Interest expense decreased to $11.4 million in 2002 from $13.3 million in 2001, a decrease of $1.9 million, or 14.3%. The decrease was due to a lower debt balance, as total debt decreased approximately $8.7 million in 2002 from 2001, and lower average interest rates. Interest rates on Libor based borrowings decreased from 3.6% at December 31, 2001 to 3.1% at December 31, 2002.

      Income Tax Expense. Income tax expense decreased to $16.3 million in 2002 from $17.4 million in 2001, a decrease of $1.1 million, or 6.3%. The Company’s effective income tax rate decreased to 46.4% in 2002 from 52.5% in 2001. The reduced effective income tax rate was primarily the result of the release of valuation allowances against certain deferred income tax assets in the United States and the impact of the enactment of changes in Mexico’s future corporate statutory rates on net deferred income tax liabilities partially offset by valuation allowances against certain pretax expenses in the United States. Excluding the impact of the release of the valuation allowance of $2.3 million and the impact of the enactment of changes in the Mexico rate of $1.2 million, the effective tax rate would have been 56.4% in 2002.

      Net Income. Net income increased to $18.8 million in 2002 from $15.8 million in 2001, an increase of $3.0 million, or 19.0%. The increase was due to a $9.4 million increase in gross profit, a $0.2 million favorable change in loss (gain) on sale of assets, a $1.9 million decrease in interest expense, a $0.2 million favorable change in other income (expense), a $1.1 million decrease in tax expense, offset by a $8.0 million increase in

16


Table of Contents

selling, general and administrative expenses, a $1.5 million increase in exchange loss and a $0.2 million loss on the cumulative effect of accounting change, compared to a $0.1 million gain on the cumulative effect of accounting change in the prior year.

Year Ended December 31, 2001 Compared to Year Ended December 31, 2000

      Net Sales. Net sales for 2001 increased to $376.2 million from $321.2 million in 2000, an increase of $55.0 million, or 17.1%. The Company’s average ending number of consultants worldwide increased 17.9% to approximately 362,000 consultants in 2001, an increase of 55,000 consultants over the 2000 average. The Company’s consultant productivity decreased 0.6% between 2001 and 2000. Consultant productivity in Mexico increased 3.5%.

      In Mexico, net sales, excluding intersegment sales, for 2001 increased to $247.5 million from $199.8 million in 2000, an increase of $47.7 million, or 23.9%. Sales in Mexico in local currency increased by 22.3% over 2000 net sales. The year-to-year increase was driven by an increase in the average number of consultants, an increase in consultant productivity and an increase in average consultant branches, or leaders. Mexico defines a branch or leader as a consultant with twelve or more active consultants in her downline. The average number of leaders in 2001 increased 20.4% compared to the 2000 average. In Mexico, the average number of consultants in 2001 increased to approximately 229,000, or 19.6% over the 2000 average.

      In the United States, net sales, excluding intersegment sales, for 2001 increased to $79.6 million from $74.1 million in 2000, an increase of $5.5 million, or 7.4%. During the later part of 2000, the U.S. established two distinct selling divisions to focus on the individual characteristics of the Hispanic Division and the General Division. The focus on the distinct needs of the consultants in each of the selling divisions contributed to the overall sales increase. Net sales in the Hispanic Division increased 8.1% and net sales in the General Division increased 6.4% compared to 2000 sales. The year-to-year increase was also driven by an overall increase in the number of consultants and an increase in the percentage of active consultants, partially offset by a decrease in productivity. In the U.S., the average number of consultants in 2001 increased to approximately 66,000, or 7.8% above the 2000 average. The percent of ordering consultants increased to 53.5% of all consultants, as compared to 49.6% in 2000. Consultant productivity decreased 6.1% over consultant productivity in 2000.

      In Europe, net sales, excluding intersegment sales, for 2001 decreased to $26.4 million from $26.9 million in 2000, a decrease of $0.5 million, or 1.9%. The decline in net sales was primarily attributed to unfavorable exchange rates due to the weakening of local currency compared to the U.S. dollar. If exchange rates remained constant between 2000 and 2001, net sales would have increased nominally. In Europe, the average number of consultants was relatively constant at an average of 17,000 consultants each year.

      Gross Profit. Gross profit in 2001 increased to $289.2 million from $241.7 million in 2000, an increase of $47.5 million, or 19.7%. Gross profit as a percentage of sales (gross margin) increased to 76.9% in 2001 from 75.2% in 2000.

      In Mexico, gross margin improved primarily due to reduced product costs, while prices increased in line with inflation. During 2001, the peso strengthened 5.2% compared to the U.S. dollar in 2000. The strengthening of the peso resulted in reduced product costs as the Company benefited from foreign currency gains as some inventory and components are purchased in U.S. dollar-denominated transactions. These gains were partially offset by derivative losses on forward contracts used to purchase inventory and accounted for using hedge accounting. Mexico’s fourth quarter 2000 gross margin included certain adjustments related to changes in cost accounting estimates, totaling $3 million. These changes resulted in increased margins of 76.3% in the fourth quarter of 2001 compared to 67.3% in the fourth quarter of 2000 and 76.0% for the year ended December 31, 2001 compared to 75.6% for the year ended December 31, 2000.

      In the United States, the gross margin decreased as a result of a more aggressive promotional mix. In 2001, the U.S. sold less regular resale items and more promotional and non-resale items. In 2001, 53.3% of resale items sold were promotional products, compared to 45.0% in 2000. Regular resale items typically contribute a greater margin than promotional or non-resale items.

17


Table of Contents

      In Europe, gross margin in 2001 increased to approximately 79.2% compared to 76.6% in 2000 primarily due to the favorable impact of exchange rates on product costs.

      Selling, General and Administrative Expenses. SG&A expenses in 2001 increased to $232.9 million from $196.6 million in 2000, an increase of $36.3 million, or 18.5%. SG&A expenses as a percentage of net sales increased in 2001 to 62.0% from 61.2% in 2000.

      In Mexico, SG&A expenses as a percentage of net sales increased to 47.2% for 2001 compared to 43.3% in 2000. The primary factors for the increase in SG&A expenses as a percentage of net sales were sales promotional expenses, distribution costs and administrative expenses. Sales promotional expenses increased because there was additional promotional activity in 2001 in an effort to generate sales. Distribution costs increased proportionally more than sales due to the shipment of more small packages. Administrative expense increased primarily due to additional expenses related to reserves for uncollectible accounts receivable. Due to declining consultant liquidity, Mexico charged $7.7 million to bad debt expense during 2001, of which $3.8 million was charged during the fourth quarter.

      In the United States, SG&A, as a percentage of net sales, decreased to 62.4% from 63.3%. Selling expenses increased proportionally more than sales due to the implementation of the expanded e-commerce platform in 2001. In 2001, there was approximately $1.2 million of increased incremental e-commerce related expenses. The percentage increase in selling expenses is partially offset by a decrease in sales promotional expense and administrative expense, as a percentage of net sales. Expenditures on major events were scaled back, which resulted in a decrease in sales promotional expenses, and cost savings measures were employed in 2001 in an effort to reduce administrative expense.

      In Europe, SG&A expenses in 2001 decreased to 72.3% of net sales compared to 75.5% in 2000, primarily as a result of the Company’s repositioning and restructuring activities in Europe in the second half of 2000.

      Developing markets, particularly Brazil, incurred additional SG&A expenses in 2001 compared to 2000 due to the growing nature of the business and an increase in the allowance for bad debts as a result of declining consultant liquidity and economic difficulties. Corporate expenses increased $1.8 million because of increased compensation expenses in 2001, primarily related to bonuses, compared to 2000 and increased infrastructure expenses to support the growing business.

      Restructuring and Impairment Charges. There were no restructuring and impairment charges for 2001 compared to $2.6 million for 2000. In 2000, the Company recorded approximately $1.6 million of restructuring charges and approximately $1.0 million of asset impairment charges. The restructuring charges in 2000 related to the Company’s repositioning activities in Europe, and consisted primarily of severance costs. The asset impairment charges consisted of approximately $0.3 million related to the Company’s repositioning activities in Europe and approximately $0.7 million relating to the writedown of certain capitalized computer software costs in the United States. In 2000, the Company consolidated the sales support and administrative functions for Austria, Italy, and the Netherlands in Germany. Field sales personnel continue to perform sales and marketing functions in those locations. The Company closed its Poland operation, and began serving that territory through a distributor in 2001.

      Exchange Loss. The Company’s net foreign exchange loss in 2001 was $9.7 million compared to $11.7 million in 2000, a decrease in exchange loss of $2.0 million. The Company’s foreign exchange gains and losses primarily result from its operations in Mexico. The net exchange loss has three primary elements: gains or losses on forward currency contracts, unrealized and realized gains or losses on the remeasurement of U.S. dollar-denominated debt, and gains or losses on transactions denominated in foreign currencies.

      Effective January 1, 2001, the Company adopted SFAS No. 133, “Accounting for Derivative Instruments and Hedging Activities.” SFAS No. 133, as amended and interpreted, establishes accounting and reporting standards for derivative instruments and hedging activities and requires such instruments to be measured and recorded at fair value. The derivative instruments the Company utilized did not qualify for hedge accounting under applicable standards prior to adoption of SFAS No. 133, and accordingly such instruments were marked-to-market with gains and losses included as a component of exchange loss in the statement of operations for the year ended December 31, 2000. Under SFAS No. 133, certain derivative contracts do not

18


Table of Contents

qualify for hedge accounting and the resulting fair value is recorded as a component of exchange loss. Under SFAS No. 133, the Company’s use of forward contracts and option contracts to hedge certain forecasted transactions qualified for hedge accounting as of January 2001. Unrealized gains and losses from such derivative instruments are deferred as a separate component of other comprehensive income, and are recognized in income at the same time that the underlying hedged exposure is recognized in income. This accounting treatment results in the matching of gains and losses from certain forward exchange contracts with the corresponding gains and losses generated by the underlying hedged transaction.

      In 2001, the Company continued to use forward contracts to protect against potential devaluation of the Mexican peso by selling Mexican pesos and buying U.S. dollars. Throughout 2001, the forward currency contract pricing reflected the market’s expectation that the peso would devalue relative to the dollar. However, in 2001, the peso to U.S. dollar exchange rate strengthened, resulting in exchange losses of $12.2 million related to forward contracts. Upon implementation of SFAS 133 on January 1, 2001, the Company had certain forward contracts not designated as hedges. During 2001, the Company recognized foreign exchange losses totaling $11.4 million on certain forward contracts not designated as hedges under SFAS No. 133. As the Company utilized hedge accounting pursuant to SFAS No. 133 for forward contracts to hedge certain forecasted transactions, certain losses were deferred as a separate component of other comprehensive income and recognized in income at the same time that the underlying hedged exposure was recognized in income. During 2001, $5.5 million of losses were deferred and $0.8 million was recognized as a component of exchange loss and $1.0 million was recognized as cost of sales, resulting in $3.7 million of exchange losses deferred as a component of other comprehensive income at December 31, 2001. The contracts were remeasured each month and the fair value of the contracts was included in current liabilities. As the Mexican peso strengthened in 2001, the Company recognized $2.8 million of exchange gains on the remeasurement of U.S. dollar-denominated debt in 2001. Additionally, the Company recognized $0.3 million of net unrealized and realized exchange losses on other transactions denominated in foreign currencies.

      In 2000, the peso to U.S. dollar exchange rate was stable, resulting in $10.0 million of exchange losses on forward contracts. The remeasurement of U.S. dollar-denominated debt in 2000 resulted in an exchange loss of $0.7 million, as the peso weakened against the U.S. dollar at year-end. Net realized and unrealized losses on other foreign currency transactions were $0.6 million.

      Interest Expense. Interest expense decreased to $13.3 million in 2001 from $15.7 million in 2000, a decrease of $2.4 million, or 15.3%. The decrease was due to a lower debt balance, as total debt decreased approximately $15.9 million from 2000 to 2001, and lower average interest rates.

      Other Income (Expense). Other expense in 2001 was nominal compared to other income for 2000 of $1.6 million, which consisted primarily of income related to the recovery of the effect of inflation from a receivable due from the Mexican government related to taxes.

      Income Tax Expense. Income tax expense increased to $17.4 million in 2001 from $10.0 million in 2000, an increase of $7.4 million, or 74.0%. The increase in income tax expense is the result of increased income generated by the Company’s Mexico and U.S. subsidiaries in 2001 compared to 2000 and approximately $0.6 million of tax provision related to certain tax adjustments in Europe. In 2001, the Company’s effective income tax rate decreased to 52.5% from a 59.9% effective income tax rate in 2000. The decrease in the effective income tax rate was driven by taxable income generated by the Company’s European subsidiary in 2001, compared to a tax loss without any tax benefit in 2000. This decrease in the effective income tax rate was partially offset by higher effective income tax rates in the Company’s Mexico and U.S. subsidiaries.

      Net Income. Net income increased to $15.8 million in 2001 from $6.3 million in 2000, an increase of $9.5 million, or 150.8%. The increase was due to a $47.5 million increase in gross profit, a $2.6 million decrease in restructuring and impairment charges, a $2.0 million decrease in exchange loss, a $2.4 million decrease in interest expense, a $0.3 million decrease in extraordinary loss on early extinguishment of debt, net of tax, and a $0.1 million gain on the cumulative effect of accounting change, net of tax, partially offset by a $36.3 million increase in selling, general and administrative expenses, a $1.7 million decrease in other income (expense), and a $7.4 million increase in income tax expense.

19


Table of Contents

New Accounting Pronouncements

      In June 2001, the Financial Accounting Standards Board (“FASB”) approved two new statements: SFAS No. 141, “Business Combinations” and SFAS No. 142, “Goodwill and Other Intangible Assets.” SFAS No. 141 requires combinations entered into after June 30, 2001 to be accounted for using the purchase method of accounting. SFAS No. 142 requires that goodwill not be amortized, but be tested for impairment at least annually. SFAS No. 142 was effective for fiscal years beginning after December 15, 2001 to all goodwill and other intangible assets recognized in an entity’s statement of financial position at that date, regardless of when those assets were initially recognized. The Company adopted SFAS No. 142 on January 1, 2002. In accordance with such adoption, the Company identified all reporting units in conjunction with the provisions of SFAS No. 142 and allocated all goodwill accordingly. Prior to June 30, 2002, the Company completed the transitional goodwill impairment test required by SFAS No. 142. Due to general market uncertainty in Colombia, the Company revised its projections and recorded an impairment loss of $0.2 million associated with its Colombia reporting unit. The impairment loss has been recorded as a cumulative effect of accounting change in the accompanying consolidated statements of income. No other impairment was identified in connection with the annual impairment test. The changes in the carrying amount of goodwill for the year ended December 31, 2002 were as follows (in millions):

                                         
United All Consolidated
Goodwill States Mexico Europe Others Total






Balance as of December 31, 2001
  $ 32.2     $ 32.4     $ 5.9     $ 0.6     $ 71.1  
Translation effect
          (3.9 )     (0.6 )     (0.1 )     (4.6 )
Impairment losses
                      (0.2 )     (0.2 )
     
     
     
     
     
 
Balance as of December 31, 2002
  $ 32.2     $ 28.5     $ 5.3     $ 0.3     $ 66.3  
     
     
     
     
     
 

      The Company’s other intangible assets consist of trademarks. During the year ended December 31, 2002, the Company determined trademarks to have an indefinite life and performed the transitional impairment test as required under SFAS No. 142. Based upon the transitional and annual test, the Company determined that there was no impairment of trademarks. The carrying value of trademarks was $44.6 million as of December 31, 2002.

      In accordance with SFAS No. 142, the Company discontinued amortization of goodwill and other intangible assets with an indefinite life. A reconciliation of previously reported net income to amounts adjusted for the exclusion of goodwill and trademark amortization, net of the related income tax effects, where applicable, is as follows (in millions):

                         
Years Ended December 31,

2002 2001 2000



Net income
  $ 18.8     $ 15.8     $ 6.3  
Goodwill amortization, net of tax
          1.8       1.9  
Trademark amortization, net of tax
          0.8       0.9  
     
     
     
 
Adjusted net income
  $ 18.8     $ 18.4     $ 9.1  
     
     
     
 

      In November 2001, the Emerging Issues Task Force (“EITF”) issued EITF Issue No. 01-9, “Accounting for Consideration Given by a Vendor to a Customer or a Reseller of the Vendor’s Products.” This new guidance provides that consideration from a vendor to a reseller is generally presumed to be a reduction of the selling prices of the vendor’s products, and, therefore, should be characterized as a reduction of revenue when recognized in the vendor’s income statement. On January 1, 2002, the Company adopted EITF Issue No. 01-9 and reclassified commissions paid to consultants of $3.9 million and $3.4 million on their personal sales, previously reported as a component of selling, general and administrative expenses, as a reduction in net sales and selling, general and administrative expenses for the years ended December 31, 2001 and 2000, respectively.

20


Table of Contents

      On January 1, 2002, the Company adopted SFAS No. 144, “Accounting for the Impairment or Disposal of Long-Lived Assets.” SFAS No. 144 supersedes SFAS No. 121, “Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to be Disposed of.” SFAS No. 144 retains substantially all of the requirements of SFAS No. 121, while resolving certain implementation issues and addressing the accounting for a component of a business accounted for as a discontinued operation. SFAS No. 144 was adopted with no significant impact on the Company’s financial position or results of operations.

      In April 2002, the FASB issued SFAS No. 145, “Rescission of FASB Statements No. 4, 44, and 64, Amendment of FASB Statement No. 13, and Technical Corrections.” This Statement rescinds or modifies existing authoritative pronouncements including FASB Statement No. 4 “Reporting Gains and Losses from Extinguishment of Debt.” As a result of the issuance of SFAS No. 145, gains and losses from extinguishment of debt should be classified as extraordinary items only if they meet the criteria in Accounting Principles Board (“APB”) Opinion No. 30, “Reporting the Results of Operations-Reporting the Effects of Disposal of a Segment of a business, and Extraordinary, Unusual and Infrequently Occurring Events and Transactions.” Applying the provisions of APB Opinion No. 30 will distinguish transactions that are part of an entity’s recurring operations from those that are unusual or infrequent or that meet the criteria for classification as an extraordinary item. The provisions of this Statement related to the rescission of SFAS No. 4 shall be applied in fiscal years beginning after May 15, 2002. Any gain or loss on extinguishment of debt that was classified as an extraordinary item in prior periods presented that does not meet the criteria in APB Opinion No. 30 for classification as an extraordinary item shall be reclassified. The Company is currently evaluating the impact that this statement may have on any potential future extinguishments of debt. Upon adoption of SFAS No. 145, the Company will reclassify items previously reported as extraordinary items as a component of operating income on the accompanying consolidated statements of income.

      In June 2002, the FASB approved SFAS No. 146, “Accounting for Costs Associated with Exit or Disposal Activities.” This statement addresses financial accounting and reporting for costs associated with exit or disposal activities and nullifies EITF Issue No. 94-3, “Liability Recognition for Certain Employee Termination Benefits and Other Costs to Exit an Activity.” The provisions of this statement are effective for exit or disposal activities that are initiated after December 31, 2002, with early application encouraged. The Company is currently evaluating the impact that this statement may have on any potential future exit or disposal activities.

      During 2002, the FASB issued SFAS No. 148, “Accounting for Stock Based Compensation — Transaction and Disclosure, an amendment to FASB Statement No. 123.” This Statement requires more extensive disclosure, including interim disclosure, related to stock based compensation for all companies and permits additional transition methods for companies that elect to use the fair value method for employee stock compensation. This statement is effective for fiscal years ending after December 15, 2002. The Company adopted the disclosure requirements of SFAS No. 148.

Critical Accounting Policies and Estimates

      Management’s Discussion and Analysis of Financial Condition and Results of Operations are based on the Company’s consolidated financial statements, which have been prepared in conformity with accounting principles generally accepted in the United States of America. These principles require the appropriate application of certain accounting policies, many of which require management to make estimates and assumptions about future events and their impact on amounts reported in the Company’s consolidated financial statements and related notes. Since future events and their impact cannot be determined with certainty, the actual results may differ from management’s estimates. Such differences could be material to the consolidated financial statements.

      Management believes that the application of accounting policies, and the estimates inherently required therein, are reasonable. These accounting policies and estimates are constantly reevaluated, and adjustments are made when facts and circumstances dictate a change. Historically, the application of accounting policies has been appropriate, and actual results have not differed materially from those determined using necessary estimates.

21


Table of Contents

      The Company’s accounting policies are more fully described in Note 2 to the audited consolidated financial statements included in Item 8. “Financial Statements and Supplementary Data”. Certain critical accounting policies are described below.

      Accounts Receivable. The Company maintains an allowance for doubtful accounts for estimated losses resulting from the inability of consultants to make payments. An allowance is calculated based on historical experience and the age of the outstanding receivables. If the financial condition of consultants were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required.

      Inventory Obsolescence. The Company writes down its inventory to provide for estimated obsolete or unsalable inventory based on assumptions about future demand for its products. If future demand is less favorable than management’s assumptions, additional inventory write-downs may be required. Likewise, favorable future demand and market conditions could positively impact future operating results if inventory that has been written-down is sold.

      Foreign Currency Contracts. The Company enters into foreign currency forward and option contracts to reduce the effect of adverse exchange rate fluctuations in the exchange rate of the Mexican peso to the U.S. dollar. The Company places forward and option contracts based on its forecasted U.S. dollar cash outflows from Jafra S.A. over a rolling twelve-month period and does not hedge transactions that are not included in the twelve-month forecast on the date the forward or option contract is initiated. As a matter of policy, the Company does not hold or issue forward or option contracts for trading or speculative purposes nor does it enter into contracts or agreements containing “embedded” derivative features or involving leveraged derivatives. If the Mexican peso were to significantly strengthen during the year compared to the U.S. dollar, the Company may incur additional losses on option contracts open as of the balance sheet date. See Item 7A. “Quantitative and Qualitative Disclosures about Market Risk”.

      Contingencies. The Company accounts for contingencies in accordance with Statement of Financial Accounting Standards (“SFAS”) No. 5, “Accounting for Contingencies”. SFAS No. 5 requires that the Company record an estimated loss from a loss contingency when information available prior to issuance of the Company’s financial statements indicates that it is probable that an asset has been impaired or a liability has been incurred at the date of the financial statements and the amount of the loss can be reasonably estimated. Accounting for contingencies such as legal and income tax matters requires management to use judgment. Many of these legal and tax contingencies can take years to be resolved. Generally, as the time period increases over which the uncertainties are resolved, the likelihood of changes to the estimate of the ultimate outcome increases. Management believes that the accruals for these matters are adequate.

      Income Taxes. Deferred income tax assets have been established for net operating loss carryforwards of certain foreign subsidiaries and foreign tax credits originating in the United States, which are reduced by a valuation allowance. The net operating loss carryforwards expire in varying amounts over a future period of time. Realization of the income tax carryforwards are dependent on generating sufficient taxable income prior to expiration of the carryforwards. Although realization is not assured, management believes it is more likely than not that the net carrying value of the income tax carryforwards will be realized. The amount of the income tax carryforwards that is considered realizable, however, could change if estimates of future taxable income during the carryforward period are adjusted.

      Impairment of Long-Lived Assets and Goodwill. Long-lived assets are reviewed for impairment, based on undiscounted cash flows, whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. If this review indicates that the carrying amount of the long-lived assets is not recoverable, the Company will recognize an impairment loss, measured by the future discounted cash flow method. Goodwill is evaluated for impairment based on SFAS No. 142, “Goodwill and Other Intangible Assets”. SFAS No. 142 requires that goodwill not be amortized, but be tested for impairment annually.

22


Table of Contents

Liquidity and Capital Resources

      The Acquisition was consummated on April 30, 1998. As part of the financing for the Acquisition, $100.0 million of notes were issued, $41.5 million of borrowings were initially drawn down under the senior credit agreement ($25.0 million under the term loan facility and $16.5 million under the revolving credit facility), and $82.9 million of cash was contributed as an equity investment by CD&R Fund V, certain members of management, certain directors and other persons. The purchase price for the Jafra Business, after final adjustments determined in 1999, was approximately $212.4 million (excluding $12.0 million of financing fees and expenses), consisting of $202.5 million in cash and $9.9 million of Acquisition fees.

      The Company’s liquidity needs arise primarily from principal and interest payments under the notes, the term loan facility and the revolving credit facility. The notes represent several obligations of Jafra Cosmetics International, Inc. (“JCI”) and Jafra Cosmetics International, S.A. de C.V. (“Jafra S.A.”) in the initial amount of $60 million and $40 million (subsequently reduced in 1999 and 2000 by the repurchases), respectively, with each participating on a pro rata basis upon redemption. The notes mature in 2008 and bear a fixed interest rate of 11.75% payable semi-annually.

      Borrowings under the senior credit agreement are payable in quarterly installments of principal and interest through April 30, 2004. Scheduled term loan principal payments under the term loan facility will be approximately $5.9 million and $2.5 million for each of the years from 2003 through 2004, respectively. Borrowings under the revolving credit facility (zero as of December 31, 2002) mature on April 30, 2004. Borrowings under the senior credit agreement currently bear interest at an annual rate of LIBOR plus a margin of 1.625% or an alternate base rate (the higher of the prime rate or federal funds rate plus 0.5%, plus an applicable margin of 0.625%). The interest rate in effect at December 31, 2002 was approximately 3.1% for the LIBOR-based borrowings. At December 31, 2002, the Company did not have any prime-based borrowings. If the Company had prime-based borrowings at December 31, 2002, the rate would have been approximately 4.9%. Borrowings under the senior credit agreement are secured by substantially all of the assets of JCI and Jafra S.A. Interest expense in 2002 was $11.4 million, including approximately $1.4 million of non-cash amortization of deferred financing fees. During 2002, cash paid for interest was approximately $10.2 million.

      Both the Indenture, dated as of April 30, 1998, under which the notes were issued, and the senior credit agreement contain certain covenants that limit the Company’s ability to incur additional indebtedness, pay cash dividends and make certain other payments. The Indenture and the senior credit agreement also require the Company to maintain certain financial ratios including a minimum EBITDA to cash interest expense coverage ratio and a maximum debt to EBITDA ratio. At December 31, 2002, the Company was in compliance with all covenants. As of December 31, 2002, the Company had irrevocable standby letters of credit outstanding totaling $2.8 million.

      The notes are unsecured and are generally non-callable for five years from the date of issuance. Thereafter, the notes will be callable at premiums declining to par in the eighth year.

      Consents and waivers, dated June 30, 2001 and November 19, 1999, to the senior credit agreement allow the Company to repurchase the notes in the open market from time to time, with the aggregate purchase prices for all such notes repurchased not to exceed $50.0 million. Aggregate repurchases as of December 31, 2002 were $24.8 million.

      As of December 31, 2002, the Company had outstanding $84.4 million of debt, consisting of approximately $75.2 million (face amount) of notes, $8.4 million of term loans due under the credit agreement, and $0.8 million of foreign bank borrowings.

      During the year ended December 31, 2001, Jafra S.A. repaid the balance remaining under a one-year term originally due on August 16, 2001, and entered into an unsecured foreign bank loan agreement. Under this agreement, Jafra S.A. had the peso equivalent of $0.8 million at a weighted average fixed interest rate of 18.5% outstanding at December 31, 2002. Principal and interest payments are due monthly through January 25, 2005.

23


Table of Contents

      The following schedule details the payment schedule for debt and lease obligations as of December 31, 2002:

Payments Due by Period

As of December 31, 2002
                                         
Contractual Obligations Total 2003 2004 - 2005 2006 - 2007 Thereafter






(Dollars in thousands)
11 3/4% senior subordinated notes due 2008
  $ 75,180     $     $     $     $ 75,180  
Term loan
    8,375       5,875       2,500              
Unsecured foreign bank loan agreement
    828       614       214              
Lease obligations
  $ 18,848     $ 3,481     $ 7,663     $ 7,177     $ 167  

      The Company believes, but no assurance can be given, that its existing cash, cash flow from operations and availability under the senior credit agreement will provide sufficient liquidity to meet the Company’s cash requirements and working capital needs over the next year. The Company has experienced reduced consultant liquidity in certain foreign subsidiaries. Reduced consultant liquidity could result in future reduced cash flows from operations, which may require the Company to use available funds under the Senior Credit Agreement.

Outsourcing of Manufacturing Functions

      The Company entered into a manufacturing agreement, dated as of June 10, 1999, with a third-party contractor (the “contractor’). Subject to the terms and conditions of the manufacturing agreement, the contractor has agreed to manufacture all of the Company’s requirements for certain cosmetic and skin care products for an initial term of five years expiring in 2004. Following the expiration of the initial five-year term, the manufacturing agreement will be automatically extended for additional one-year terms unless terminated by six months’ prior written notice by either party. The manufacturing agreement provides for price renegotiations by the contractor if the Company’s quarterly or annual purchase volume falls below specified minimums. The manufacturing agreement requires the contractor to maintain insurance to cover costs associated with any product liability or product recall caused by the acts or omissions of the contractor. In addition, the Company is obligated to purchase materials acquired by the contractor based upon product forecasts provided by the Company if the contractor is unable to sell such materials to a third party. There have been no such repurchases to date. The contractor is solely responsible for obtaining the inventories, manufacturing the inventories at its current location in Chino, California, complying with applicable laws and regulations, and performing quality assurance functions.

      During the fourth quarter of 2000, the contractor obtained $1.0 million of advances from the Company in exchange for an unsecured promissory note. The note bears interest at an annual rate of 9% and is payable in monthly installments commencing on February 15, 2001. On April 15, 2002, the unsecured promissory note was amended to advance an additional $0.3 million to the contractor. At December 31, 2002, approximately $0.1 million of the note was outstanding and was included in receivables in the accompanying consolidated balance sheets.

Restructuring Activities

      During 2001, the Company paid out approximately $1.0 million in charges related to year 2000 repositioning activities in Europe consisting primarily of severance costs. During 2002, the remaining $0.2 million was paid out against the remaining accrual.

Cash Flows

      Net cash provided by operating activities was $43.1 million in 2002, consisting of $48.0 million provided by net income adjusted for depreciation, and other non-cash items included in net income, less $4.9 million used in changes in operating assets and liabilities. The significant elements of the net cash used in changes in

24


Table of Contents

operating assets and liabilities were a $14.3 million increase in accounts receivable, partially offset by $5.7 million increase in prepaid expenses and other current assets, and $1.8 million increase in other non current assets. Net cash provided by operating activities was $30.1 million in 2001, consisting of $36.8 million provided by net income adjusted for depreciation, amortization, and other non-cash items included in net income, less $6.7 million used in changes in operating assets and liabilities. The significant elements of the net cash used in changes in operating assets and liabilities in 2001 were a $15.8 million increase in accounts receivable and a $1.0 million decrease in accounts payable and accrued liabilities, partially offset by a reduction of $2.8 million in prepaid expenses and other current assets and a $7.4 million increase in income tax payable/prepaid.

      Net cash used in investing activities was $11.3 million in 2002, compared to $11.7 million in 2001, a decrease of $0.4 million. In 2002, investing activities consisted primarily of capital expenditures of $11.0 million, primarily in the Company’s United States and Mexico subsidiaries. A significant portion of the 2002 capital expenditures related to information technology and production equipment. In 2001, investing activities consisted primarily of capital expenditures of $4.5 million in the Company’s U.S. subsidiary, $6.0 million in the Company’s Mexico subsidiaries, and $0.9 million in other subsidiaries.

      Capital expenditures in 2003 are expected to be approximately $13.0 million, comprised of approximately $4.5 million of information technology expenditures and $5.9 million of production equipment expenditures. These capital expenditures will be funded by cash from operations or borrowings under the revolving credit facility.

      Net cash used in financing activities was $8.7 million in 2002 compared to $16.6 million in 2001, a decrease of $7.9 million. In 2002, the Company made net repayments of $6.1 million under the term loan facility, $1.8 million under the revolving credit facility and $0.8 million repayment of the foreign bank debt. In 2001, the Company made net repayments of $12.7 million under the existing revolving credit facility and $4.5 million under the existing term loan facility and paid $0.8 million for the repurchase of common stock. In 2001, the cash used in financing activities was partially offset by net proceeds of $1.3 million from an unsecured foreign bank loan agreement at Jafra S.A.

      The effect of exchange rate changes on cash was $2.6 million in 2002 compared to $1.0 million for 2001 relating to fluctuations in the exchange rate of the Mexican peso and South American currencies, primarily the Brazilian real and the Argentine peso.

Foreign Operations

      Net sales outside of the United States aggregated 76%, 79% and 77% of the Company’s total net sales for the fiscal years 2002, 2001 and 2000, respectively. In addition, as of December 31, 2002, international subsidiaries comprised approximately 71% of the Company’s consolidated total assets. Accordingly, the Company has experienced and continues to be exposed to foreign exchange risk. The Company has implemented a hedging program to protect against potential devaluation of the Mexican peso. See Item 7A. “Quantitative and Qualitative Disclosures About Market Risk”.

      The Company’s subsidiary in Mexico, Jafra S.A. generated approximately 64% of the Company’s net sales for 2002 compared to 66% for 2001, substantially all of which was denominated in Mexican pesos. During 2002, the peso weakened against the U.S. dollar. Net sales in Mexico for 2002 would have increased $9.4 million, or 3.7%, from the reported amounts if average exchange rates in 2002 remained the same as in 2001.

      Mexico has experienced periods of high inflation in the past and has been considered a hyperinflationary economy. As of January 1, 1999, the Company has accounted for its Mexican operations using the peso as its functional currency. Because the functional currency in Mexico is the Mexican peso, gains and losses of remeasuring debt to the U.S. dollar from the peso are included as a component of net income. In 2002, the remeasurement of U.S. dollar-denominated debt resulted in an exchange loss of $5.2 million, most of which was unrealized. Jafra S.A. had $32.4 million of U.S. dollar-denominated third-party debt and $21.9 million of U.S. dollar-denominated intercompany current payables as of December 31, 2002.

25


Table of Contents

      The Company is also exposed to foreign exchange risk due to its operations in South America. During 2002, most South American currencies devalued against the U.S. dollar. Measured in U.S. dollars, South America sales decreased 11% in 2002 compared to 2001. If currencies remained stable between 2002 and 2001, South America net sales would have increased 16%.

European Economic and Monetary Union

      On January 1, 1999, eleven of the fifteen member countries of the European Union established fixed conversion rates between their existing sovereign currencies and the euro. The participating countries adopted the euro as their common legal currency on that date. The euro traded on currency exchanges and was available for non-cash transactions during the transition period between January 1, 1999 and January 1, 2002. During this transition period, the existing currencies remained legal tender in the participating countries as denominations of the euro and public and private parties paid for goods and services using either the euro or the participating countries’ existing currencies.

      During the transition period, the Company utilized the respective country’s existing currency as the functional currency. During 2001, the Company modified its current systems to achieve a euro compliant system. The system modifications were conducted without significant cost and did not have any adverse affects on the business or operations. Effective January 1, 2002, the Company adopted the euro as its functional currency for its European subsidiaries, except for Switzerland, without any material adverse affects on the business or operations.

Business Trends and Initiatives

      The Company has experienced sales growth in Mexico, due primarily to increases in the number of consultants. Additionally, the Mexico subsidiary contributes a significant portion of the Company’s consolidated net sales. In 2002, the Company’s Mexican subsidiary generated 64% of the Company’s consolidated net sales, compared to 66% in 2001 and 62% in 2000. In local currency, net sales growth was 5% in 2002, compared to 22% in 2001. The Mexico peso devalued 13% between December 31, 2001 and December 31, 2002. The weakening of the Mexico peso during 2002 resulted in 2% net sales growth measured in US dollars compared to 5% sales growth measured in local currency in 2002.

      The Company’s U.S. subsidiary has experienced significant sales growth in the past two years. In 2000, the U.S. subsidiary employed a strategy to bifurcate its operations into two distinct divisions, the Hispanic Division and the General Division. The two distinct divisions allow management to tailor programs and product offerings to meet the needs of each division. In 2002, the U.S. subsidiary also initiated certain program changes to focus on consultant productivity. The U.S. subsidiary contributed 24% to total 2002 net sales. U.S. net sales increased 16% in 2002, compared to 7% in 2001 and 1% in 2000.

      Due to the favorable exchange rate impact, net sales in Europe for 2002 increased 2% compared to net sales in 2001. In local currencies, European net sales decreased in 2002 compared to 2001. Except for the favorable impact of exchange in 2002, European net sales have declined over the past three years. Europe has also experienced declines in both the number and productivity of consultants (except for the favorable impact of exchange on 2002 productivity). European sales have declined from approximately 11% of the Company’s business in 1999 to approximately 7% of the Company’s business in 2002. The Company is also considering certain plans to minimize losses in the European markets, which may include exiting some or all of the European markets through sale or discontinuation of operations.

      Since 1999, the Company has made significant investments in new markets in South America. During 2002, South American countries in which the Company operates faced challenging macroeconomic environments. The South American operations were unfavorably impacted by exchange rates in 2002 compared to

26


Table of Contents

2001. Net sales in South America decreased 11% measured in U.S. dollars, but increased 16% measured in local currencies in 2002 compared to 2001. The Company’s Brazilian subsidiary’s net sales measured in U.S. dollars increased 11% and measured in local currency increased 40% in 2002 compared to 2001. The Company is considering certain plans to minimize losses in the South American markets, which may include exiting some or all of the South American markets through sale or discontinuation of operations.

Information Concerning Forward-Looking Statements

      This Form 10-K may contain forward-looking statements which include assumptions about future market conditions, operations and results. These statements are based on current expectations and are subject to risks and uncertainties. They are made pursuant to safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Among those forward-looking statements, are, without limitation, (i) the statements in “Business — Strategy” concerning (a) the Company’s belief that its market position and distribution network of approximately 269,000 consultants in Mexico positions the Company to continue to grow the business by capturing additional market share, (b) the Company’s belief that in the General Division the Company will to continue to leverage e-commerce capabilities, (c) the Company’s belief that in the Hispanic Division the Company will continue to leverage its market position in Mexico in areas of training, recruitment and marketing, (d) the Company’s intent to continue to stimulate sales and new consultant recruitment efforts through recognition events, incentives, gifts and free travel for consultants, (e) the Company’s belief that new product introductions are fundamental to the Company’s direct selling business model in that they serve to motivate consultants and give them new and exciting products to demonstrate and market to their clients (f) the Company’s belief that its direct selling business model will continue to generate significant organic growth, (g) the Company may consider plans to exit certain non-core markets, in Thailand, and some or all of South America and Europe through either a sale or discontinuation of their operations; (ii) the statements in “Business — Products” concerning (a) the Company’s plan to launch new products that address skin pigmentation in 2003, (b) the Company’s consideration of expanding its product line to include nutritional and wellness products (iii) the statements in “Business — Independent Sales Force” that the Company believes that public recognition of sales accomplishments serves the dual purpose of identifying successful role models and boosting consultant morale, (iv) the statements in “Business — International Operations” that the Company may consider plans to exit certain non-core markets, including Thailand and some or all of South America and Europe through either a sale or discontinuation of their operations; (v) the statement in “Business — Manufacturing” that finished goods and raw materials used in the Company’s products generally are available or can be obtained to Company specifications from more than one potential supplier; (vi) the statement in “Business — Distribution” that management believes its facilities are adequate to meet demand in its existing markets for the foreseeable future; (vi) the statements in “Business — Competition” that the Company believes that the senior management team with a strong direct selling track record, motivated direct sales force, prestige quality product lines, product development capabilities, geographic diversification, short delivery cycle, and manufacturing technology are significant factors in establishing and maintaining its competitive position; (vii) “Business — Management Information Systems” concerning (a) the Company’s expectation that waves two and three, which relate to the order entry and remaining commercial systems, will be implemented in the second quarter of 2003, (b) the Company’s anticipation that this new system may be leveraged to improve computer operations in Mexico, Puerto Rico and the Dominican Republic during 2004; (viii) the statement in “Business — Environmental Matters” that the Company believes that environmental laws and regulations will not have a material adverse effect on its capital expenditures, earnings or competitive position; (ix) other statements as to management’s or the Company’s expectations, intentions and beliefs presented in “Business”; (x) the statement in “Properties” that the Company’s properties are suitable to meet its anticipated requirements; (xi) the statement in “Legal Proceedings” that the Company believes that the resolution of the routine legal matters in which it is involved will not have a material adverse effect on the Company’s business, financial condition or results of operations; (xii) the statement in “— Market for Registrant’s Common Equity and Related Stockholder Matters” that the Parent does not expect to pay for the foreseeable future, regular dividends on shares of its Common Stock; (xiii) the statement in “— Critical

27


Table of Contents

Accounting Policies and Estimates” concerning; (a) management’s belief that the application of accounting policies, and estimates inherently required therein, are reasonable; (b) management’s belief that the accruals for contingencies are adequate; (c) management’s belief that it is more likely than not that the net carrying value of the income tax carryforwards will be realized; (xiv) the statement in “— Liquidity and Capital Resources” (a) that the Company believes that it will have sufficient liquidity to meet its cash requirements and working capital needs over the next year; (b) reduced consultant liquidity could result in future reduced cash flows from operations, which may require the Company to use available funds under the Senior Credit Agreement; (xv) the statement in “— Cash Flows” that the Company expects capital expenditures in 2003 to be approximately $13.0 million, (xvi) the statements in “— Business Trends and Initiatives” (a) that the Company is considering certain plans to minimize losses in the European markets, which may include exiting some or all of the European markets through sale or discontinuation of operations and (b) that the Company is considering certain plans to minimize losses in the South American markets, which may include exiting some or all of the South American markets through sale or discontinuation of operations; (xvii) other statements as to management’s or the Company’s expectations or beliefs presented in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

      Forward-looking statements are based upon management’s current expectations and beliefs concerning future developments and their potential effects upon the Company. There can be no assurance that future developments will be in accordance with management’s expectations or that the effect of future developments on the Company will be those anticipated by management. The following important factors, and those important factors described elsewhere in this report (including, without limitation, those discussed in “Business — Strategy,” “— International Operations,” “— Distribution,” “— Manufacturing,” “— Management Information Systems,” “— Environmental Matters,” “Properties,” “Legal Proceedings” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Results of Operations,” “— New Accounting Pronouncements,” “Critical Accounting Policies and Estimates,” “— Liquidity and Capital Resources,” “— Foreign Operations,” “— European Economic and Monetary Union” and “— Business Trends and Initiatives”), or in other Securities and Exchange Commission filings, could affect (and in some cases have affected) the Company’s actual results and could cause such results to differ materially from estimates or expectations reflected in such forward-looking statements:

  •  The Company’s high degree of leverage could have important consequences to the Company, including but not limited to the following: (i) the Company’s ability to obtain additional financing for working capital, capital expenditures, acquisitions, general corporate purposes or other purposes may be impaired in the future; (ii) a substantial portion of the Company’s cash flow from operations must be dedicated to the payment of principal and interest on its indebtedness, thereby reducing the funds available to the Company for other purposes; (iii) certain of the Company’s borrowings will be at variable rates of interest, which could cause the Company to be vulnerable to increases in interest rates and (iv) the Company may be more vulnerable to economic downturns and be limited in its ability to withstand competitive pressures.
 
  •  The Company’s ability to make scheduled payments or to refinance its obligations with respect to its indebtedness, and to comply with the covenants and restrictions contained in the instruments governing such indebtedness, will depend on its financial and operating performance, which, in turn, is subject to prevailing economic and competitive conditions and to certain financial, business and other factors beyond its control, including operating difficulties, increased operating costs, market cyclicality, product prices, the response of competitors, regulatory developments, and delays in implementing strategic projects.
 
  •  The Company’s ability to meet its debt service and other obligations will depend in significant part on the extent to which the Company can successfully implement its business strategy. The components of

28


Table of Contents

  the Company’s strategy are subject to significant business, economic and competitive uncertainties and contingencies, many of which are beyond the control of the Company.
 
  •  The Company’s ability to conduct and expand its business outside the United States and the amount of revenues derived from foreign markets are subject to the risks inherent in international operations. The Company’s international operations may be adversely affected by import duties or other legal restrictions on imports, currency exchange control regulations, fluctuations in currency exchange rates, transfer pricing regulations, the possibility of hyperinflationary conditions and potentially adverse tax consequences, among other things. Given the balance of payment deficits and shortages in foreign exchange reserves that many such economies, including the Mexican economy, have suffered in recent years, there can be no assurance that the governments of nations in which the Company operates, or intends to expand, will not take actions that materially adversely affect the Company and its business.
 
  •  The direct selling cosmetics and personal care products business is highly competitive. A number of the Company’s competitors, including Avon and Mary Kay, are significantly larger and have substantially greater resources and less leverage than the Company, which may provide them with greater flexibility to respond to changing business and economic conditions than the Company. An increase in the amount of competition faced by the Company, or the inability of the Company to compete successfully, could have a material adverse effect on the Company’s business, financial condition and results of operations.
 
  •  The Company’s ability to anticipate changes in market and industry trends and to successfully develop and introduce new and enhanced products on a timely basis will be a critical factor in its ability to grow and to remain competitive. There can be no assurance that new products and product enhancements will be completed on a timely basis or will enjoy market acceptance following their introduction. In addition, the anticipated development schedules for new or improved products are inherently difficult to predict and are subject to delay or change as a result of shifting priorities in response to customers’ requirements and competitors’ new product introductions.
 
  •  The Company is subject to or affected by governmental regulations concerning, among other things, (i) product formulation, (ii) product claims and advertising, whether made by the Company or its consultants, (iii) fair trade and distributor practices and (iv) environmental, health and safety matters. In addition, new regulations could be adopted or any of the existing regulations could be changed at any time in a manner that could have a material adverse effect on the Company’s business and results of operations. Present or future health or safety or food and drug regulations could delay or prevent the introductions of new products into a given country or marketplace or suspend or prohibit the sale of existing products in such country or marketplace. The Company believes that it is in compliance in all material respects with such laws and regulations now in effect.

      While the Company periodically reassesses material trends and uncertainties affecting the Company’s results of operations and financial condition in connection with its preparation of management’s discussion and analysis of results of operations and financial condition contained in its quarterly and annual reports, the Company does not intend to review or revise any particular forward-looking statement referenced in this report in light of future events.

Item 7A.     Quantitative and Qualitative Disclosures About Market Risk

      The Company is exposed to certain market risks arising from transactions in the normal course of its business, and from debt incurred in connection with the Acquisition. Such risk is principally associated with interest rate and foreign exchange fluctuations, as well as changes in the Company’s credit standing.

Interest Rate Risk

      The Company has U.S. dollar-denominated debt obligations in both the United States and Mexico that have fixed and variable interest rates and mature on various dates. The Company also has Mexican peso

29


Table of Contents

denominated-debt obligations in Mexico that have fixed interest rates and mature on various dates. The tables below present principal cash flows and related interest rates by fiscal year of maturity:

Debt Obligation Information at December 31, 2002

(Amounts in U.S. dollars in 000’s)
                                                                   
Expected Year of Maturity Fair Value

December 31,
2003 2004 2005 2006 2007 Thereafter Total 2002(1)








Senior subordinated notes, term loan, revolving credit facility
and unsecured bank debt,
                                                               
 
Fixed rate (US$)
  $ 614     $ 214     $     $     $     $ 75,180     $ 76,008     $ 77,888  
 
Average Interest Rate
    18.47 %     18.47 %                       11.75 %                
 
Variable Rate (US$)
  $ 5,875     $ 2,500     $     $     $     $     $ 8,375     $ 8,375  
 
Average Interest Rate
    3.1 %     3.1 %                                        

Debt Obligation Information at December 31, 2001

(Amounts in U.S. dollars in 000’s)
                                                                   
Expected Year of Maturity Fair Value

December 31,
2002 2003 2004 2005 2006 Thereafter Total 2001(1)








Senior subordinated notes, term loan, revolving credit facility and unsecured bank debt
                                                               
 
Fixed Rate (US$)
  $ 688     $ 688     $ 233     $     $     $ 75,180     $ 76,789     $ 82,052  
 
Average Interest Rate
    18.66 %     18.66 %     18.66 %                 11.75 %                
 
Variable Rate (US$)
  $ 5,500     $ 6,500     $ 4,300     $     $     $     $ 16,300     $ 16,300  
 
Average Interest Rate
    4.25 %     4.25 %     4.72 %                                  


(1)  The Company’s estimate of the fair value of its senior subordinated notes was based on discussions with one of the Company’s largest bondholders, and an analysis of current market interest rates and the Company’s credit rating. The Company’s revolving credit facilities and the term loan are variable rate debt, and the interest rate spread paid by the Company is adjusted for changes in certain financial ratios of the Company. The fair value of the revolving credit facilities, the term loan and the unsecured bank agreement approximated their carrying amounts at December 31, 2002 and 2001.

      As of December 31, 2002, the Company had $8.4 million of variable interest rate debt outstanding. If variable interest rates had increased by 10%, the Company would have incurred $0.1 million of additional interest expense during 2002.

Foreign Currency Risk

      The Company operates globally, with manufacturing facilities in Mexico and distribution facilities in various locations around the world. With the exception of most intercompany product sales between European subsidiaries, all intercompany product sales are denominated in U.S. dollars, as are some expenses, including interest payments with respect to almost all of its outstanding indebtedness. In addition, 76% of the Company’s 2002 revenue was generated in countries with a functional currency other than the U.S. dollar. As a result, the Company’s earnings and cash flows are exposed to fluctuations in foreign currency exchange rates.

      As part of its overall strategy to reduce the risk of adverse exchange rate fluctuations in Mexico, the Company entered into foreign currency exchange contracts. Prior to March 2002, the Company purchased forward exchange contracts (“forward contracts” or “forwards”) to hedge its foreign currency exposures to the Mexican peso. In March 2002, in accordance with previously approved policies, the Company modified its hedging program to include the use of foreign currency option contracts (“option contracts” or “options”). In order to offset its current outstanding forward contracts to sell Mexican pesos, the Company entered into forward contracts to buy Mexican pesos. Also, on that date, the Company entered into a series of U.S. dollar

30


Table of Contents

option contracts. The exchange rate at which the option contracts may be exercised is based upon the market rate at the time the contracts are placed. The Company purchased exchange rate put options, which gives the Company the right, but not the obligation, to sell Mexican pesos at a specified U.S. dollar exchange rate (“strike rate”). These contracts provide protection in the event the Mexican peso weakens beyond the option strike rate. In conjunction with the put options, and as part of a zero-cost option collar structure, the Company sold Mexican peso call options, which gives the counterparty the right, but not the obligation, to buy Mexican pesos from the Company at a specified strike rate. The effect of these call options would be to limit the benefit the Company would otherwise derive from the strengthening of the Mexican peso beyond the strike rate. As the volatility of the U.S. dollar/ Mexican peso exchange rate increased throughout 2002, the scope of the company’s unhedged currency risk has been increasing. Currently, the hedging contracts the Company is acquiring, which expire in early 2004, protect it only against 27% or greater devaluation in the Mexican peso, a range that tends to expand with increased volatility in the U.S. dollar/ Mexican peso rate such as has occurred during 2002. Consequently, the existing zero-cost collars will not protect the Company against (i) fluctuations in exchange rates within this expanding range or (ii) against a prolonged, gradual decline in the value of the Mexican peso against the U.S. dollar.

      The Company places forward contracts and option contracts based on forecasted U.S. dollar cash outflows from Jafra S.A. over a rolling twelve-month period and does not hedge transactions that are not included in the twelve-month forecast on the date the forward contract is initiated. As a matter of policy, the Company does not hold or issue forward contracts or option contracts for trading or speculative purposes, nor does it enter into contracts or agreements containing “embedded” derivative features nor is the Company a party to leveraged derivatives. The Company regularly monitors its foreign currency exposures and ensures that contract amounts do not exceed the amounts of the underlying exposures. In addition, as the Company generally purchases hedging instruments on a rolling twelve-month basis, there can be no assurance that instruments protecting it to the same or a similar extent will be available in the future on reasonable terms, if at all. Unprotected declines in the value of the Mexican peso against the U.S. dollar will adversely affect the Company’s ability to pay its dollar-denominated expenses.

      Prior to adoption of SFAS No. 133, the forward contracts the Company utilized did not qualify for hedge accounting under the applicable accounting standards, and accordingly such instruments were marked-to-market with gains and losses included as a component of exchange loss in the statements of income for the year ended December 31, 2000. However, under SFAS No. 133, the Company’s use of forward and option contracts to hedge certain forecasted transactions does qualify for hedge accounting. Gains and losses from such derivative instruments arising subsequent to January 1, 2001 are deferred as a separate component of other comprehensive loss, and are recognized in income at the same time that the underlying hedged exposure is recognized in income. This accounting treatment results in the matching of gains and losses from such forward and option contracts with the corresponding gains and losses generated by the underlying hedged transactions. Under SFAS No. 133, certain of the Company’s forward and option contracts do not qualify for hedge accounting and, therefore, are remeasured based on fair value, with gains and losses included as a component of net income. As of December 31, 2002, the Company had no outstanding forward contracts. As of December 31, 2002, the fair value of the option contracts is included in other receivables in current assets in the accompanying consolidated balance sheets.

      The outstanding foreign currency option contracts had a notional value denominated in Mexican pesos of $523,000,000 in put and call positions at December 31, 2002 and mature at various dates through December 31, 2003. The outstanding foreign currency forward contracts had notional values denominated in Mexican pesos of $688,873,000 at December 31, 2001 and matured in 2002. Notional amounts do not quantify the Company’s market or credit exposure or represent the Company’s assets or liabilities, but are used in the calculation of cash settlements under the contracts.

31


Table of Contents

      The following table provides information about the details of the Company’s option contracts as of December 31, 2002 (in thousands):

                                 
Coverage in
Mexican Average Strike Fair Value in
Foreign Currency Pesos Price U.S. Dollars(1) Maturity Date





At December, 2002:
                               
Purchased puts (Company may sell peso/buy USD)
                               
Mexican peso
  $ 149,000       10.31-10.48     $ (113 )     Jan.-Mar. 2003  
Mexican peso
    100,000       11.05-12.19       77       Apr.-June 2003  
Mexican peso
    150,000       11.76-12.79       131       July-Aug 2003  
Mexican peso
    124,000       12.51-12.91       21       Oct.-Dec. 2003  
     
             
         
    $ 523,000             $ 116          
     
             
         
Written calls (Counterparty may buy peso/sell USD)
                               
Mexican peso
  $ 149,000       9.01-9.02     $ (207 )     Jan.-Mar. 2003  
Mexican peso
    100,000       9.50-9.84       (144 )     Apr.-June 2003  
Mexican peso
    150,000       9.69-10.19       (112 )     July-Aug 2003  
Mexican peso
    124,000       10.15-10.19       (55 )     Oct.-Dec. 2003  
     
             
         
    $ 523,000             $ (518 )        
     
             
         

(1)  The Fair Value of the option contracts presented above, an unrealized loss of $402,000 at December 31, 2002, represents the carrying value and was recorded in other receivables in the consolidated balance sheets.

      The tables below describe the forward contracts that were outstanding at December 31, 2001 (in thousands):

December 31, 2001:

                                 
Forward Position Weighted
In Mexican Maturity Average Fair Value in
Foreign Currency Pesos(1) Date Contract Rate U.S. Dollars(1)





Buy US dollar/sell Mexican peso
  $ 108,715       1/31/02       10.19     $ 1,128  
Sell Mexican peso/buy US dollar
    (20,000 )     1/31/02       9.35       (34 )
Buy US dollar/sell Mexican peso
    71,787       2/28/02       10.26       756  
Sell Mexican peso/buy US dollar
    (20,000 )     2/28/02       9.47       (48 )
Buy US dollar/sell Mexican peso
    94,371       3/27/02       10.46       1,102  
Sell Mexican peso/buy US dollar
    (40,000 )     3/27/02       9.48       (80 )
Buy US dollar/sell Mexican peso
    85,000       4/30/02       10.23       748  
Sell Mexican peso/buy US dollar
    (30,000 )     4/30/02       9.62       (84 )
Buy US dollar/sell Mexican peso
    81,000       5/31/02       10.11       559  
Sell Mexican peso/buy US dollar
    (25,000 )     5/31/02       9.71       (75 )
Buy US dollar/sell Mexican peso
    80,000       6/28/02       9.95       375  
Sell Mexican peso/buy US dollar
    (30,000 )     6/28/02       9.78       (88 )
Buy US dollar/sell Mexican peso
    48,000       7/31/02       10.07       242  
Buy US dollar/sell Mexican peso
    100,000       8/30/02       10.05       410  
Buy US dollar/sell Mexican peso
    45,000       9/30/02       10.09       169  
Buy US dollar/sell Mexican peso
    110,000       10/31/02       10.09       338  
Buy US dollar/sell Mexican peso
    30,000       11/29/02       10.27       122  
     
                     
 
    $ 688,873                     $ 5,540  
     
                     
 

(1)  The Fair Value of the forward positions presented above, an unrealized loss of $5,540,000 at December 31, 2001 represents the carrying value of the forward contracts and was recorded in accrued liabilities in the accompanying consolidated balance sheets.

32


Table of Contents

      Prior to entering into foreign currency hedging contracts, the Company evaluates the counter parties’ credit ratings. Credit risk represents the accounting loss that would be recognized at the reporting date if counter parties failed to perform as contracted. The Company does not currently anticipate non-performance by such counter parties.

      Based upon the outstanding option contracts at December 31, 2002, if the peso to U.S. dollar exchange rate strengthened by 10%, a $2.5 million foreign currency loss on the settlement of option contracts would result. However, gains would be realized on the Company’s underlying hedged transactions.

      The Company’s Mexican subsidiary, Jafra S.A. had U.S. dollar-denominated debt of $32.4 million and $35.6 million at December 31, 2002 and 2001, respectively. During 2002, the value of the peso to the U.S. dollar decreased by 13.5%, and Jafra S.A. incurred a $5.2 million foreign currency transaction loss related to the remeasurement and repayment of U.S. dollar-denominated debt.

      Based upon the $32.4 million of outstanding debt at December 31, 2002, a 10% decline in the peso to U.S. dollar exchange rate would result in a $3.2 million foreign currency exchange loss.

33


Table of Contents

Item 8. Financial Statements and Supplementary Data

INDEX TO FINANCIAL STATEMENTS AND FINANCIAL STATEMENT SCHEDULES*

           
Page

Consolidated Financial Statements — CDRJ Investments (Lux) S.A. and Subsidiaries
       
 
Independent Auditors’ Reports
    35  
 
Consolidated Balance Sheets — As of December 31, 2002 and 2001
    37  
 
Consolidated Statements of Income — For the years ended December 31, 2002 , 2001 and 2000
    38  
 
Consolidated Statements of Stockholders’ Equity — For the years ended December 31, 2002, 2001 and 2000
    39  
 
Consolidated Statements of Cash Flows — For the years ended December 31, 2002, 2001 and 2000
    40  
 
Notes to Consolidated Financial Statements
    41  
 
Consolidated Financial Statements — Jafra Cosmetics International, Inc. and Subsidiaries
       
 
Independent Auditors’ Reports
    63  
 
Consolidated Balance Sheets — As of December 31, 2002 and 2001
    65  
 
Consolidated Statements of Income — For the years ended December 31, 2002, 2001 and 2000
    66  
 
Consolidated Statements of Stockholder’s Equity — For the years ended December 31, 2002, 2001 and 2000
    67  
 
Consolidated Statements of Cash Flows — For the years ended December 31, 2002, 2001 and 2000
    68  
 
Notes to Consolidated Financial Statements
    69  
 
Consolidated Financial Statements — Jafra Cosmetics International, S.A. de C.V. and Subsidiaries
       
 
Independent Auditors’ Reports
    86  
 
Consolidated Balance Sheets — As of December 31, 2002 and 2001
    88  
 
Consolidated Statements of Income — For the years ended December 31, 2002, 2001 and 2000
    89  
 
Consolidated Statements of Stockholders’ Equity — For the years ended December 31, 2002, 2001 and 2000
    90  
 
Consolidated Statements of Cash Flows — For the years ended December 31, 2002, 2001 and 2000
    91  
 
Notes to Consolidated Financial Statements
    92  
Schedule II — Valuation and Qualifying Accounts
    107  


Schedules other than those listed above have been omitted because they are not applicable.

34


Table of Contents

INDEPENDENT AUDITORS’ REPORT

To the Board of Directors and Stockholders of

CDRJ Investments (Lux) S.A.
Luxembourg

      We have audited the accompanying consolidated balance sheet of CDRJ Investments (Lux) S.A. and subsidiaries (the “Company”) as of December 31, 2001, and the related consolidated statements of income, stockholders’ equity, and cash flows for each of the two years in the period ended December 31, 2001. These financial statements and the financial statement schedule are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements and the financial statement schedule based on our audits.

      We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

      In our opinion, such consolidated financial statements referred to above present fairly, in all material respects, the financial position of CDRJ Investments (Lux) S.A. and subsidiaries as of December 31, 2001, and the results of their operations and their cash flows for each of the two years in the period ended December 31, 2001, in conformity with accounting principles generally accepted in the United States of America. Also, in our opinion, the financial statement schedule referred to above, when considered in relation to the basic consolidated financial statements taken as a whole, presents fairly in all material respects the information set forth therein.

DELOITTE & TOUCHE, LLP

Los Angeles, California

March 6, 2002 (February 24, 2003, as
to paragraphs 21 and 22 of Note 2)

35


Table of Contents

INDEPENDENT AUDITORS’ REPORT

To the Board of Directors and Stockholders of

CDRJ Investments (Lux) S.A.
Luxembourg

      We have audited the accompanying consolidated balance sheets of CDRJ Investments (Lux) S.A. and subsidiaries (the “Company”) as of December 31, 2002, and the related consolidated statement of income, stockholders’ equity, and cash flows for the year then ended. Our audit also included the financial statement schedule for the year ended December 31, 2002 listed at Item 15(a)(2). These financial statements and schedule are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements and schedule based on our audit.

      We conducted our audit in accordance with auditing standards generally accepted in the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

      In our opinion, such consolidated financial statements referred to above present fairly, in all material respects, the financial position of CDRJ Investments (Lux) S.A. and subsidiaries as of December 31, 2002, and the results of their operations and their cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States. Also, in our opinion, the related financial statement schedule for the year ended December 31, 2002, when considered in relation to the basic financial statements taken as a whole, presents fairly in all material respects the information set forth therein.

      As discussed in Note 2 to the consolidated financial statements, effective January 1, 2002, the Company adopted Statement of Financial Accounting Standards No. 142.

  /s/ Ernst & Young, LLP

Los Angeles, California

February 21, 2003

36


Table of Contents

CDRJ INVESTMENTS (LUX) S.A. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(In thousands, except share amounts)

ASSETS

                     
December 31, December 31,
2002 2001


Current assets:
               
 
Cash and cash equivalents
  $ 27,206     $ 6,748  
 
Receivables, less allowances for doubtful accounts of $8,396 in 2002 and $7,267 in 2001
    41,126       43,898  
 
Inventories
    35,286       40,515  
 
Prepaid income taxes
    258        
 
Prepaid expenses and other current assets
    4,977       7,851  
 
Deferred income taxes
          55  
     
     
 
   
Total current assets
    108,853       99,067  
Property and equipment, net
    60,722       59,598  
Other assets:
               
 
Goodwill
    66,305       71,148  
 
Trademarks
    44,570       50,560  
 
Deferred financing fees and other, net
    7,840       10,763  
     
     
 
   
Total
  $ 288,290     $ 291,136  
     
     
 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
               
 
Current portion of long-term debt
  $ 6,489     $ 6,188  
 
Accounts payable
    18,636       26,516  
 
Accrued liabilities
    44,824       40,916  
 
Income taxes payable
    4,939       7,130  
 
Deferred income taxes
    2,073       4,094  
     
     
 
   
Total current liabilities
    76,961       84,844  
Long-term debt
    77,894       86,901  
Deferred income taxes
    21,186       20,311  
Other long-term liabilities
    3,787       3,088  
     
     
 
   
Total liabilities
    179,828       195,144  
     
     
 
Commitments and contingencies
           
Stockholders’ equity:
               
 
Common stock, par value $2.00; authorized, 1,020,000 shares; issued and outstanding, 831,888 shares in 2002 and 2001
    1,664       1,664  
 
Additional paid-in capital
    81,921       81,921  
 
Retained earnings
    37,145       18,373  
 
Accumulated other comprehensive loss
    (12,268 )     (5,966 )
     
     
 
   
Total stockholders’ equity
    108,462       95,992  
     
     
 
   
Total
  $ 288,290     $ 291,136  
     
     
 

See accompanying notes to consolidated financial statements.

37


Table of Contents

CDRJ INVESTMENTS (LUX) S.A. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME

(In thousands)
                             
Years Ended December 31,

2002 2001 2000



Net sales
  $ 390,978     $ 376,153     $ 321,228  
Cost of sales
    92,434       86,996       79,559  
     
     
     
 
   
Gross profit
    298,544       289,157       241,669  
Selling, general and administrative expenses
    240,869       232,865       196,561  
Restructuring and impairment charges
                2,626  
Loss (gain) on sale of assets
    (76 )     69       150  
     
     
     
 
   
Income from operations
    57,751       56,223       42,332  
Other income (expense):
                       
 
Exchange loss, net
    (11,148 )     (9,658 )     (11,652 )
 
Interest expense, net
    (11,437 )     (13,308 )     (15,659 )
 
Other, net
    119       (123 )     1,563  
     
     
     
 
Income before income taxes, extraordinary item and cumulative effect of accounting change
    35,285       33,134       16,584  
Income tax expense
    16,269       17,420       9,934  
     
     
     
 
Income before extraordinary item and cumulative effect of accounting change
    19,016       15,714       6,650  
Extraordinary loss on early extinguishment of debt, net of income tax benefit of $195
                315  
     
     
     
 
Income before cumulative effect of accounting change
    19,016       15,714       6,335  
Cumulative effect of accounting change, net of income tax expense of $0 in 2002 and $82 in 2001
    (244 )     126        
     
     
     
 
Net income
  $ 18,772     $ 15,840     $ 6,335  
     
     
     
 

See accompanying notes to consolidated financial statements.

38


Table of Contents

CDRJ INVESTMENTS (LUX) S.A. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(In thousands, except for shares)
                                                     
Years Ended December 31,

2002 2001 2000



Shares Amount Shares Amount Shares Amount






Common Stock:
                                               
 
Balance, beginning of year
    831,888     $ 1,664       834,293     $ 1,669       830,659     $ 1,661  
 
Issuance of common stock
                474       1       4,424       9  
 
Exercise of stock options
                210             158       1  
 
Repurchase of common stock
                (3,089 )     (6 )     (948 )     (2 )
     
     
     
     
     
     
 
 
Balance, end of year
    831,888       1,664       831,888       1,664       834,293       1,669  
     
     
     
     
     
     
 
Additional Paid-in Capital:
                                               
 
Balance, beginning of year
            81,921               82,128               81,381  
 
Issuance of common stock
                          99               912  
 
Exercise of stock options
                          52               32  
 
Repurchase of common stock
                          (358 )             (197 )
             
             
             
 
 
Balance, end of year
            81,921               81,921               82,128  
             
             
             
 
Retained Earnings:
                                               
 
Balance, beginning of year
            18,373               2,942               (3,393 )
 
Net income
            18,772               15,840               6,335  
 
Repurchase of common stock
                          (409 )              
             
             
             
 
 
Balance, end of year
            37,145               18,373               2,942  
             
             
             
 
Accumulated Other Comprehensive Loss:
                                               
 
Balance, beginning of year
            (5,966 )             (5,572 )             (3,855 )
 
Net unrealized and deferred realized losses on derivatives
            (264 )             (3,746 )              
 
Tax benefit on unrealized and deferred realized losses on derivatives
            92               1,311                
 
Currency translation adjustments
            (6,130 )             2,041               (1,717 )
             
             
             
 
 
Balance, end of year
            (12,268 )             (5,966 )             (5,572 )
     
     
     
     
     
     
 
   
Total Stockholders’ Equity
    831,888     $ 108,462       831,888     $ 95,992       834,293     $ 81,167  
     
     
     
     
     
     
 
Comprehensive Income:
                                               
 
Net income
          $ 18,772             $ 15,840             $ 6,335  
 
Unrealized and deferred realized losses on derivatives
            (4,192 )             (5,504 )              
 
Reclassified to exchange loss
            1,167               797                
 
Reclassified to cost of sales
            2,761               961                
 
Tax benefit on unrealized and deferred realized losses on derivatives
            92               1,311                
 
Currency translation adjustments
            (6,130 )             2,041               (1,717 )
             
             
             
 
   
Total Comprehensive Income
          $ 12,470             $ 15,446             $ 4,618  
             
             
             
 

See accompanying notes to consolidated financial statements.

39


Table of Contents

CDRJ INVESTMENTS (LUX) S.A. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)
                                 
Years Ended December 31,

2002 2001 2000



Cash flows from operating activities:
                       
 
Net income
  $ 18,772     $ 15,840     $ 6,335  
   
Extraordinary loss on early extinguishment of debt, net of taxes
                315  
   
Cumulative effect of accounting change, net of taxes
    244       (126 )      
     
     
     
 
 
Income before extraordinary item and cumulative effect of accounting change
    19,016       15,714       6,650  
 
Adjustments to reconcile income before extraordinary item and cumulative effect of accounting change to net cash provided by operating activities:
                       
   
Loss (gain) on sale of property and equipment
    (76 )     69       150  
   
Depreciation and amortization
    5,611       7,749       7,632  
   
Provision for uncollectible accounts receivable
    12,376       9,464       5,958  
   
Amortization of deferred financing fees
    1,405       1,434       1,430  
   
Asset impairment charge
                1,019  
   
Unrealized foreign exchange and derivative losses (gains)
    8,857       (683 )     2,918  
   
Deferred realized foreign exchange gains (losses)
    181       (827 )      
   
Deferred income taxes
    587       3,913       3,430  
   
Changes in operating assets and liabilities:
                       
     
Receivables
    (14,296 )     (15,839 )     (10,536 )
     
Inventories
    720       (917 )     (7,856 )
     
Prepaid expenses and other current assets
    5,688       2,795       (1,688 )
     
Other assets
    1,787       192       (927 )
     
Accounts payable and accrued liabilities
    1,716       (1,033 )     12,065  
     
Income taxes payable/prepaid
    (1,141 )     7,376       12,156  
     
Other long-term liabilities
    699       722       57  
     
     
     
 
       
Net cash provided by operating activities
    43,130       30,129       32,458  
     
     
     
 
Cash flows from investing activities:
                       
 
Proceeds from sale of property and equipment
    225       93       675  
 
Purchases of property and equipment
    (11,011 )     (11,372 )     (7,105 )
 
Other
    (531 )     (408 )     (760 )
     
     
     
 
       
Net cash used in investing activities
    (11,317 )     (11,687 )     (7,190 )
     
     
     
 
Cash flows from financing activities:
                       
 
Repurchase of subordinated notes
                (10,597 )
 
Repayments under term loan facility
    (6,125 )     (4,500 )     (3,500 )
 
Net repayments under revolving credit facility
    (1,800 )     (12,700 )     (10,500 )
 
Net (repayments) borrowings of bank debt
    (781 )     1,263       346  
 
Net issuance of common stock
          152       954  
 
Repurchase of common stock
          (773 )     (199 )
     
     
     
 
       
Net cash used in financing activities
    (8,706 )     (16,558 )     (23,496 )
     
     
     
 
 
Effect of exchange rate changes on cash
    (2,649 )     (974 )     (840 )
     
     
     
 
 
Net increase in cash and cash equivalents
    20,458       910       932  
 
Cash and cash equivalents at beginning of year
    6,748       5,838       4,906  
     
     
     
 
 
Cash and cash equivalents at end of year
  $ 27,206     $ 6,748     $ 5,838  
     
     
     
 
Supplemental disclosure of cash flow information
                       
 
Cash paid (received) during the year for:
                       
 
Interest
  $ 10,173     $ 11,538     $ 15,027  
 
Income Taxes
    8,327       5,319       (5,652 )

      At December 31, 2002, the Company had deferred net gains of $0.4 million on foreign currency option contracts recorded as other comprehensive loss and other receivables. At December 31, 2001, the Company had deferred losses of $2.9 million on foreign currency forward contracts recorded in accrued liabilities and other comprehensive income. Additionally, the related deferred income tax benefit of $1.3 million related to the deferred losses was recorded as a component of the net deferred income tax liability and other comprehensive income.

See accompanying notes to consolidated financial statements.

40


Table of Contents

CDRJ INVESTMENTS (LUX) S.A. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 
(1)  Basis of Presentation and Description of Business

Basis of Presentation

      CDRJ Investments (Lux) S.A., a Luxembourg société anonyme (the “Parent”), Jafra Cosmetics International, Inc., a Delaware corporation (“JCI”), Jafra Cosmetics International, S.A. de C.V., a sociedad anonima de capital variable organized under the laws of the United Mexican States (“Jafra S.A.”) and certain other subsidiaries of the Parent were organized by Clayton, Dubilier & Rice Fund V Limited Partnership, a Cayman Islands exempted limited partnership managed by Clayton, Dubilier & Rice, Inc. (“CD&R”) to acquire (the “Acquisition”) the worldwide Jafra Cosmetics business (the “Jafra Business”) of The Gillette Company (“Gillette”). JCI and Jafra S.A. are indirect, wholly owned subsidiaries of the Parent. The Parent is a holding company that conducts all its operations through its subsidiaries. The Parent and its subsidiaries are collectively referred to as the “Company.” The Acquisition was completed on April 30, 1998.

      The accompanying consolidated financial statements for the years ended December 31, 2002, 2001 and 2000 reflect the operations of the Parent and its subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.

Description of Business

      The Company is an international manufacturer and marketer of premium skin and body care products, color cosmetics, fragrances, and other personal care products. The Company markets its products primarily in 15 countries, 14 outside the United States, and a number of additional countries through distributors, through a direct selling, multilevel distribution system comprised of self-employed salespersons (known as “consultants”).

 
(2)  Summary of Significant Accounting Policies

      Use of Estimates. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

      Cash and Cash Equivalents. Cash and cash equivalents include cash, time deposits and all highly liquid debt instruments purchased with a maturity of three months or less.

      Inventories. Inventories are stated at the lower of cost, as determined by the first-in, first-out basis, or market.

      Property and Equipment. Property and equipment are stated at cost. Depreciation of property and equipment is provided for over the estimated useful lives of the respective assets using the straight-line method. Estimated useful lives are 20 or 40 years for buildings, the lesser of 20 or 40 years or the term of the lease for improvements, 5 to 15 years for machinery and equipment and 3 to 8 years for hardware and software. Maintenance and repairs, including cost of minor replacements, are charged to operations as incurred. Costs of additions and betterments are added to property and equipment accounts provided that such expenditures increase the useful life or the value of the asset.

      Intangible Assets. Intangible assets principally consist of goodwill and trademarks. On January 1, 2002, the Company adopted Statement of Financial Accounting Standards (“SFAS”) No. 142, “Goodwill and other Intangible Assets” which requires the Company to not amortize goodwill and certain other indefinite life intangible assets, but to test those intangible assets for impairment at least annually. Prior to adoption of SFAS No. 142, goodwill and other intangible assets were amortized using the straight-line method over a period of 40 years. Goodwill of $77.9 million and trademarks of $53.8 million, resulted from the Company’s

41


Table of Contents

CDRJ INVESTMENTS (LUX) S.A. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

acquisition of the Jafra Business from Gillette. The book value of goodwill and trademarks was $66,305,000 and $44,570,000 at December 31, 2002, respectively. (See “New Accounting Standards”).

      Deferred Financing Costs. In connection with the acquisition of the Jafra Business, the Company incurred approximately $12.0 million of costs related to the 11.75% Senior Subordinated Notes due 2008 (the “Notes”), the revolving credit facility and the term loan facility (see Note 6). Such costs are being amortized on a basis that approximates the interest method over the expected term of the related debt. Accumulated amortization at December 31, 2002 and 2001 was $6,554,000 and $5,566,000, respectively.

      Impairment of Long-Lived Assets and Goodwill. Long-lived assets are reviewed for impairment, based on undiscounted cash flows, whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. If this review indicates that the carrying amount of the long-lived assets is not recoverable, the Company will recognize an impairment loss, measured by the future discounted cash flow method. Goodwill is tested for impairment annually, or whenever events or changes in circumstances indicate that the carrying amount of goodwill may not be recoverable based on the provisions of SFAS No. 142. (see “New Accounting Standards”).

      Foreign Currency Forward and Option Contracts. During 2002 and 2001, the Company entered into foreign currency forward contracts. In 2002, the Company entered into forward currency option contracts. The Company enters into these contracts to reduce the effect of potentially adverse exchange rate fluctuations in the exchange rate of the Mexican peso to the U.S. dollar. Effective January 1, 2001, the Company adopted SFAS No. 133, “Accounting for Derivative Instruments and Hedging Activities.” SFAS No. 133, as amended and interpreted, establishes accounting and reporting standards for derivative instruments and hedging activities and requires that all derivative instruments be recorded based on fair value. In connection with the adoption of SFAS No. 133, at January 1, 2001, the Company recorded a net gain of $126,000 (net of a tax effect of $82,000) as a cumulative transition adjustment to earnings. This adjustment relates to derivatives not designated as hedges prior to adoption of SFAS No. 133, and represents the difference between the carrying value and the fair value of such instruments.

      As a matter of policy, the Company does not hold or issue foreign currency forward contracts or foreign currency option contracts for trading or speculative purposes. The forward contracts utilized by the Company did not qualify for hedge accounting under the applicable accounting standards prior to adoption of SFAS No. 133 on January 1, 2001, and accordingly such instruments were marked-to-market each month based upon the change in the spot rate from the date of contract inception to the balance sheet date. The premium on such contracts was amortized to expense over the life of the contracts. However, under SFAS No. 133, the Company’s use of forward contracts and option contracts to hedge certain forecasted transactions qualifies for hedge accounting. Gains and losses from qualifying hedged derivative instruments are deferred as a separate component of other comprehensive loss, and are recognized in income at the same time that the underlying hedged exposure is recognized in income. This accounting treatment results in the matching of gains and losses from such forward contracts and option contracts with the corresponding gains and losses generated by the underlying hedged transactions. Under SFAS No. 133, certain of the Company’s foreign currency forward contracts and option contracts do not qualify for hedge accounting and therefore, are remeasured based on fair value, with gains and losses included as a component of net income. At December 31, 2001, the carrying value of the forward contracts was $5,540,000 and was included in accrued liabilities in the accompanying consolidated balance sheets. At December 31, 2002, the carrying value of the option contracts was $402,000 and was included in other receivables in the accompanying consolidated balance sheets.

      Fair Value of Financial Instruments. The carrying amounts of cash and cash equivalents, accounts receivable, and accounts payable approximate fair value because of the short-term maturities of these instruments. The fair value of the Notes and other fixed rate long-term debt at December 31, 2002 and 2001 was $77,888,000 and $82,052,000, respectively, based upon discussions with one of the Company’s largest bondholders and an analysis of current market interest rates and the Company’s credit rating. As the

42


Table of Contents

CDRJ INVESTMENTS (LUX) S.A. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

Company’s revolving credit facility and the term loan are variable rate debt, and the interest rate spread paid by the Company is adjusted for changes in certain financial ratios of the Company, the fair value of the revolving credit facility and the term loan approximated their carrying amounts at December 31, 2002 and 2001.

      Revenue Recognition. The Company recognizes revenue when title passes at shipment in accordance with its shipping terms. Amounts billed to consultants for shipping and handling costs are included in net sales. Sales are reduced by commissions paid to consultants on their personal sales.

      Shipping and Handling Costs. Shipping and handling costs of $32,119,000, $28,736,000 and $24,716,000 for the years ended December 31, 2002, 2001 and 2000, respectively, are included in selling, general and administrative expenses.

      Research and Development. Research and development costs are expensed as incurred. Total research and development expense aggregated $1,469,000, $1,842,000 and $1,901,000 for the years ended December 31, 2002, 2001 and 2000, respectively.

      Income Taxes. The Company accounts for income taxes under the balance sheet approach that requires the recognition of deferred income tax assets and liabilities for the expected future consequences of events that have been recognized in the Company’s financial statements or income tax returns. Management provides a valuation allowance for deferred income tax assets when it is more likely than not that a portion of such deferred income tax assets will not be realized.

      Foreign Currency Translation. The functional currency for foreign subsidiaries is generally the local currency. Assets and liabilities of such foreign subsidiaries are translated into U.S. dollars at current exchange rates, and related revenues and expenses are translated at average exchange rates in effect during the period. Resulting translation adjustments are recorded as a component of other comprehensive loss.

      Approximately 76%, 79% and 77% of the Company’s net sales for the years ended December 31, 2002, 2001 and 2000, respectively, were generated by operations located outside of the United States. Mexico is the Company’s largest foreign operation, accounting for 64%, 66% and 62% of the Company’s net sales for the years ended December 31, 2002, 2001 and 2000, respectively. As such, the Company’s results of operations are subject to fluctuations in the exchange rate of the Mexican peso to the U.S. dollar.

      Additionally, Jafra S.A. had outstanding U.S. dollar-denominated debt of $32,447,000 and $35,572,000 at December 31, 2002 and 2001, respectively. This debt is remeasured at each reporting date, subjecting the Company to additional foreign exchange risk.

      New Accounting Standards. Effective January 1, 2001, the Company adopted SFAS No. 133, “Accounting for Derivative Instruments and Hedging Activities.” SFAS No. 133, as amended and interpreted, established accounting and reporting standards for derivative instruments, including certain derivative instruments embedded in other contracts, and for hedging activities. All derivatives, whether designated in hedging relationships or not, are required to be recorded on the balance sheet at fair value. If the derivative is designated in a fair-value hedge, the changes in the fair value of the derivative and the underlying hedged item are recognized concurrently in earnings. If the derivative is designated in a cash-flow hedge, changes in the fair value of the derivative are recorded in other comprehensive income (loss) (“OCI”) and are recognized in the statement of operations when the hedged item affects earnings. SFAS No. 133 defined new requirements for designation and documentation of hedging relationships as well as ongoing effectiveness assessments in order to use hedge accounting. For a derivative that does not qualify as a hedge, changes in fair value are recognized concurrently in earnings. As of January 1, 2001, the Company recorded a net gain of $126,000 (net of a tax effect of $82,000) as a cumulative transition adjustment to earnings. This adjustment relates to derivatives not designated as hedges prior to adoption of SFAS No. 133, and represents the difference between the carrying

43


Table of Contents

CDRJ INVESTMENTS (LUX) S.A. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

value as measured by the difference in the spot rate to the forward rate and the fair value as determined by forward rates of such instruments at January 1, 2001.

      In June 2001, the Financial Accounting Standards Board (“FASB”) approved two new statements: SFAS No. 141, “Business Combinations” and SFAS No. 142, “Goodwill and Other Intangible Assets.” SFAS No. 141 requires business combinations entered into after June 30, 2001 to be accounted for using the purchase method of accounting. SFAS No. 142 requires that goodwill not be amortized, but be tested for impairment at least annually. SFAS No. 142 was effective for fiscal years beginning after December 15, 2001 to all goodwill and other intangible assets recognized in an entity’s statement of financial position at that date, regardless of when those assets were initially recognized. The Company adopted SFAS No. 142 on January 1, 2002. In accordance with such adoption, the Company identified all reporting units in conjunction with the provisions of SFAS No. 142 and allocated all goodwill accordingly. Prior to June 30, 2002, the Company completed the transitional goodwill impairment test required by SFAS No. 142. Due to general market uncertainty in Colombia, the Company revised its projections and recorded an impairment loss of $244,000 associated with its Colombia reporting unit. The impairment loss has been recorded as a cumulative effect of accounting change in the accompanying consolidated statements of income. No other impairment was identified in connection with the annual impairment test. The changes in the carrying amount of goodwill for the year ended December 31, 2002 are as follows (in thousands):

                                         
United All Consolidated
Goodwill States Mexico Europe Others Total






Balance as of December 31, 2001
  $ 32,188     $ 32,401     $ 5,937     $ 622     $ 71,148  
Translation effect
          (3,853 )     (637 )     (109 )     (4,599 )
Impairment losses
                      (244 )     (244 )
     
     
     
     
     
 
Balance as of December 31, 2002
  $ 32,188     $ 28,548     $ 5,300     $ 269     $ 66,305  
     
     
     
     
     
 

      The Company’s other intangible assets consist of trademarks. During the year ended December 31, 2002, the Company determined trademarks to have an indefinite life and performed the transitional and annual impairment test as required under SFAS No. 142. Based upon the transitional and annual test, the Company determined that there was no impairment of trademarks. The carrying value of trademarks was $44,570,000 as of December 31, 2002.

      In accordance with SFAS No. 142, the Company discontinued amortization of goodwill and other intangible assets with an indefinite life. A reconciliation of previously reported net income to amounts adjusted for the exclusion of goodwill and trademark amortization, net of the related income tax effects, where applicable, is as follows (in thousands):

                         
Years Ended December 31,

2002 2001 2000



Net income
  $ 18,772     $ 15,840     $ 6,335  
Goodwill amortization, net of tax
          1,717       1,876  
Trademark amortization, net of tax
          822       882  
     
     
     
 
Adjusted net income
  $ 18,772     $ 18,379     $ 9,093  
     
     
     
 

      In November 2001, the Emerging Issues Task Force (“EITF”) issued EITF Issue No. 01-9, “Accounting for Consideration Given by a Vendor to a Customer or a Reseller of the Vendor’s Products.” This new guidance provides that consideration from a vendor to a reseller is generally presumed to be a reduction of the selling prices of the vendor’s products, and, therefore, should be characterized as a reduction of revenue when recognized in the vendor’s income statement. On January 1, 2002, the Company adopted EITF Issue No. 01-9 and reclassified commissions paid to consultants of $3,928,000 and $3,460,000 on their personal sales,

44


Table of Contents

CDRJ INVESTMENTS (LUX) S.A. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

previously reported as a component of selling, general and administrative expenses, as a reduction in net sales and selling, general and administrative expenses for the years ended December 31, 2001 and 2000, respectively.

      On January 1, 2002, the Company adopted SFAS No. 144, “Accounting for the Impairment or Disposal of Long-Lived Assets.” SFAS No. 144 supersedes SFAS No. 121, “Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to be Disposed of.” SFAS No. 144 retains substantially all of the requirements of SFAS No. 121, while resolving certain implementation issues and addressing the accounting for a component of a business accounted for as a discontinued operation. SFAS No. 144 was adopted with no significant impact on the financial position or results of operations of the Company.

      In April 2002, the FASB issued SFAS No. 145, “Rescission of FASB Statements No. 4, 44, and 64, Amendment of FASB Statement No. 13, and Technical Corrections.” This Statement rescinds or modifies existing authoritative pronouncements including SFAS No. 4 “Reporting Gains and Losses from Extinguishment of Debt.” As a result of the issuance of SFAS No. 145, gains and losses from extinguishment of debt should be classified as extraordinary items only if they meet the criteria in Accounting Principles Board (“APB”) Opinion 30, “Reporting the Results of Operations-Reporting the Effects of Disposal of a Segment of a Business, and Extraordinary, Unusual and Infrequently Occurring Events and Transactions.” Applying the provisions of APB Opinion 30 will distinguish transactions that are part of an entity’s recurring operations from those that are unusual or infrequent or that meet the criteria for classification as an extraordinary item. The provisions of this Statement related to the rescission of SFAS No. 4 shall be applied in fiscal years beginning after May 15, 2002. Any gain or loss on extinguishment of debt that was classified as an extraordinary item in prior periods presented that does not meet the criteria in APB Opinion 30 for classification as an extraordinary item shall be reclassified. The Company is currently evaluating the impact that this statement may have on any potential future extinguishments of debt. Upon adoption of SFAS No. 145, the Company will reclassify items previously reported as extraordinary items as a component of operating income in the accompanying statements of income.

      In June 2002, the FASB approved SFAS No. 146, “Accounting for Costs Associated with Exit or Disposal Activities.” This statement addresses financial accounting and reporting for costs associated with exit or disposal activities and nullifies EITF Issue No. 94-3, “Liability Recognition for Certain Employee Termination Benefits and Other Costs to Exit an Activity.” The provisions of this statement are effective for exit or disposal activities that are initiated after December 31, 2002, with early application encouraged. The Company is currently evaluating the impact that this statement may have on any potential future exit or disposal activities.

      During 2002, the FASB issued SFAS No. 148, “Accounting for Stock Based Compensation — Transaction and Disclosure, an amendment to FASB Statement No. 123.” This Statement requires more extensive disclosure, including interim disclosure, related to stock based compensation for all companies and permits additional transition methods for companies that elect to use the fair value method for employee stock compensation. This statement is effective for fiscal years ending after December 15, 2002, with early adoption regarding annual disclosures encouraged. The Company adopted the disclosure requirements of SFAS No. 148. (See Note 13).

      Reclassifications. Certain reclassifications were made to the prior year financial statements to conform to current year presentation.

45


Table of Contents

CDRJ INVESTMENTS (LUX) S.A. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(3) Inventories

      Inventories consist of the following at December 31, 2002 and 2001 (in thousands):

                   
2002 2001


Raw materials and supplies
  $ 5,239     $ 5,923  
Finished goods
    30,047       34,592  
     
     
 
 
Total inventories
  $ 35,286     $ 40,515  
     
     
 

(4) Property and Equipment

      Property and equipment consist of the following at December 31, 2002 and 2001 (in thousands):

                 
2002 2001


Land
  $ 16,448     $ 17,833  
Buildings and improvements
    17,452       18,523  
Machinery equipment and other
    42,153       34,640  
     
     
 
      76,053       70,996  
Less accumulated depreciation
    15,331       11,398  
     
     
 
Property and equipment, net
  $ 60,722     $ 59,598  
     
     
 

(5) Accrued Liabilities

      Accrued liabilities consist of the following at December 31, 2002 and 2001 (in thousands):

                 
2002 2001


Sales promotions, commissions and overrides
  $ 15,104     $ 14,230  
Accrued restructuring charges (Note 10)
          201  
Accrued interest
    1,498       1,549  
Compensation and other benefit accruals
    8,633       8,311  
State and local sales taxes and other taxes
    12,644       4,912  
Unrealized losses on forward contracts
          5,540  
Other
    6,945       6,173  
     
     
 
Total accrued liabilities
  $ 44,824     $ 40,916  
     
     
 

46


Table of Contents

CDRJ INVESTMENTS (LUX) S.A. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(6) Debt

      Debt consists of the following at December 31, 2002 and 2001 (in thousands):

                   
2002 2001


Subordinated Notes, unsecured, interest payable semi-annually at 11.75% due in 2008
  $ 75,180     $ 75,180  
Term loan, secured, principal and interest due in quarterly installments through April 30, 2004, interest rates at 3.1% and 4.3% at December 31, 2002 and 2001, respectively
    8,375       14,500  
Revolving loan, secured, due April 30, 2004, weighted average interest rates of 5.4% at December 31, 2001
          1,800  
Unsecured foreign bank loan agreement, principal and interest due in monthly installments through January 25, 2005, weighted average interest rates of 18.5% and 18.7% at December 31, 2002 and 2001, respectively
    828       1,609  
     
     
 
 
Total debt
    84,383       93,089  
Less current maturities
    6,489       6,188  
     
     
 
Long-term debt
  $ 77,894     $ 86,901  
     
     
 

      The Company’s long-term debt matures as follows (in thousands): $6,489 in 2003, $2,714 in 2004, $0 in 2005, 2006 and 2007, and $75,180 thereafter.

      On April 30, 1998, JCI and Jafra S.A. borrowed $125 million by issuing $100 million aggregate principal amount of 11.75% Subordinated Notes due 2008 (the “Notes”) pursuant to an Indenture dated April 30, 1998 (the “Indenture”) and $25 million under a senior credit agreement.

      At the date of issuance, the Notes represented the several obligations of JCI and Jafra S.A. in the amount of $60 million and $40 million, respectively, with each participating on a pro rata basis upon redemption. The Notes mature in 2008 and bear a fixed interest rate of 11.75% payable semi-annually.

      Each of JCI and Jafra S.A. is an indirect, wholly owned subsidiary of the Parent and has fully and unconditionally guaranteed the obligations under the Notes of the other on a senior subordinated basis, subject to a 30-day standstill period prior to enforcement of such guarantees. In addition, the Parent has fully and unconditionally guaranteed the Notes on a senior subordinated basis. JCI currently has no U.S. subsidiaries. Each acquired or organized U.S. subsidiary of JCI will also be required to fully and unconditionally guarantee the Notes jointly and severally, on a senior subordinated basis. Each existing subsidiary of Jafra S.A. fully and unconditionally guarantees the Notes jointly and severally, on a senior subordinated basis, and each subsequently acquired or organized subsidiary of Jafra S.A. will fully and unconditionally guarantee the Notes jointly and severally, on a senior subordinated basis. The nonguarantor entities are the Parent’s indirect European subsidiaries in Austria, Germany, Italy, the Netherlands, Poland, and Switzerland; its indirect South American subsidiaries in Argentina, Brazil, Chile, Colombia, Peru, and Venezuela; and its indirect subsidiaries in the Dominican Republic and Thailand. All guarantor and nonguarantor entities are either direct or indirect wholly owned subsidiaries of the Parent. The Notes were registered in a registered exchange offer, effective as of January 25, 1999, under the Securities Act of 1933, as amended.

      The Notes are unsecured and are generally non-callable for five years. Thereafter, the Notes will be callable at premiums declining to par in the eighth year.

      Consents and waivers, dated June 30, 2001 and November 19, 1999, to the senior credit agreement, as described below, allow the Company to repurchase the Notes in the open market from time to time, with the aggregate purchase price for all such Notes repurchased not to exceed $50 million. Aggregate repurchases as of December 31, 2002 were $24.8 million. During 2000, the Company retired Notes of JCI and Jafra S.A.,

47


Table of Contents

CDRJ INVESTMENTS (LUX) S.A. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

prior to maturity, with a face value of $6.5 million and $4.3 million, respectively. The debt repurchases in 2000 resulted in an extraordinary loss of $315,000, net of an income tax benefit of $195,000. In connection with the early retirement of the Notes as described above, a portion of the unamortized deferred financing costs was written off and included in the determination of the extraordinary loss on early extinguishment of debt. In 2000, $733,000 of the unamortized deferred financing fees were written off.

      In addition, JCI and Jafra S.A. entered into a senior credit agreement that provides for senior secured credit facilities in an aggregate principal amount of $90 million, consisting of a multicurrency revolving credit facility of $65 million and a term loan facility of $25 million. Borrowings under the term loan facility are payable in quarterly installments of principal and interest over six years through April 30, 2004. Borrowings under the revolving credit facility mature on April 30, 2004. Borrowings under the senior credit agreement currently bear interest at an annual rate of LIBOR plus a margin of 1.625% or an alternate base rate (the higher of the prime rate or federal funds rate plus 0.5%, plus an applicable margin of 0.625%). The interest rate in effect at December 31, 2002 was approximately 3.1% for the LIBOR-based borrowings. Borrowings under the senior credit agreement are secured by substantially all of the assets of JCI and Jafra S.A. No amounts were outstanding under the revolving credit facility at December 31, 2002.

      Both the Indenture and the senior credit agreement contain certain covenants that limit the Company’s ability to incur additional indebtedness, pay cash dividends and make certain other payments. These debt agreements also require the Company to maintain certain financial ratios including a minimum EBITDA to cash interest expense coverage ratio and a maximum debt to EBITDA ratio.

      During the year ended December 31, 2001, Jafra S.A. repaid the balance remaining under a one-year term loan originally due on August 16, 2001, and entered into an unsecured foreign bank loan agreement. Under this agreement, Jafra S.A. had the peso equivalent of $828,000 outstanding at December 31, 2002 at a weighted average fixed interest rate of 18.5%. Principal and interest payments are due monthly through January 25, 2005.

      As of December 31, 2002, the Company had irrevocable standby letters of credit outstanding totaling $2.8 million. These letters of credit, expiring on various dates through February 17, 2003, collateralize the Company’s obligation to a third-party in connection with certain lease agreements.

(7) Income Taxes

      The Company’s income before income taxes consists of the following (amounts in thousands):

                         
Years Ended December 31,

2002 2001 2000



Income before income taxes, extraordinary item and cumulative effect of accounting change:
                       
United States
  $ 12,859     $ 13,530     $ 9,741  
Foreign
    22,426       19,604       6,843  
     
     
     
 
    $ 35,285     $ 33,134     $ 16,584  
     
     
     
 

48


Table of Contents

CDRJ INVESTMENTS (LUX) S.A. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

      Actual income tax expense differs from the “expected” tax expense (computed by applying the U.S. Federal corporate rate of 35% to income before income taxes) as a result of the following:

                         
Years Ended December 31,

2002 2001 2000



Provision for income taxes at federal statutory rate
  $ 12,350     $ 11,597     $ 5,804  
Foreign income subject to tax other than at federal statutory rate
    3,461       4,270       2,339  
Foreign tax and other credits
    (2,312 )     (3,230 )     (1,724 )
State income taxes
    548       544       243  
Valuation allowance — domestic
    19       944       (616 )
Valuation allowance — foreign
    2,270       2,939       3,794  
Other
    (67 )     356       94  
     
     
     
 
Income tax expense
  $ 16,269     $ 17,420     $ 9,934  
     
     
     
 

      The components of the provision for income taxes are as follows (in thousands):

                               
Years Ended December 31,

2002 2001 2000



Current:
                       
 
Federal
  $ 178     $ 140     $ 72  
     
     
     
 
 
Foreign:
                       
   
Mexico
    15,177       13,303       6,086  
   
Europe
    (297 )     641       49  
   
Other
    76       190       54  
     
     
     
 
      14,956       14,134       6,189  
 
State
    548       544       243  
     
     
     
 
     
Total current
    15,682       14,818       6,504  
Deferred — foreign
    (646 )     1,506       2,539  
Deferred — domestic
    2,016       2,407       891  
Foreign deferred allocated to other comprehensive income
    (783 )     (1,311 )      
     
     
     
 
     
Total deferred
    587       2,602       3,430  
     
Total income taxes on income before income taxes, extraordinary item and cumulative effect of accounting change
    16,269       17,420       9,934  
Income tax benefit on early extinguishment of debt
                (195 )
Income tax expense on cumulative effect of accounting change
          82        
     
     
     
 
     
Total income tax expense
  $ 16,269     $ 17,502     $ 9,739  
     
     
     
 

49


Table of Contents

CDRJ INVESTMENTS (LUX) S.A. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

      The components of deferred income tax assets and deferred income tax liabilities at December 31, 2002 and 2001 are as follows (in thousands):

                     
2002 2001


Deferred income tax assets:
               
 
Accounts receivable
  $ 2,454     $ 1,733  
 
Net operating loss carryforward
    15,112       13,457  
 
Disallowed interest expense
          26  
 
Accrued bonuses
    33       301  
 
Foreign tax and other credit carryforwards
    2,193       5,333  
 
Accrued sales promotions
    1,977       2,273  
 
Other accrued liabilities
    5,233       1,963  
 
Other
    1,738       4,776  
     
     
 
   
Total deferred income tax assets
    28,740       29,862  
 
Less valuation allowance
    (17,578 )     (15,289 )
     
     
 
   
Net deferred income tax assets
    11,162       14,573  
Deferred income tax liabilities:
               
 
Transaction and deferred financing costs
    (235 )     (494 )
 
Property and equipment
    (4,406 )     (4,194 )
 
Trademark and goodwill
    (18,129 )     (20,272 )
 
Inventories
    (7,914 )     (13,399 )
 
Other
    (3,737 )     (564 )
     
     
 
   
Total deferred income tax liabilities
    (34,421 )     (38,923 )
     
     
 
   
Net deferred income tax liabilities
  $ (23,259 )   $ (24,350 )
     
     
 

      The Company records a valuation allowance on the deferred income tax assets to reduce the total to an amount that management believes is more likely than not to be realized. The valuation allowances at December 31, 2002 and 2001 were based upon the Company’s estimates of the future realization of deferred income tax assets. Valuation allowances at December 31, 2002 and 2001 were provided principally to offset operating loss carryforwards and foreign tax credit carryforwards of the Company’s U.S., European and South American subsidiaries. Valuation allowances at December 31, 2002 were also provided to offset certain pretax expenses at the company’s U.S. subsidiary.

      At December 31, 2002, the Company’s deferred income tax assets for carryforwards totaled $17,305,000 comprised of foreign asset and other credit carryforwards of $2,193,000 and net operating loss carryforwards of $15,112,000. At December 31, 2001, the Company’s deferred income tax assets for carryforwards totaled $18,790,000, comprised of U.S. foreign and foreign asset tax credits of $4,775,000, alternative minimum tax and research and development credits of $558,000 and tax loss carryforwards of certain foreign subsidiaries of $13,457,000. These deferred income tax assets were reduced by a valuation allowance of $17,578,000 and $15,289,000 as December 31, 2002 and 2001, respectively. The tax loss and certain credit carryforwards expire in varying amounts between 2003 and 2012. Realization of the income tax carryforwards is dependent on generating sufficient taxable income prior to expiration of the carryforwards. Although realization is not assured, management believes it is more likely than not that the net carrying value of the income tax carryforwards will be realized.

      Income tax expense for the year ended December 31, 2002 was reduced by $1,169,000 as the result of as the result of the enactment of changes in the Mexico corporate statutory tax rate and the related impact on Jafra S.A.’s net deferred income tax liabilities. The enactment in Mexico will reduce the Mexico corporate income tax rate annually in one-percent increments from 35% to 32% beginning January 1, 2003 through 2005

50


Table of Contents

CDRJ INVESTMENTS (LUX) S.A. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(8) Benefit Plans

      Certain employees of the Company’s German subsidiary participate in a defined benefit pension plan covering key employees (the “Germany Plan”). Benefits are based on age, years of service and the level of compensation during the final years of employment. The Company’s funding policy is to contribute annually to the Germany Plan the amount necessary to meet the minimum funding standards. The Company recognized pension expense of $48,000 and $278,000 for the years ended December 31, 2002 and 2001, respectively, and recognized pension income of $18,000 for the year ended December 31, 2000 due to the departure of certain employees.

      Under Mexican labor laws, employees of Jafra S.A. and its subsidiaries are entitled to a payment when they leave the Company if they have fifteen or more years of service. In addition, the Company makes government mandated employee profit sharing distributions equal to ten percent of the taxable income of the subsidiary in which they are employed. Total expense under these programs was $1,222,000, $995,000 and $345,000 for the years ended December 31, 2002, 2001 and 2000, respectively. The total liability was approximately $1,724,000 and $1,010,000 at December 31, 2002 and 2001, respectively, and is classified as a noncurrent liability in the accompanying consolidated balance sheets.

      The Company’s U.S. subsidiary has an employee savings plan which permits participants to make voluntary contributions by salary deferrals pursuant to section 401(k) of the Internal Revenue Code, which allows employees to defer up to 20% of their total compensation, subject to statutory limitations. Employee contributions of up to 10% of compensation are matched by the Company at the rate of 50 cents per dollar. Employees do not vest in the Company contribution until they have reached two years of service, at which time they become fully vested. The Company’s expense under this program was $618,000, $600,000 and $620,000 for the years ended December 31, 2002, 2001 and 2000, respectively.

      The Company’s U.S. subsidiary also has a supplemental excess benefit savings plan, which permits participants to make unlimited voluntary contributions. Employee contributions are matched on the same basis as under the employee savings plan, and the vesting provisions are the same. The Company’s expense under this program was $207,000, $177,000 and $213,000 for the years ended December 31, 2002, 2001 and 2000, respectively. Employee and employer contributions under such plan are placed into a “rabbi” trust exclusively for the uses and purposes of plan participants and general creditors of the Company. The Company has recorded an asset and the related liability in the accompanying consolidated balance sheets of $2,411,000 and $1,880,000 at December 31, 2002 and 2001, respectively.

(9) Related Party Transactions

      Pursuant to a consulting agreement entered into following the Acquisition, until the 10th anniversary of the Acquisition or the date on which CD&R Fund V no longer has an investment in the Company or until the termination by either party with 30 days notice, CD&R will receive an annual fee (and reimbursement of out-of-pocket expenses) for providing advisory, management consulting and monitoring services to the Company. On January 1, 2000, the annual fee was $400,000. As of January 1, 2001, the annual fee was increased to $1,000,000. As required by the terms of the Company’s lending arrangements, such fees are determined by arm’s-length negotiation and are believed by the Company to be reasonable. The amendment, effective January 1, 2001, adds to CD&R’s services under the agreement financial advisory, investment banking and similar services with respect to future proposals for an acquisition, merger, recapitalization, or other similar transaction directly or indirectly involving the Company or any of its subsidiaries. The fee for such additional services in connection with future transactions would be an amount equal to 1% of the transaction value for the transaction to which such fee relates. Such transaction fees may be increased upon approval of a majority of the members of the Company’s Board of Directors who are not employees of the Company, CD&R or any affiliate of CD&R. The amendment also provides that if any employee of CD&R is appointed to an executive management position (or a position of comparable responsibility) in the Company or any of its subsidiaries,

51


Table of Contents

CDRJ INVESTMENTS (LUX) S.A. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

the annual fee will be increased by an amount to be determined by CD&R, the amount of such increase not to exceed 100% of the existing annual fee in effect at that time. The CD&R fees incurred during the years ended December 31, 2002, 2001 and 2000 were $1,000,000, $1,000,000 and $400,000, respectively. In addition, certain officers and directors of CD&R or its affiliates serve as directors of the Company.

      Prior to 2000, the Company engaged Guidance Solutions (“Guidance”), a corporation in which an investment fund managed by CD&R has an investment, to develop its e-commerce systems. Under the agreement entered into by the Company and Guidance, the Company agreed to pay fees of approximately $2.0 million to Guidance in connection with planning, defining, designing and consulting services performed related to the Company’s e-commerce initiative. During the year ended December 31, 2000, the Company paid fees to Guidance of $1,798,000. The Company terminated its agreement with Guidance and executed a settlement and mutual release agreement effective September 30, 2000. Upon execution of this agreement in October of 2000, Guidance paid the Company $25,000 and agreed to pay the Company an aggregate additional sum of $475,000, payable in quarterly installments plus interest at 9.5% per annum, beginning in January 2001 through October 2005. At December 31, 2002, the balance was paid in full.

      Members of management financed a portion of the cash purchase price of the shares of Company common stock they acquired through loans from the Chase Manhattan Bank on market terms. To help members of management obtain such terms for such financing, the Company fully and unconditionally guaranteed up to 75% of the purchase price for the shares of Company common stock purchased by each such member of management in 1998 and 2000. As of December 31, 2002, the outstanding guarantee was $2,145,000.

(10) Restructuring and Impairment Charges and Related Accruals

      Prior Years Restructuring and Impairment Charges. During 2001, the Company wrote-off $0.2 million of intangible assets as the Company determined that the undiscounted cash flows were less than the carrying amount of the assets due to a downturn in the political and economic environment in Argentina. The amount was classified in selling, general and administration in the accompanying consolidated statements of income. In 2000, the Company recorded approximately $1.6 million of restructuring charges and approximately $1.0 million of asset impairment charges. The restructuring charges of approximately $1.6 million related to the Company’s repositioning activities in Europe, primarily severance costs, of which $1.4 million was paid in 2000 and 2001 and the remaining $0.2 million was paid in 2002. The asset impairment charges of $1.0 million consisted of approximately $0.3 million related to the Company’s repositioning activities in Europe and approximately $0.7 million relating to the write-down of certain capitalized computer software costs in the United States.

      The components of the additions and/or adjustments to the aforementioned accruals include severance, lease costs, fixed asset disposals, and other exit costs, and are summarized as follows (in thousands):

                     
Years Ended December 31,

2001 2000


Additions — charges to income:
               
 
Severance
  $ (84 )   $ 1,210  
 
Lease costs
    80       295  
 
Other
    4       102  
     
     
 
   
Total additions
          1,607  

52


Table of Contents

CDRJ INVESTMENTS (LUX) S.A. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

      A rollforward of the activity of the restructuring accruals is summarized as follows (in thousands):

                         
Years Ended December 31,

2002 2001 2000



Opening balance
  $ 201     $ 699     $ 1,105  
Additions
                1,607  
Charges against reserves
    (201 )     (498 )     (2,013 )
     
     
     
 
Ending balance
  $     $ 201     $ 699  
     
     
     
 

      The remaining costs at each year-end included in the restructuring accrual are summarized as follows (in thousands):

                 
December 31,

2001 2000


Severance
  $     $ 385  
Lease costs and other
    201       314  
     
     
 
    $ 201     $ 699  
     
     
 

      The principal component of the restructuring accruals was severance. A summary of the severance activity is as follows (dollar amounts in thousands):

                                 
Years Ended December 31,

2001 2000


# of # of
Employees Amount Employees Amount




Opening balance
    16     $ 385       43     $ 1,105  
Planned terminations
                35       1,210  
Adjustment to planned terminations
          (84 )            
Actual terminations
    (16 )     (301 )     (62 )     (1,930 )
     
     
     
     
 
Ending balance
        $       16     $ 385  
     
     
     
     
 

(11) Financial Reporting for Business Segments

      Segment information has been prepared in accordance with SFAS No. 131, “Disclosure about Segments of an Enterprise and Related Information” (“SFAS 131”). SFAS No. 131 requires disclosure of certain information regarding operating segments, products and services, geographic areas of operations and major customers.

      The Company’s business is comprised of one industry segment, direct selling, with worldwide operations. The Company is organized into geographical business units that each sell the full line of Jafra cosmetics, skin care, body care, fragrances, and other products. The Company has three reportable business segments: Mexico, the United States, and Europe. Business results for subsidiaries in South America, the Dominican Republic, and Thailand are combined and included in the following table under the caption “All Others.”

      The accounting policies used to prepare the information reviewed by the Company’s chief operating decision makers are the same as those described in the summary of significant accounting policies. The Company evaluates performance based on segment operating income, excluding reorganization and restructuring charges, unusual gains and losses, and amortization of goodwill and intangibles. Consistent with the information reviewed by the Company’s chief operating decision makers, corporate costs, foreign exchange gains and losses, interest expense, other nonoperating income or expense, and income taxes are not allocated to

53


Table of Contents

CDRJ INVESTMENTS (LUX) S.A. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

operating segments. The effects of intersegment sales (net sales and related gross profit) are excluded from the computation of segment operating income.

                                                         
Corporate,
United All Total Unallocated Consolidated
Mexico States Europe Others Segments and Other Total







(Dollars in thousands)
Year ended December 31, 2002
                                                       
Net sales
  $ 251,546     $ 92,143     $ 26,932     $ 20,357     $ 390,978     $     $ 390,978  
Operating profit (loss)
    66,245       15,620       1,224       (6,148 )     76,941       (19,190 )     57,751  
Depreciation and amortization
    2,121       2,631       411       448       5,611             5,611  
Capital expenditures
    4,124       6,298       174       415       11,011             11,011  
Segment assets
    178,629       82,532       18,673       9,890       289,724       (1,434 )     288,290  
Goodwill
    28,548       32,188       5,300       269       66,305             66,305  
Year ended December 31, 2001
                                                       
Net sales
    247,514       79,611       26,329       22,699       376,153             376,153  
Operating profit (loss)
    71,289       11,580       1,795       (5,931 )     78,733       (22,510 )     56,223  
Depreciation and amortization
    3,908       2,709       610       406       7,633       116       7,749  
Capital expenditures
    6,024       4,529       230       589       11,372             11,372  
Segment assets
    193,379       67,792       17,788       13,313       292,272       (1,136 )     291,136  
Year ended December 31, 2000
                                                       
Net sales
    199,777       74,137       26,882       20,432       321,228             321,228  
Operating profit (loss)
    64,364       10,709       247       (6,044 )     69,276       (26,944 )     42,332  
Depreciation and amortization
    4,231       2,111       905       385       7,632             7,632  
Capital expenditures
    2,262       3,662       109       1,072       7,105             7,105  
Segment assets
  $ 177,086     $ 68,843     $ 18,254     $ 13,165     $ 277,348     $ (404 )   $ 276,944  

      Additional business segment information regarding product lines is as follows:

                                                     
2002 2001 2000



Sales by Percentage Sales by Percentage Sales by Percentage
Product Line of Total Product Line of Total Product Line of Total
($ in millions) Sales ($ in millions) Sales ($ in millions) Sales






Skin care
  $ 68.8       18.2 %   $ 69.4       19.0 %   $ 65.8       21.0 %
Color cosmetics
    99.5       26.2       94.3       25.8       82.4       26.2  
Fragrances
    126.6       33.4       125.4       34.3       103.7       33.0  
Body care and personal care
    42.1       11.1       37.0       10.1       29.6       9.4  
Other(1)
    42.0       11.1       39.3       10.8       32.6       10.4  
     
     
     
     
     
     
 
 
Subtotal before shipping and other fees less commissions
    379.0       100.0 %     365.4       100.0 %     314.1       100.0 %
             
             
             
 
Shipping and other fees less commissions
    12.0               10.8               7.1          
     
             
             
         
   
Total
  $ 391.0             $ 376.2             $ 321.2          
     
             
             
         


(1)  Includes sales aids (e.g., party hostess gifts, demonstration products, etc.) and promotional materials, which typically do not qualify for commissions or overrides.

54


Table of Contents

CDRJ INVESTMENTS (LUX) S.A. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(12) Commitments and Contingencies

      The Company leases office and warehouse facilities as well as manufacturing, transportation and data processing equipment under operating leases which expire at various dates through 2008. The leases contain certain renewal options and require payment of property taxes, utilities, common area maintenance and insurance and contain rent escalation clauses based on consumer price indices. Future minimum lease payments under noncancelable operating leases as of December 31, 2002 are (in thousands):

         
2003
  $ 3,841  
2004
    3,879  
2005
    3,784  
2006
    3,592  
2007
    3,585  
2008
    167  
     
 
    $ 18,848  
     
 

      Rental expense was $3,781,000, $3,473,000 and $5,953,000 for the years ended December 31, 2002, 2001 and 2000, respectively.

      Other income for 2000 included approximately $1.4 million of income related to a recovery of the effect of inflation from a receivable due from the Mexican government related to taxes.

      During 2002, the Company initiated product replacement for a certain product sold in 2001 and 2002. The total cost of the product replacement is approximately $400,000. However, management believes that the majority of the cost will be recovered pursuant to contractual obligations with the third-party manufacturer. (See Note 14).

      The Company has implemented a structure in a certain foreign jurisdiction to minimize import taxes. While management believes this structure adequately protects and minimizes the Company’s exposure to import taxes, the Company may be adversely impacted if this structure does not withstand challenges by local tax authorities. Management believes that the resolution of a tax authority challenge, if any, will not have a material adverse effect on the Company’s business, financial condition or results of operations.

      In accordance with FASB Statement No. 144, “Accounting for the Impairment or Disposal of Long-Lived Assets”, the Company recorded impairment losses on long-lived assets used in operations when events and circumstances indicate that long-lived assets might be impaired and undiscounted cash flows estimated to be generated by those assets are less than the carrying amounts of those assets. Subsequent to December 31, 2002, the Company is considering strategic decisions to exit certain non-core markets in South America, Thailand and some or all of Europe through sale or discontinuance of these operations. As of December 31, 2002, no decision had been made on these non-core markets and the undiscounted cash flows indicated that such carrying amounts were expected to be recovered. Given certain strategic decisions made, it is reasonably possible that the estimate of undiscounted cash flows may change in the near term resulting in a need to write down those assets to fair value. In accordance with FASB 142, Goodwill and Other Intangible Assets, the transitional and annual impairment test indicated that fair value of the reporting units associated with the non-core markets exceeded the carrying value, including goodwill, at December 31, 2002.

      The Company is involved from time to time in routine legal matters incidental to its business. The Company believes that the resolution of such matters will not have a material adverse effect on the Company’s business, financial condition or results of operations.

55


Table of Contents

CDRJ INVESTMENTS (LUX) S.A. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(13) Management Incentive Arrangements

Company Plan

      Effective 1998, the Company adopted a stock incentive plan (the “Stock Incentive Plan”), which provides for the sale to members of senior management of up to 52,141 shares of common stock of the Parent and the issuance of options to purchase up to 104,282 additional shares of common stock. The Company reserved 156,423 shares for issuance under the Stock Incentive Plan, and as of December 31, 2002, 42,121 shares and 84,242 options were outstanding. A summary of the status and activity of shares purchased under the Stock Incentive Plan is as follows:

                 
Number Price Per
of Shares Share


Shares outstanding at December 31, 1999
    38,392          
Shares issued in 2000
    4,424       206  
Options exercised in 2000
    158       100  
Shares repurchased in 2000
    (948 )   $ 210  
     
         
Shares outstanding at December 31, 2000
    42,026          
Shares issued in 2001
    474       210  
Options exercised in 2001
    210       150  
Shares repurchased in 2001
    (589 )   $ 250  
     
         
Shares outstanding at December 31, 2001
    42,121          
Shares issued in 2002
           
Options exercised in 2002
           
Shares repurchased in 2002
           
     
         
Shares outstanding at December 31, 2002
    42,121          
     
         

      The purchase price of shares issued in 2000 and 2001 and options exercised in 2000 and 2001 represented the estimated fair value at the respective dates of issuance and exercise, except as discussed below. In 2000, 316 shares were issued at a price below fair value, and the Company recognized compensation expense of approximately $19,000. In 2001, 210 shares were issued at a price below fair value, and the Company recognized compensation expense of approximately $21,000. Under certain circumstances, the management stockholders can require the Company to repurchase their shares, subject to a holding period of at least seven months from the date such shares were acquired, for an amount not to exceed fair value.

      In connection with the purchase of common stock of the Parent, certain members of senior management were granted options to purchase two additional shares of common stock for each share purchased at an exercise price equal to the fair value at the date of grant under the Stock Incentive Plan. The options have a life of ten years from the date of grant. Fifty percent of the options granted are expected to vest in three equal installments on each of the first three anniversaries of the date of grant, subject to the continuous employment of the grantee (“Option Type 1”). The remaining fifty percent of the options become vested as follows, subject to the continuous employment of the grantee: (a) up to one-third of the options become vested as of each of the first three anniversaries of the date of grant if the Company achieves at least 85% of its EBITDA target for the immediately preceding fiscal year, (b) if less than one-third of the total number of options shall have become vested as provided in clause(a) above, the portion that has not become so vested shall become vested as of the first day of the fiscal year following the fiscal year, if any, that the Company achieves its cumulative EBITDA target, and (c) any options that do not become vested as provided above will become vested on the

56


Table of Contents

CDRJ INVESTMENTS (LUX) S.A. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

ninth anniversary of the date of grant (“Option Type 2”). A summary of the status and activity of the options under the Stock Incentive Plan is as follows:

                                                 
2002 2001 2000



Weighted Average Weighted Average Weighted Average
Shares Exercise Price Shares Exercise Price Shares Exercise Price






Outstanding at beginning of year
    84,242     $ 112.36       84,052     $ 111.69       76,784     $ 101.03  
Granted
                948       210.00       8,848       205.71  
Exercised
                (210 )     150.00       (158 )     100.00  
Canceled
                (548 )     163.80       (1,422 )     122.22  
     
             
             
         
Outstanding at year-end
    84,242     $ 112.36       84,242     $ 112.36       84,052     $ 111.69  
     
             
             
         
Options exercisable at year-end
    66,615     $ 109.92       63,528     $ 105.32       37,655     $ 100.70  
Options available for grant
    19,093             19,093             19,493        

      The following table summarizes information about options outstanding as of December 31, 2002:

                                         
Outstanding Exercisable


Weighted Average
Exercise Number Remaining Contractual Weighted Average Number Weighted Average
Price of Options Life (Yrs.) Exercise Price of Options Exercise Price






$100.00
    74,256       5.75     $ 100.00       60,117     $ 100.00  
$150.00
    948       6.92       150.00       902       150.00  
$210.00
    9,038       7.63       210.00       5,596       210.00  
     
                     
         
      84,242       5.96     $ 112.36       66,615     $ 109.92  
     
                     
         

      The Company applies Accounting Principles Board Opinion No. 25, “Accounting for Stock Issued to Employees”, and related Interpretations in accounting for these options. As the options were granted with exercise prices equal to the fair value at the date of grant, no compensation cost was recognized by the Company upon issuance of such options. The fair value of each option granted by the Company was estimated using the minimum value option pricing model. The assumptions used in this pricing model and the weighted average fair value of options granted during 2001 and 2000 are summarized as follows:

                                 
2001 2000


Option Option Option Option
Type 1 Type 2 Type 1 Type 2




Risk-free interest rate
    5.80 %     5.80 %     6.30 %     6.30 %
Expected option life (in years)
    5.0       7.0       5.0       7.0  
Expected volatility
    0.0 %     0.0 %     0.0 %     0.0 %
Expected dividend yield
    0.0 %     0.0 %     0.0 %     0.0 %
Weighted average fair value per option
  $ 52.20     $ 69.28     $ 56.00     $ 73.97  

57


Table of Contents

CDRJ INVESTMENTS (LUX) S.A. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

Pro Forma Compensation Cost

      Had the Company recorded compensation cost based on the fair value of options granted at the grant date, as prescribed by FASB Statement No. 123 “Accounting for Stock Based Compensation,” pro forma net income would have been as follows (in thousands):

                         
Years Ended December 31,

2002 2001 2000



Net income, as reported
  $ 18,772     $ 15,840     $ 6,335  
Pro forma compensation cost
    92       348       680  
     
     
     
 
Pro forma net income
  $ 18,680     $ 15,492     $ 5,655  
     
     
     
 

Employment Agreements

      Certain senior executive officers have employment agreements which provide for annual bonuses if the Company achieves the performance goals established under its annual incentive plan for executives.

      The Company has a bonus plan for U.S. based employees which provides that 50% of the bonus earned by any Vice President or Director shall be deferred and shall vest in three equal annual installments. As of December 31, 2002 and 2001, $415,000 and $372,000 of bonuses were deferred, respectively. The Company recognizes compensation expense as the vesting requirements are met.

(14) Manufacturing Agreement

      The Company and a third-party contractor (the “Contractor”) entered into a manufacturing agreement, dated as of June 10, 1999, (the “Manufacturing Agreement”). Subject to the terms and conditions of the Manufacturing Agreement, the Contractor has agreed to manufacture all of the Company’s requirements for certain cosmetic and skin care products for an initial term of five years. Following the expiration of the initial five-year term, the Manufacturing Agreement will be automatically extended for additional one-year terms unless terminated by six months’ prior written notice by either party. The Manufacturing Agreement provides for price renegotiations by the Contractor if the Company’s quarterly or annual purchase volume falls below specified minimums. The Manufacturing Agreement requires the Contractor to maintain insurance to cover costs associated with any product liability or product recall caused by the acts or omissions of the Contractor. In addition, the Company is obligated to purchase materials acquired by the Contractor based upon product forecasts provided by the Company if the Contractor is unable to sell such materials to a third-party. There have been no such repurchases to date. The Contractor is solely responsible for obtaining the inventories, manufacturing the inventories at its current location in Chino, California, complying with applicable laws and regulations, and performing quality assurance functions.

      During the fourth quarter of 2000, the Contractor obtained $1,000,000 of advances from the Company in exchange for an unsecured promissory note. The note bears interest at an annual rate of 9% and is payable in monthly installments commencing on February 15, 2001. On April 15, 2002, the unsecured promissory note was amended to advance an additional $320,000 to the contractor. At December 31, 2002 and 2001, approximately $101,000 and $349,000, of the note was outstanding and was included in receivables in the accompanying consolidated balance sheets, respectively.

 
(15)  Foreign Currency Forward and Option Contracts

      The Company is exposed to currency risk relating to its forecasted U.S. dollar-denominated expenditures at Jafra S.A. As part of its overall strategy to reduce the risk of adverse potential exchange rate fluctuations in Mexico, the Company enters into foreign currency exchange contracts. Prior to March 2002, the Company purchased forward exchange contracts (“forward contracts” or “forwards”) to hedge its foreign currency

58


Table of Contents

CDRJ INVESTMENTS (LUX) S.A. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

exposures to the Mexican peso. In March 2002, in accordance with previously approved policies, the Company modified its hedging program to include the use of foreign currency option contracts (“option contracts”). The Company places forward contracts or option contracts based on its forecasted U.S. dollar cash outflows from Jafra S.A. over a rolling 12 month period and does not hedge transactions that are not included in the 12 month forecast on the date the forward contract is initiated. As a matter of policy, the Company does not hold or issue forward contracts for trading or speculative purposes nor does it enter into contracts or agreements containing “embedded” derivative features. Prior to entering into forward contracts or option contracts, the Company evaluates the counter parties’ credit ratings. Credit risk represents the accounting loss that would be recognized at the reporting date if counter parties failed to perform as contracted. The Company does not currently anticipate non-performance by such counter parties.

      Effective January 1, 2001, the Company adopted SFAS No. 133, “Accounting for Derivative Instruments and Hedging Activities.” SFAS No. 133, as amended and interpreted, establishes accounting and reporting standards for derivative instruments and hedging activities and requires that all derivative instruments be recorded based on fair value. In connection with the adoption of SFAS No. 133, at January 1, 2001, the Company recorded a net gain of $126,000 (net of a tax effect of $82,000) as a cumulative transition adjustment to earnings. This adjustment relates to derivatives not designated as hedges prior to adoption of SFAS No. 133, and represents the difference between the carrying value and the fair value of such instruments. Under SFAS No. 133, the Company’s use of forward contracts or option contracts to hedge certain forecasted transactions does qualify for hedge accounting. Gains and losses from such derivatives are deferred as a separate component of other comprehensive loss, and are recognized in income at the same time that the underlying hedged exposure is recognized in income. This accounting treatment results in the matching of gains and losses from such forward contracts or option contracts with the corresponding gains and losses generated by the underlying hedged transactions. Contracts that do not qualify for hedge accounting under SFAS No. 133 are remeasured based on fair value and the gains and losses are included as a component of net income.

      The forward contracts utilized by the Company did not qualify for hedge accounting under the applicable accounting standards prior to adoption of SFAS No. 133 on January 1, 2001, and accordingly such instruments were marked-to-market with gains and losses included as a component of exchange loss in the statements of income for the year ended December 31, 2000.

      The Company currently designates certain of its forward contracts and option contacts as cash flow hedges of forecasted U.S. dollar-denominated inventory purchases, forecasted U.S. dollar-denominated intercompany charges from JCI to Jafra S.A., forecasted management fee charges from JCI to Jafra S.A., and U.S. dollar-denominated interest payments. On the date the Company enters into a derivative contract, management designates the derivative as a hedge of the identified exposure. The Company formally documents all relationships between hedging instruments and hedged items, as well as its risk-management objective and strategy for undertaking various hedge transactions. In this documentation, the Company specifically identifies the forecasted transaction that has been designated as a hedged item and states how the hedging instrument is expected to hedge the risks related to the hedged item. The Company formally measures effectiveness of its hedging relationships both at the hedge inception and on an ongoing basis in accordance with its risk management policy. For all qualifying and highly effective cash flow hedges, the changes in the fair value of the derivative are deferred as a component of other comprehensive loss. Such amounts will be reclassified from other comprehensive loss into net income when the underlying hedged exposure is recognized in income. For U.S. dollar-denominated inventory purchases, this will occur upon sale to an outside party of the related inventory. For intercompany charges and interest, this will occur at the date such charges are recorded by Jafra S.A.

      During the year ended December 31, 2002, the Company recognized losses of approximately $2,605,000 on forward contracts and gains of approximately $886,000 on option contracts (including reclassification of

59


Table of Contents

CDRJ INVESTMENTS (LUX) S.A. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

other comprehensive loss) as a component of exchange loss in the accompanying consolidated statements of income. During the year ended December 31, 2001, the Company recognized approximately $12,188,000 of losses on forward contracts as a component of exchange loss in the accompanying consolidated statements of income. During the year ended December 31, 2000, the Company recognized approximately $10,050,000 of losses as a component of exchange loss on forward contracts that did not qualify for hedge accounting under accounting standards prior to the adoption of SFAS No. 133.

      Additionally, during the year ended December 31, 2001, the Company deferred as a component of other comprehensive loss $5,504,000 of losses on forward contracts qualifying for hedge accounting under SFAS No. 133. Of this amount, approximately $797,000 was reclassified as exchange loss and $961,000 was reclassified as cost of sales upon recognition of the underlying hedged exposure prior to December 31, 2001. As of December 31, 2001, the Company had deferred as a component of other comprehensive income (loss) $3,746,000 of losses on forward contracts.

      During the year ended December 31, 2002, the Company deferred approximately an additional $1,782,000 of losses on forward contracts qualifying for hedge accounting under SFAS No. 133. Of the total amount deferred, during the year ended December 31, 2002, approximately $1,650,000 of other comprehensive loss was reclassified into exchange loss and approximately $3,139,000 was reclassified into cost of sales upon the recognition of the underlying hedged exposure. The Company expects that substantially all of the remaining loss of $739,000, deferred as a component of other comprehensive loss, will be recognized into income within the next twelve months.

      During the year ended December 31, 2002, the Company deferred as a component of other comprehensive loss $1,336,000 of gains on option contracts qualifying for hedge accounting under SFAS No. 133. Of this amount, approximately $483,000 of other comprehensive loss was reclassified to exchange loss and approximately $378,000 was reclassified as a cost of sales offset upon the recognition of the underlying hedged exposure. The Company expects substantially all of the remaining gain of approximately $475,000, deferred as a component of other comprehensive loss, to be recognized into income within the next twelve months.

      The fair value of the forward contacts at December 31, 2001 represented an unrealized loss of $5,540,000 consisting of $2,920,000 of unrealized losses recorded as a component of other comprehensive loss for qualifying hedges and $2,620,000 of unrealized losses recorded as a component of exchange loss for non-qualifying hedges under SFAS No. 133. As of December 31, 2002, the Company had no outstanding forward contracts. The fair value of the option contracts at December 31, 2002 represented an unrealized gain of approximately $402,000, consisting of $382,000 of unrealized gains recorded as a component of other comprehensive loss for qualifying hedges and $21,000 of unrealized gains for non-qualifying hedges under SFAS No. 133.

      During the year ended December 31, 2002, the ineffectiveness generated by the Company’s forward contracts and option contracts designated as hedges was insignificant. Certain hedged forecasted transactions do not appear probable of occurring due to timing differences between the original and current forecasts, and accordingly $164,000 of gains were reclassified into earnings.

      The outstanding option contracts had a notional value denominated in Mexican pesos of $523,000,000 in put and call positions at December 31, 2002 and mature at various dates through December 31, 2003. The outstanding forward contracts had notional values denominated in Mexican pesos of $688,873,000 at December 31, 2001 and matured in 2002. Notional amounts do not quantify market or credit exposure or represent assets or liabilities of the Company, but are used in the calculation of cash settlements under the contracts.

60


Table of Contents

CDRJ INVESTMENTS (LUX) S.A. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

      The following table provides information about the details of the Company’s option contracts as of December 31, 2002 (in thousands):

At December 31, 2002:

                                 
Coverage in Fair Value in
Foreign Currency Mexican Pesos Average Strike Price U.S. Dollars(1) Maturity Date





Purchased Puts (Company may sell Peso/buy USD)
                               
Mexican Peso
  $ 149,000       10.31-10.48     $ (113 )     Jan.-Mar. 2003  
Mexican Peso
    100,000       11.05-12.19       77       Apr.-June 2003  
Mexican Peso
    150,000       11.76-12.79       131       July-Aug 2003  
Mexican Peso
    124,000       12.51-12.91       21       Oct.-Dec. 2003  
     
             
         
    $ 523,000             $ 116          
     
             
         
Written Calls (Counterparty may buy Peso/sell USD)
                               
Mexican Peso
  $ 149,000       9.01-9.02     $ (207 )     Jan.-Mar. 2003  
Mexican Peso
    100,000       9.50-9.84       (144 )     Apr.-June 2003  
Mexican Peso
    150,000       9.69-10.19       (112 )     July-Aug 2003  
Mexican Peso
    124,000       10.15-10.19       (55 )     Oct.-Dec. 2003  
     
             
         
    $ 523,000             $ (518 )        
     
             
         

(1)  The fair value of the option contracts presented above, an unrealized gain of $402,000 at December 31, 2002, represents the carrying value and has been recorded in other receivables in the accompanying consolidated balance sheets.

61


Table of Contents

CDRJ INVESTMENTS (LUX) S.A. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

      The tables below describe the forward contracts that were outstanding at December 31, 2001 (in thousands):

December 31, 2001:

                                 
Forward Position
In Mexican Maturity Weighted Average Fair Value in
Foreign Currency Pesos(1) Date Contract Rate U.S. Dollars(1)





Buy US Dollar/sell Mexican Peso
  $ 108,715       1/31/02       10.19     $ 1,128  
Sell Mexican Peso/buy US Dollar
    (20,000 )     1/31/02       9.35       (34 )
Buy US Dollar/sell Mexican Peso
    71,787       2/28/02       10.26       756  
Sell Mexican Peso/buy US Dollar
    (20,000 )     2/28/02       9.47       (48 )
Buy US Dollar/sell Mexican Peso
    94,371       3/27/02       10.46       1,102  
Sell Mexican Peso/buy US Dollar
    (40,000 )     3/27/02       9.48       (80 )
Buy US Dollar/sell Mexican Peso
    85,000       4/30/02       10.23       748  
Sell Mexican Peso/buy US Dollar
    (30,000 )     4/30/02       9.62       (84 )
Buy US Dollar/sell Mexican Peso
    81,000       5/31/02       10.11       559  
Sell Mexican Peso/buy US Dollar
    (25,000 )     5/31/02       9.71       (75 )
Buy US Dollar/sell Mexican Peso
    80,000       6/28/02       9.95       375  
Sell Mexican Peso/buy US Dollar
    (30,000 )     6/28/02       9.78       (88 )
Buy US Dollar/sell Mexican Peso
    48,000       7/31/02       10.07       242  
Buy US Dollar/sell Mexican Peso
    100,000       8/30/02       10.05       410  
Buy US Dollar/sell Mexican Peso
    45,000       9/30/02       10.09       169  
Buy US Dollar/sell Mexican Peso
    110,000       10/31/02       10.09       338  
Buy US Dollar/sell Mexican Peso
    30,000       11/29/02       10.27       122  
     
                     
 
    $ 688,873                     $ 5,540 (1)
     
                     
 

(1)  The Fair Value of the forward positions presented above, an unrealized loss of $5,540,000 at December 31, 2001, represents the carrying value of the forward contracts and has been recorded in accrued liabilities in the accompanying consolidated balance sheets.
 
(16)  Fourth Quarter Adjustments

      During the fourth quarter of 2001, the Company recorded a total of approximately $4,288,000 to bad debt expense due to declining consultant liquidity as a result of the general slowdown of the economy in Mexico and Brazil. During the fourth quarter of 2000, the Company recorded certain adjustments related to changes in cost accounting estimates, which resulted in an increase to cost of sales of approximately $3,000,000.

62


Table of Contents

INDEPENDENT AUDITORS’ REPORT

To the Board of Directors and Stockholder of

Jafra Cosmetics International, Inc.
Westlake Village, California

      We have audited the accompanying consolidated balance sheets of Jafra Cosmetics International, Inc. and subsidiaries (the “Company”), an indirect, wholly owned subsidiary of CDRJ Investments (Lux) S.A., as of December 31, 2001, and the related consolidated statements of income, stockholder’s equity, and cash flows for each of the two years in the period ended December 31, 2001. These financial statements and financial statement schedule are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements and financial statement schedule based on our audits.

      We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

      In our opinion, such consolidated financial statements referred to above present fairly, in all material respects, the financial position of Jafra Cosmetics International, Inc. and subsidiaries as of December 31, 2001, and the results of their operations and their cash flows for each of the two years in the period ended December 31, 2001, in conformity with accounting principles generally accepted in the United States of America. Also, in our opinion, the financial statement schedule referred to above, when considered in relation to the basic consolidated financial statements taken as a whole, presents fairly in all material respects the information set forth therein.

DELOITTE & TOUCHE, LLP

Los Angeles, California

March 6, 2002 (February 24, 2003, as
to paragraphs 16 and 17 of Note 2)

63


Table of Contents

INDEPENDENT AUDITORS’ REPORT

To the Board of Directors and Stockholder of

Jafra Cosmetics International, Inc.
Westlake Village, California

      We have audited the accompanying consolidated balance sheet of Jafra Cosmetics International, Inc. and subsidiaries (the “Company”), an indirect, wholly owned subsidiary of CDRJ Investments (Lux) S.A., as of December 31, 2002, and the related consolidated statement of income, stockholder’s equity, and cash flows for the year then ended. Our audit also included the financial statement schedule for the year ended December 31, 2002 listed at Item 15(a)(2). These financial statements and schedule are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audit.

      We conducted our audit in accordance with auditing standards generally accepted in the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

      In our opinion, such consolidated financial statements present fairly, in all material respects, the financial position of Jafra Cosmetics International, Inc. and subsidiaries as of December 31, 2002, and the results of their operations and their cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States. Also, in our opinion, the related financial statement schedule for the year ended December 31, 2002, when considered in relation to the basic financial statements taken as a whole, presents fairly in all material respects the information set forth therein.

      As discussed in Note 2 to the consolidated financial statements, effective January 1, 2002, the Company adopted Statement of Financial Accounting Standards No. 142.

  /s/ ERNST & YOUNG, LLP

Los Angeles, California

February 21, 2003

64


Table of Contents

JAFRA COSMETICS INTERNATIONAL, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(In thousands, except share amounts)
                     
December 31,

2002 2001


ASSETS
Current assets:
               
 
Cash and cash equivalents
  $ 13,088     $ 4,081  
 
Receivables, less allowances for doubtful accounts of $613 in 2002 and $523 in 2001.
    5,713       6,447  
 
Inventories
    11,974       8,677  
 
Receivables from affiliates
    25,608       23,633  
 
Prepaids and other current assets
    2,554       1,665  
 
Deferred income taxes
          55  
     
     
 
   
Total current assets
    58,937       44,558  
Property and equipment, net
    26,357       22,742  
Other assets:
               
 
Goodwill
    37,488       38,125  
 
Notes receivable from affiliates
    10,694       3,902  
 
Deferred financing fees, net
    2,375       3,004  
 
Other
    3,938       3,716  
     
     
 
   
Total
  $ 139,789     $ 116,047  
     
     
 
 
LIABILITIES AND STOCKHOLDER’S EQUITY
Current liabilities:
               
 
Current portion of long-term debt
  $ 4,000     $ 3,000  
 
Accounts payable
    5,944       5,591  
 
Accrued liabilities
    12,230       12,709  
 
Income taxes payable
    815       965  
 
Deferred income taxes
    643        
 
Payables to affiliates
    20,435       2,639  
     
     
 
   
Total current liabilities
    44,067       24,904  
Long-term debt
    47,108       52,908  
Deferred income taxes
    4,671       3,353  
Other long-term liabilities
    3,787       3,088  
     
     
 
   
Total liabilities
    99,633       84,253  
     
     
 
Commitments and contingencies
           
Stockholder’s equity:
               
 
Common stock, par value $.01; authorized, issued and outstanding, 1,000 shares in 2002 and 2001.
           
 
Additional paid-in capital
    39,649       39,649  
 
Retained earnings (deficit)
    3,249       (5,376 )
 
Accumulated other comprehensive loss
    (2,742 )     (2,479 )
     
     
 
   
Total stockholder’s equity
    40,156       31,794  
     
     
 
   
Total
  $ 139,789     $ 116,047  
     
     
 

See accompanying notes to consolidated financial statements.

65


Table of Contents

JAFRA COSMETICS INTERNATIONAL, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME

(In thousands)
                           
Years Ended December 31,

2002 2001 2000



Net sales to third parties
  $ 125,199     $ 110,227     $ 102,267  
Sales to affiliates
    15,817       13,442       14,297  
     
     
     
 
Net sales
    141,016       123,669       116,564  
Cost of sales
    43,778       37,383       36,063  
     
     
     
 
 
Gross profit
    97,238       86,286       80,501  
Selling, general and administrative expenses
    100,316       95,022       87,496  
Management fee income from affiliates
    (7,225 )     (8,504 )     (8,141 )
Restructuring and impairment charges
                2,392  
 
Loss on sale of assets
    1       92       147  
Royalty income from affiliates, net
    (19,775 )     (20,098 )     (14,620 )
Market subsidy expense
    5,121              
     
     
     
 
 
Income from operations
    18,800       19,774       13,227  
Other income (expense):
                       
 
Exchange gain (loss), net
    406       (225 )     (178 )
 
Interest expense, net
    (6,134 )     (6,794 )     (7,564 )
 
Other, net
    281       (189 )     9  
     
     
     
 
Income before income taxes and extraordinary item
    13,353       12,566       5,494  
Income tax expense
    4,728       6,054       3,075  
     
     
     
 
Income before extraordinary item
    8,625       6,512       2,419  
Extraordinary loss on early extinguishment of debt, net of income tax benefit of $120.
                205  
     
     
     
 
Net income
  $ 8,625     $ 6,512     $ 2,214  
     
     
     
 

See accompanying notes to consolidated financial statements.

66


Table of Contents

JAFRA COSMETICS INTERNATIONAL, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF STOCKHOLDER’S EQUITY

(In thousands, except for shares)
                                                     
Years Ended December 31,

2002 2001 2000



Shares Amount Shares Amount Shares Amount






Capital Stock:
                                               
 
Balance, beginning of year
    1,000     $       1,000     $       1,000     $  
     
     
     
     
     
     
 
 
Balance, end of year
    1,000             1,000             1,000        
Additional Paid-in Capital:
                                               
 
Balance, beginning of year
            39,649               39,649               38,749  
 
Capital contributions by parent
                                        900  
             
             
             
 
 
Balance, end of year
            39,649               39,649               39,649  
Retained Earnings (Deficit):
                                               
 
Balance, beginning of year
            (5,376 )             (11,888 )             (14,102 )
 
Net income
            8,625               6,512               2,214  
             
             
             
 
 
Balance, end of year
            3,249               (5,376 )             (11,888 )
Accumulated Other Comprehensive
                                               
 
Loss:
                                               
 
Balance, beginning of year
            (2,479 )             (2,223 )             (2,319 )
 
Currency translation adjustments
            (263 )             (256 )             96  
             
             
             
 
 
Balance, end of year
            (2,742 )             (2,479 )             (2,223 )
     
     
     
     
     
     
 
   
Total Stockholder’s Equity
    1,000     $ 40,156       1,000     $ 31,794       1,000     $ 25,538  
     
     
     
     
     
     
 
Comprehensive Income:
                                               
 
Net income
          $ 8,625             $ 6,512             $ 2,214  
 
Currency translation adjustments
            (263 )             (256 )             96  
             
             
             
 
   
Total Comprehensive Income
          $ 8,362             $ 6,256             $ 2,310  
             
             
             
 

See accompanying notes to consolidated financial statements.

67


Table of Contents

JAFRA COSMETICS INTERNATIONAL, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

                                 
Years Ended December 31,

2002 2001 2000



(In thousands)
Cash flows from operating activities:
                       
 
Net income
  $ 8,625     $ 6,512     $ 2,214  
 
Extraordinary loss on early extinguishment of debt, net of taxes
                205  
     
     
     
 
 
Income before extraordinary item
    8,625       6,512       2,419  
 
Adjustments to reconcile income before extraordinary item to net cash provided by (used in) operating activities:
                       
   
Loss on sale of property and equipment
          92       147  
   
Depreciation and amortization
    3,231       3,484       3,014  
   
Provision for uncollectible accounts receivable
    680       559       898  
   
Amortization of deferred financing fees
    629       628       633  
   
Asset impairment charge
                1,019  
   
Unrealized foreign exchange (gain) loss
    (99 )     208       249  
   
Deferred income taxes
    2,016       2,407       891  
   
Changes in operating assets and liabilities:
                       
     
Receivables
    54       (276 )     346  
     
Inventories
    (3,297 )     778       (2,287 )
     
Prepaid expenses and other current assets
    (889 )     733       (422 )
     
Affiliate receivables and payables
    15,920       (18,221 )     1,936  
     
Other assets
    309       254       841  
     
Accounts payable and accrued liabilities
    (126 )     (240 )     (1,999 )
     
Income taxes payable/prepaid
    (150 )     572       272  
     
Other long-term liabilities
    699       721       (341 )
     
     
     
 
       
Net cash provided by (used in) operating activities
    27,602       (1,789 )     7,616  
     
     
     
 
Cash flows from investing activities:
                       
 
Proceeds from sale of property and equipment
                92  
 
Purchases of property and equipment
    (6,669 )     (5,091 )     (4,418 )
 
Other
    (531 )     (408 )     (760 )
     
     
     
 
       
Net cash used in investing activities
    (7,200 )     (5,499 )     (5,086 )
     
     
     
 
Cash flows from financing activities:
                       
 
Repurchase of subordinated notes
                (6,358 )
 
Repayments under term loan facility
    (3,000 )     (2,500 )     (2,000 )
 
Net repayments under revolving credit facility
    (1,800 )     (12,700 )     (10,000 )
 
Capital contributions by Parent
                900  
 
Net transactions with affiliates
    (6,792 )     23,280       14,788  
     
     
     
 
       
Net cash (used in) provided by financing activities
    (11,592 )     8,080       (2,670 )
     
     
     
 
Effect of exchange rate changes on cash
    197       (93 )     496  
     
     
     
 
       
Net increase in cash and cash equivalents
    9,007       699       356  
Cash and cash equivalents at beginning of year
    4,081       3,382       3,026  
     
     
     
 
Cash and cash equivalents at end of year
  $ 13,088     $ 4,081     $ 3,382  
     
     
     
 
Supplemental disclosure of cash flow information
                       
 
Cash paid during the year for:
                       
   
Interest
  $ 5,847     $ 6,748     $ 9,669  
   
Income Taxes
    1,051       2,586       2,154  

See accompanying notes to consolidated financial statements.

68


Table of Contents

JAFRA COSMETICS INTERNATIONAL, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(1) Basis of Presentation and Description of Business

Basis of Presentation

      Jafra Cosmetics International, Inc., a Delaware corporation (“JCI”) is a wholly owned subsidiary of CDRJ North Atlantic (Lux) S.a.r.L., a Luxembourg société à responsabilité limitée, which is a wholly owned subsidiary of CDRJ Investments (Lux) S.A., a Luxembourg société anonyme (the “Parent”). JCI, its subsidiaries, and certain other subsidiaries of the Parent were organized by Clayton, Dubilier & Rice Fund V Limited Partnership, a Cayman Islands exempted limited partnership managed by Clayton, Dubilier & Rice, Inc. (“CD&R”) to acquire (the “Acquisition”) the worldwide Jafra Cosmetics business (the “Jafra Business”) from The Gillette Company.

      The accompanying consolidated financial statements reflect the operations of JCI and its subsidiaries (collectively, “JCI”). JCI is an operating subsidiary in the United States, and currently has operating subsidiaries in Austria, Germany, Italy, the Netherlands, Switzerland, the Dominican Republic and Thailand. All significant intercompany accounts and transactions have been eliminated in consolidation.

      In connection with the Acquisition, JCI and an affiliated company, Jafra Cosmetics International, S.A. de C.V. (“Jafra S.A.”) (the indirect, wholly owned Mexican subsidiary of the Parent) issued $100 million aggregate principal amount of 11.75% Subordinated Notes due 2008 (the “Notes”). See Note 6. The Notes represent several obligations of JCI and Jafra S.A., with each participating on a pro rata basis upon redemption. JCI and Jafra S.A. have fully and unconditionally guaranteed the obligations under the Notes of the other on a senior subordinated basis, subject to a 30-day standstill period prior to enforcement of such guarantees. As the cross-guarantee of JCI and Jafra S.A. is subject to a 30-day standstill period, the Parent is filing these separate financial statements of JCI as a schedule to its Annual Report on Form 10-K for the year ended December 31, 2002.

Description of Business

      JCI markets its products, which consist of premium skin and body care products, color cosmetics, fragrances, and other personal care products, primarily in the United States, but also through subsidiaries in Austria, Germany, Italy, the Netherlands, Switzerland, the Dominican Republic and Thailand and in a number of additional countries through distributors. JCI utilizes a direct selling, multilevel distribution system comprised of self-employed salespersons (known as “consultants”).

(2) Summary of Significant Accounting Policies

      Use of Estimates. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

      Cash and Cash Equivalents. Cash and cash equivalents include cash, time deposits and all highly liquid debt instruments purchased with a maturity of three months or less.

      Inventories. Inventories, which consist of finished goods, are stated at the lower of cost, as determined by the first-in, first-out basis, or market.

      Property and Equipment. Property and equipment are stated at cost. Depreciation of property and equipment is provided for over the estimated useful lives of the respective assets using the straight-line method. Estimated useful lives are 40 years for buildings, the lesser of 40 years or the term of the lease for improvements, 5 to 15 years for machinery and equipment and 5 to 8 years for hardware and software.

69


Table of Contents

JAFRA COSMETICS INTERNATIONAL, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Maintenance and repairs, including cost of minor replacements, are charged to operations as incurred. Costs of additions and betterments are added to property and equipment accounts provided that such expenditures increase the useful life or the value of the asset.

      Intangible Assets. Intangible assets principally consist of goodwill and trademarks. On January 1, 2002, JCI adopted Statement of Financial Accounting Standards (“SFAS”) No. 142, “Goodwill and other Intangible Assets” which requires JCI to not amortize goodwill and certain other intangible assets, but to test those intangible assets for impairment at least annually. Prior to adoption of SFAS No. 142, goodwill and other intangible assets were amortized using the straight-line method over a period of 40 years. Goodwill and trademarks resulted from the Parent’s acquisition of the Jafra Business. The book value of goodwill and trademarks was $37,488,000 and $237,000 at December 31, 2002, respectively. (See “New Accounting Standards”).

      Deferred Financing Costs. In connection with the acquisition of the Jafra Business, JCI incurred approximately $7.2 million of costs related to the 11.75% Senior Subordinated Notes due 2008 (the “Notes”), the revolving credit facility and the term loan facility (see Note 6). Such costs are being amortized on a basis that approximates the interest method over the expected term of the related debt. Accumulated amortization at December 31, 2002 and 2001 was $3,129,000 and $2,500,000, respectively.

      Impairment of Long-Lived Assets and Goodwill. Long-lived assets are reviewed for impairment, based on undiscounted cash flows, whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. If this review indicates that the carrying amount of the long-lived assets is not recoverable, JCI will recognize an impairment loss, measured by the future discounted cash flow method. Goodwill is tested for impairment annually, or whenever events or changes in circumstances indicate that the carrying amount of goodwill may not be recoverable based on the provisions of SFAS No. 142. (see “New Accounting Standards” and Note 10)

      Fair Value of Financial Instruments. The carrying amounts of cash and cash equivalents, accounts receivable, and accounts payable approximate fair value because of the short-term maturities of these instruments. The fair value of the Notes at December 31, 2002 and 2001 was $46,236,000 and $48,266,000, respectively, based on discussions with one of JCI’s largest bondholders and an analysis of current market interest rates and the Parent’s credit rating. As JCI’s revolving credit facility and the term loan are variable rate debt, and the interest rate spread paid by JCI is adjusted for changes in certain financial ratios of the Parent, the fair value of the revolving credit facility and the term loan approximated their carrying amounts at December 31, 2002 and 2001.

      Revenue Recognition. JCI recognizes revenue when title passes at shipment in accordance with its shipping terms. Amounts billed to consultants for shipping and handling costs are included in net sales. Sales are reduced by commissions paid to consultants on their personal sales.

      Shipping and handling costs. Shipping and handling costs of $12,706,000, $11,265,000 and $12,170,000 for the years ended December 31, 2002, 2001 and 2000, respectively, are included in selling, general and administrative expenses.

      Research and Development. Research and development costs are expensed as incurred. Total research and development expense aggregated $1,469,000, $1,842,000 and $1,901,000 for the years ended December 31, 2002, 2001 and 2000, respectively. The portion of the above-identified research and development expenses incurred by the JCI and charged to Jafra S.A. as part of the JCI’s management fee income (see Note 9) aggregated $1,081,000, $864,000 and $978,000, for the years ended December 31, 2002, 2001 and 2000, respectively.

      Income Taxes. JCI accounts for income taxes under the balance sheet approach that requires the recognition of deferred income tax assets and liabilities for the expected future consequences of events that

70


Table of Contents

JAFRA COSMETICS INTERNATIONAL, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

have been recognized in JCI’s financial statements or income tax returns. Management provides a valuation allowance for deferred income tax assets when it is more likely than not that a portion of such deferred income tax assets will not be realized. Income tax expense of JCI is computed on a separate-company basis.

      Foreign Currency Translation. The functional currency for foreign subsidiaries is generally the local currency. Assets and liabilities of such foreign subsidiaries are translated into U.S. dollars at current exchange rates, and related revenues and expenses are translated at average exchange rates in effect during the period. Resulting translation adjustments are recorded as a component of other comprehensive loss.

      New Accounting Standards. In June 2001, the Financial Accounting Standards Board (“FASB”) approved two new statements: SFAS No. 141, “Business Combinations” and SFAS No. 142, “Goodwill and Other Intangible Assets.” SFAS No. 141 requires business combinations entered into after June 30, 2001 to be accounted for using the purchase method of accounting. SFAS No. 142 requires that goodwill not be amortized, but be tested for impairment at least annually. SFAS No. 142 was effective for fiscal years beginning after December 15, 2001 to all goodwill and other intangible assets recognized in an entity’s statement of financial position at that date, regardless of when those assets were initially recognized. JCI adopted SFAS No. 142 on January 1, 2002. In accordance with such adoption, JCI identified all reporting units in conjunction with the provisions of SFAS No. 142 and allocated all goodwill accordingly. Prior to June 30, 2002, JCI completed the transitional goodwill impairment test required by SFAS No. 142. Based on the transitional and annual impairment test, JCI determined that there was no impairment to goodwill. During the year ended December 31, 2002, no impairment was identified. The changes in the carrying amount of goodwill for the year ended December 31, 2002 are as follows:

                         
United Consolidated
Goodwill States Europe Total




Balance as of December 31, 2001
  $ 32,188     $ 5,937     $ 38,125  
Translation effect
          (637 )     (637 )
     
     
     
 
Balance as of December 31, 2002
  $ 32,188     $ 5,300     $ 37,488  
     
     
     
 

      JCI’s other intangible assets consist of trademarks. During the year ended December 31, 2002, JCI determined trademarks to have an indefinite life and performed the transitional impairment test as required under SFAS No. 142. Based upon the transitional and annual test, JCI determined that there was no impairment of trademarks. The carrying value of trademarks was $237,000 at December 31, 2002 and is included in other assets in the accompanying consolidated balance sheets.

      In accordance with SFAS No. 142, JCI discontinued amortization of goodwill and other intangible assets with an indefinite life. A reconciliation of previously reported net income to amounts adjusted for the exclusion of goodwill and trademark amortization, net of the related income tax effects, where applicable, is as follows (in thousands):

                         
Years Ended December 31,

2002 2001 2000



Net income
  $ 8,625     $ 6,512     $ 2,214  
Goodwill amortization, net of tax
          725       863  
Trademark amortization, net of tax
          26       54  
     
     
     
 
Adjusted net income
  $ 8,625     $ 7,263     $ 3,131  
     
     
     
 

      In November 2001, the Emerging Issues Task Force (“EITF”) issued EITF Issue No. 01-9, “Accounting for Consideration Given by a Vendor to a Customer or a Reseller of the Vendor’s Products.” This new guidance provides that consideration from a vendor to a reseller is generally presumed to be a reduction of the selling prices of the vendor’s products, and, therefore, should be characterized as a reduction of revenue when

71


Table of Contents

JAFRA COSMETICS INTERNATIONAL, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

recognized in the vendor’s income statement. On January 1, 2002, JCI adopted EITF Issue No. 01-9 and reclassified commissions paid to consultants of $1,417,000 and $1,254,000 on their personal sales, previously reported as a component of selling, general and administrative expenses, as a reduction in net sales and selling, general and administrative expenses for the years ended December 31, 2001 and 2000, respectively.

      On January 1, 2002, JCI adopted SFAS No. 144, “Accounting for the Impairment or Disposal of Long-Lived Assets.” SFAS No. 144 supersedes SFAS No. 121, “Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to be Disposed of.” SFAS No. 144 retains substantially all of the requirements of SFAS No. 121, while resolving certain implementation issues and addressing the accounting for a component of a business accounted for as a discontinued operation. SFAS No. 144 was adopted with no significant impact on the financial position or results of operations of JCI.

      In April 2002, the FASB issued SFAS No. 145, “Rescission of FASB Statements No. 4, 44, and 64, Amendment of FASB Statement No. 13, and Technical Corrections.” This Statement rescinds or modifies existing authoritative pronouncements including SFAS No. 4 “Reporting Gains and Losses from Extinguishment of Debt.” As a result of the issuance of SFAS No. 145, gains and losses from extinguishment of debt should be classified as extraordinary items only if they meet the criteria in Accounting Principles Board (“APB”) Opinion 30, “Reporting the Results of Operations-Reporting the Effects of Disposal of a Segment of a Business, and Extraordinary, Unusual and Infrequently Occurring Events and Transactions.” Applying the provisions of APB Opinion 30 will distinguish transactions that are part of an entity’s recurring operations from those that are unusual or infrequent or that meet the criteria for classification as an extraordinary item. The provisions of this Statement related to the rescission of SFAS No. 4 shall be applied in fiscal years beginning after May 15, 2002. Any gain or loss on extinguishment of debt that was classified as an extraordinary item in prior periods presented that does not meet the criteria in APB Opinion 30 for classification as an extraordinary item shall be reclassified. JCI is currently evaluating the impact that this statement may have on any potential future extinguishments of debt. Upon adoption of SFAS No. 145, JCI will reclassify items previously reported as extraordinary items as a component of operating income on the accompanying statements of income.

      In June 2002, the FASB approved SFAS No. 146, “Accounting for Costs Associated with Exit or Disposal Activities.” This statement addresses financial accounting and reporting for costs associated with exit or disposal activities and nullifies EITF Issue No. 94-3, “Liability Recognition for Certain Employee Termination Benefits and Other Costs to Exit an Activity.” The provisions of this statement are effective for exit or disposal activities that are initiated after December 31, 2002, with early application encouraged. JCI is currently evaluating the impact that this statement may have on any potential future exit or disposal activities.

      During 2002, the FASB issued SFAS No. 148, “Accounting for Stock Based Compensation — Transaction and Disclosure, an amendment to FASB Statement No. 123.” This Statement requires more extensive interim disclosure related to stock based compensation for all companies and permits additional transition methods for companies that elect to use the fair value method for employee stock compensation. This statement is effective for fiscal years ending after December 15, 2002, with early adoption regarding annual disclosure encouraged. JCI adopted the disclosure requirements of SFAS No. 148. (See note 13).

      Reclassifications. Certain reclassifications were made to the prior year financial statements to conform to current year presentation.

72


Table of Contents

JAFRA COSMETICS INTERNATIONAL, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

(3) Inventories

      Inventories consist of the following at December 31, 2002 and 2001 (in thousands):

                 
2002 2001


Raw materials and supplies
  $ 243     $  
Finished goods
    11,731       8,677  
     
     
 
Total inventories
  $ 11,974     $ 8,677  
     
     
 

(4) Property and Equipment

      Property and equipment consist of the following at December 31, 2002 and 2001 (in thousands):

                 
2002 2001


Land
  $ 6,188     $ 6,188  
Buildings and improvements
    7,099       6,763  
Machinery, equipment and other
    22,460       15,971  
     
     
 
      35,747       28,922  
Less accumulated depreciation
    9,390       6,180  
     
     
 
Property and equipment, net
  $ 26,357     $ 22,742  
     
     
 

(5) Accrued Liabilities

      Accrued liabilities consist of the following at December 31, 2002 and 2001 (in thousands):

                 
2002 2001


Sales promotions, commissions and overrides
  $ 2,965     $ 3,182  
Accrued restructuring charges (Note 10)
          128  
Accrued interest
    880       931  
Compensation and other benefit accruals
    4,832       4,291  
State and local sales taxes and other taxes
    1,180       1,282  
Other
    2,373       2,895  
     
     
 
Total accrued liabilities
  $ 12,230     $ 12,709  
     
     
 

(6) Debt

      Debt consists of the following at December 31, 2002 and 2001 (in thousands):

                 
2002 2001


Subordinated Notes, unsecured, interest payable semi-annually at 11.75% due in 2008. 
  $ 45,108     $ 45,108  
Term loan, secured, principal and interest due in quarterly installments through April 30, 2004, interest rates at 3.1% and 4.3% at December 31, 2002 and 2001, respectively
    6,000       9,000  
Revolving loan, secured, due April 30, 2004, weighted average interest rates of 5.4% at December 31, 2001
          1,800  
     
     
 
Total debt
    51,108       55,908  
Less current maturities
    4,000       3,000  
     
     
 
Long-term debt
  $ 47,108     $ 52,908  
     
     
 

73


Table of Contents

JAFRA COSMETICS INTERNATIONAL, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

      JCI’s long-term debt matures as follows (in thousands): $4,000 in 2003, $2,000 in 2004, $0 in 2005, 2006 and 2007 and $45,108 thereafter.

      On April 30, 1998, JCI and Jafra S.A. borrowed $125 million by issuing $100 million aggregate principal amount of 11.75% Subordinated Notes due 2008 (the “Notes”) pursuant to an Indenture dated April 30, 1998 (the “Indenture”) and $25 million under a senior credit agreement.

      At the date of issuance, the Notes represented several obligations of JCI and Jafra S.A. in the amount of $60 million and $40 million, respectively, with each participating on a pro rata basis upon redemption. The Notes mature in 2008 and bear a fixed interest rate of 11.75% payable semi-annually.

      JCI and Jafra S.A. are indirect, wholly owned subsidiaries of the Parent and have fully and unconditionally guaranteed the obligations under the Notes of the other on a senior subordinated basis, subject to a 30-day standstill period prior to enforcement of such guarantees. In addition, the Parent has fully and unconditionally guaranteed the Notes on a senior subordinated basis. JCI has no U.S. subsidiaries. Each acquired or organized U.S. subsidiary of JCI will also be required to fully and unconditionally guarantee the Notes jointly and severally, on a senior subordinated basis. Each existing subsidiary of Jafra S.A. fully and unconditionally guarantees the Notes jointly and severally, on a senior subordinated basis, and each subsequently acquired or organized subsidiary of Jafra S.A. will fully and unconditionally guarantee the Notes jointly and severally, on a senior subordinated basis. The nonguarantor entities are JCI’s indirect subsidiaries in Austria, Germany, Italy, the Netherlands, Switzerland, the Dominican Republic and Thailand, and the Parent’s indirect subsidiaries in Poland, Argentina, Brazil, Chile, Colombia, Peru, and Venezuela. All guarantor and nonguarantor entities are either direct or indirect wholly owned subsidiaries of the Parent. The Notes were registered in a registered exchange offer, effective as of January 25, 1999, under the Securities Act of 1933, as amended.

      The Notes are unsecured and are generally non-callable for five years. Thereafter, the Notes will be callable at premiums declining to par in the eighth year.

      Consents and waivers, dated June 30, 2001 and November 19, 1999, to the senior credit agreement, as described below, allow JCI and Jafra S.A. to repurchase the Notes in the open market from time to time, with the aggregate purchase price for all such Notes repurchased not to exceed $50 million. Aggregate repurchases as of December 31, 2002 were $24.8 million. During 2000, JCI retired notes, prior to maturity, with a face value of $6.5 million. The debt repurchases in 2000 resulted in an extraordinary loss of $205,000, net of an income tax benefit of $120,000. In connection with the early retirement of the Notes as described above, a portion of the unamortized deferred financing costs was written off and included in the determination of the extraordinary loss on early extinguishment of debt. In 2000, $459,000 of the unamortized deferred financing fees were written off.

      In addition, JCI and Jafra S.A. entered into a senior credit agreement that provides for senior secured credit facilities in an aggregate principal amount of $90 million, consisting of a multicurrency revolving credit facility of $65 million and a term loan facility of $25 million. Borrowings under the term loan facility are payable in quarterly installments of principal and interest over six years through April 30, 2004. Borrowings under the revolving credit facility mature on April 30, 2004. Borrowings under the senior credit agreement currently bear interest at an annual rate of LIBOR plus a margin of 1.625% or an alternate base rate (the higher of the prime rate or federal funds rate plus 0.5%, plus an applicable margin of 0.625%). The interest rate in effect at December 31, 2002 was approximately 3.1% for the LIBOR-based borrowings. Borrowings under the senior credit agreement are secured by substantially all of the assets of JCI and Jafra S.A. No amounts were outstanding under the revolving credit facility at December 31, 2002.

      Both the Indenture and the Senior Credit Agreement contain certain covenants that limit JCI’s ability to incur additional indebtedness, pay cash dividends and make certain other payments. These debt agreements also require the Parent to maintain certain financial ratios including a minimum EBITDA to cash interest expense coverage ratio and a maximum debt to EBITDA ratio.

74


Table of Contents

JAFRA COSMETICS INTERNATIONAL, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

(7) Income Taxes

      JCI’s income before income taxes consists of the following (amounts in thousands):

                           
Years Ended December 31,

2002 2001 2000



Income before income taxes and extraordinary item:
                       
 
United States
  $ 12,859     $ 13,530     $ 9,741  
 
Foreign
    494       (964 )     (4,247 )
     
     
     
 
    $ 13,353     $ 12,566     $ 5,494  
     
     
     
 

      Actual income tax expense differs from the “expected” tax expense (computed by applying the U.S. federal corporate rate of 35% to income before income taxes) as a result of the following:

                         
Years Ended December 31,

2002 2001 2000



Provision for income taxes at federal statutory rate
  $ 4,674     $ 4,398     $ 1,922  
Foreign income subject to tax other than at federal statutory rate, principally withholding taxes
    1,886       2,532       1,298  
Foreign tax and other credits
    (2,312 )     (3,230 )     (1,724 )
State income taxes
    548       544       243  
Valuation allowance — domestic
    19       944       (616 )
Valuation allowance — foreign
    23       674       1,911  
Other
    (110 )     192       41  
     
     
     
 
Income tax expense
  $ 4,728     $ 6,054     $ 3,075  
     
     
     
 

      The components of the provision for income taxes are as follows (in thousands):

                               
Years Ended December 31,

2002 2001 2000



Current:
                       
 
Federal
  $ 178     $ 140     $ 72  
 
Foreign:
                       
   
Foreign withholding taxes
    2,250       2,296       1,820  
   
Europe
    (297 )     641       49  
   
Other
    33       26        
     
     
     
 
      1,986       2,963       1,869  
 
State
    548       544       243  
     
     
     
 
     
Total current
    2,712       3,647       2,184  
Deferred — foreign
                 
Deferred — domestic
    2,016       2,407       891  
     
     
     
 
     
Total deferred
    2,016       2,407       891  
Total income taxes on income before income taxes and extraordinary item
    4,728       6,054       3,075  
Income tax benefit on early extinguishment of debt
                (120 )
     
     
     
 
     
Total income tax expense
  $ 4,728     $ 6,054     $ 2,955  
     
     
     
 

75


Table of Contents

JAFRA COSMETICS INTERNATIONAL, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

      The components of deferred income tax assets and deferred income tax liabilities at December 31, 2002 and 2001 are as follows (in thousands):

                     
2002 2001


Deferred income tax assets:
               
 
Net operating loss carryforward
  $ 6,857     $ 6,834  
 
Disallowed interest expense
          26  
 
Foreign tax and other credit carryforward
    2,071       2,646  
 
Other accrued liabilities
    180       331  
 
Other
    1,409       1,927  
     
     
 
   
Total deferred income tax assets
    10,517       11,764  
 
Less valuation allowance
    (9,522 )     (9,480 )
     
     
 
   
Net deferred income tax assets
    995       2,284  
Deferred income tax liabilities:
               
 
Property and equipment
    (2,007 )     (1,602 )
 
Trademark and goodwill
    (3,474 )     (2,631 )
 
Inventories
    (261 )     (930 )
 
Other
    (567 )     (419 )
     
     
 
   
Total deferred income tax liabilities
    (6,309 )     (5,582 )
     
     
 
   
Net deferred income tax liabilities
  $ (5,314 )   $ (3,298 )
     
     
 

      JCI records a valuation allowance on the deferred income tax assets to reduce the total to an amount that management believes is more likely than not to be realized. The valuation allowances at December 31, 2002 and 2001 were based upon JCI’s estimates of the future realization of deferred income tax assets. Valuation allowances at December 31, 2002 were provided to offset foreign operating loss carryforwards of $6,857,000 and foreign tax, other credit carryforwards of $2,071,000 and certain other pretax expenses. These amounts were reduced by a valuation allowance of $10,517,000. Valuation allowances at December 31, 2001 were provided to offset foreign operating loss carryforwards of $6,834,000 and foreign tax and other credit carryforwards of $2,646,000 resulting from JCI’s U.S. and European subsidiaries. These deferred income tax assets were reduced by a valuation allowance of $9,522,000 and $9,480,000 as December 31, 2002 and 2001, respectively. The tax loss carryforwards expire in varying amounts between 2003 and 2012. Realization of the income tax carryforwards is dependent on generating sufficient taxable income prior to expiration of the carryforwards.

(8) Benefit Plans

      Certain employees of the JCI’s German subsidiary participate in a defined benefit pension plan covering key employees (the “Germany Plan”). Benefits are based on age, years of service and the level of compensation during the final years of employment. JCI’s funding policy is to contribute annually to the Germany Plan the amount necessary to meet the minimum funding standards. JCI recognized pension expense of $48,000 and $278,000 for the years ended December 31, 2002 and 2001, respectively and recognized pension income of $18,000 for the year ended December 31, 2000 due to the departure of certain employees.

      JCI has an employee savings plan which permits participants to make voluntary contributions by salary deferrals pursuant to section 401(k) of the Internal Revenue Code, which allows employees to defer up to 20% of their total compensation, subject to statutory limitations. Employee contributions of up to 10% of compensation are matched by JCI at the rate of 50 cents per dollar. Employees do not vest in JCI’s contribution until they have reached two years of service, at which time they become fully vested. The JCI’s

76


Table of Contents

JAFRA COSMETICS INTERNATIONAL, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

expense under this program was $618,000, $600,000 and $620,000 for the years ended December 31, 2002, 2001 and 2000, respectively.

      JCI also has a supplemental excess benefit savings plan, which permits participants to make unlimited voluntary contributions. Employee contributions are matched on the same basis as under the employee savings plan, and the vesting provisions are the same. JCI’s expense under this program was $207,000, $177,000 and $213,000 for the years ended December 31, 2002, 2001 and 2000, respectively. Employee and employer contributions under such plan are placed into a “rabbi” trust exclusively for the uses and purposes of plan participants and general creditors of JCI. The JCI has recorded an asset and the related liability in the accompanying consolidated balance sheets of $2,411,000 and $1,880,000 at December 31, 2002 and 2001, respectively.

(9) Related Party Transactions

      JCI distributes skin and body products to other subsidiaries of the Parent (“affiliates”). Sales to affiliates, primarily in Mexico and South America, were $15,817,000, $13,442,000 and $14,297,000 for the years ended December 31, 2002, 2001 and 2000, respectively. These sales were made at cost plus a markup ranging from 0 to 11%. JCI also purchases color and fragrance products from the Parent’s Mexico affiliate (“Jafra S.A.”) totaling $13,592,000, $9,849,000 and $8,856,000 for the years ended December 31, 2002, 2001 and 2000, respectively.

      In addition, JCI provides certain management services, such as legal, accounting and treasury, management oversight, and other administrative functions to affiliates. The cost of these services is included in selling, general and administrative expenses in the accompanying consolidated statements of income. JCI charges out a portion of these management expenses to its affiliates based upon charges identified to specific affiliates and upon a formula using the percentage of revenues of each affiliate to the total consolidated revenues of the Parent. JCI believes the amounts and methods of allocations are reasonable and approximate the cost of the actual services provided. The management fee income, which consists of amounts billed to affiliates in Mexico and South America, was $7,225,000, $8,504,000 and $8,141,000 for the years ended December 31, 2002, 2001 and 2000, respectively.

      During 1999, JCI sold U.S. trademarks and German trademarks to Jafra S.A. As a result of these sales, Jafra S.A. charges JCI a fee for the right to use the Jafra trademark in the United States and Europe. The total royalty expense charged by Jafra S.A. to JCI was $2,443,000, $1,639,000 and $1,126,000 for the years ended December 31, 2002, 2001 and 2000, respectively, and is offset against royalty income from affiliates in the accompanying consolidated statements of income.

      JCI owns the worldwide rights to its multi-level sales know-how (referred to as the “Jafra Way”). The Jafra Way was initially developed in the United States for lineage, training, and compensation of consultants. JCI charges Jafra S.A. a royalty for the use of the Jafra Way. The royalty fees charged by JCI were $22,218,000, $21,737,000 and $15,746,000 for the years ended December 31, 2002, 2001 and 2000, respectively, and were based upon a percentage of Jafra S.A.’s sales.

      JCI has granted loans to certain affiliates at annual interest rates ranging from 6% to 9%. Such loans are due to be repaid five years from the date of grant, with no prepayment penalty. Notes receivable from affiliates at December 31, 2002 and 2001 consists primarily of loans JCI has made to subsidiaries of the Parent to fund certain of their operations in South America. Net interest income from affiliates, was $351,000, $703,000 and $2,126,000 the years ended December 31, 2002, 2001 and 2000, respectively.

      JCI reimburses certain foreign affiliates for the expenses that they incur in establishing a direct selling, multilevel distribution system and customer base in new markets. Such subsidies amounted to $5,121,000 in 2002 and $0 in 2001 and 2000.

77


Table of Contents

JAFRA COSMETICS INTERNATIONAL, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

      Pursuant to a consulting agreement entered into following the Acquisition, until the 10th anniversary of the Acquisition or the date on which CD&R Fund V no longer has an investment in the Parent or until the termination by either party with 30 days notice, CD&R will receive an annual fee (and reimbursement of out-of-pocket expenses) for providing advisory, management consulting and monitoring services to the Parent. On January 1, 2000, the annual fee was $400,000. As of January 1, 2001, the annual fee was increased to $1,000,000. As required by the terms of the Parent’s lending arrangements, such fees are determined by arm’s-length negotiation and are believed by the Parent to be reasonable. The amendment, effective January 1, 2001, adds to CD&R’s services under the agreement financial advisory, investment banking and similar services with respect to future proposals for an acquisition, merger, recapitalization, or other similar transaction directly or indirectly involving the Parent or any of its subsidiaries. The fee for such additional services in connection with future transactions would be an amount equal to 1% of the transaction value for the transaction to which such fee relates. Such transaction fees may be increased upon approval of a majority of the members of the Parent’s Board of Directors who are not employees of the Parent, CD&R or any affiliate of CD&R. The amendment also provides that if any employee of CD&R is appointed to an executive management position (or a position of comparable responsibility) in the Parent or any of its subsidiaries, the annual fee will be increased by an amount to be determined by CD&R, the amount of such increase not to exceed 100% of the existing annual fee in effect at that time. The CD&R fees incurred during the years ended December 31, 2002, 2001 and 2000 were $1,000,000, $1,000,000 and $400,000, respectively. These fees were recorded as selling, general, and administrative expenses in the accompanying consolidated statements of income, and a portion of the fees was allocated to affiliates as part of JCI’s management fee income from affiliates. Certain officers and directors of CD&R or its affiliates serve as directors of the Parent.

      Prior to 2000, JCI engaged Guidance Solutions (“Guidance”), a corporation in which an investment fund managed by CD&R has an investment, to develop its e-commerce systems. Under the agreement entered into by both parties, JCI agreed to pay fees of approximately $2.0 million to Guidance in connection with planning, defining, designing and consulting services performed related to its e-commerce initiative. During the years ended December 31, 2000, JCI paid fees to Guidance of $1,798,000. A portion of these amounts was allocated to JCI’s affiliates. JCI terminated its agreement with Guidance and executed a settlement and mutual release agreement effective September 30, 2000. Upon execution of this agreement in October of 2000, Guidance paid JCI $25,000 and agreed to pay the JCI an aggregate additional sum of $475,000, payable in quarterly installments plus interest at 9.5% per annum, beginning in January 2001 through October 2005. As of December 31, 2002, the balance was paid in full.

(10) Restructuring and Impairment Charges and Related Accruals

      Prior Years Restructuring and Impairment Charges. In 2000, JCI recorded approximately $1.4 million of restructuring charges and approximately $1.0 million of asset impairment charges. The restructuring charges of approximately $1.4 million related to the JCI’s repositioning activities in Europe, primarily severance, of which $1.3 million was paid in 2000 and 2001 and the remaining $0.1 million was paid in 2002. The asset impairment charges of $1.0 million consisted of approximately $0.3 million related to JCI’s repositioning activities in Europe and approximately $0.7 million related to the write-down of certain capitalized computer software costs in the United States.

78


Table of Contents

JAFRA COSMETICS INTERNATIONAL, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

      The components of the additions and/or adjustments to the aforementioned accruals include severance, lease costs, fixed asset disposals, and other exit costs, and are summarized as follows (in thousands):

                     
Years Ended
December 31,

2001 2000


Additions — charges to income:
               
 
Severance
  $ (84 )   $ 1,170  
 
Lease costs
    80       170  
 
Other
    4       84  
     
     
 
   
Total additions
  $     $ 1,424  
     
     
 

      A rollforward of the activity of the restructuring accruals is summarized as follows (in thousands):

                           
Years Ended December 31,

2002 2001 2000



Opening balance
  $ 128     $ 516     $ 1,105  
Additions
                1,424  
Charges against reserves
    (128 )     (388 )     (2,013 )
     
     
     
 
 
Ending balance
  $     $ 128     $ 516  
     
     
     
 

      The remaining costs at each year-end included in the restructuring accrual are summarized as follows (in thousands):

                 
December 31,

2001 2000


Severance
  $     $ 346  
Lease costs and other
    128       170  
     
     
 
    $ 128     $ 516  
     
     
 

      The principal component of the restructuring accruals was severance. A summary of the severance activity is as follows (dollar amounts in thousands):

                                   
Years Ended December 31,

2001 2000


Number of Number of
Employees Amount Employees Amount




Opening balance
    10     $ 346       43     $ 1,105  
Planned terminations
                29       1,170  
Adjustment to planned terminations
          (84 )            
Actual terminations
    (10 )     (262 )     (62 )     (1,929 )
     
     
     
     
 
 
Ending balance
        $       10     $ 346  
     
     
     
     
 

(11) Financial Reporting for Business Segments

      Segment information has been prepared in accordance with SFAS No. 131, “Disclosure about Segments of an Enterprise and Related Information”. SFAS No. 131 requires disclosure of certain information regarding operating segments, products and services, geographic areas of operations and major customers.

      JCI’s business is comprised of one industry segment, direct selling, with worldwide operations, principally in the United States and Europe. JCI is organized into geographical business units that each sell the full line

79


Table of Contents

JAFRA COSMETICS INTERNATIONAL, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

of Jafra cosmetics, skin care, body care, fragrances, and other products. JCI has two reportable business segments: the United States and Europe. Business results for subsidiaries in the Dominican Republic and Thailand are combined and included in the following table under the caption “All Others”.

      The accounting policies used to prepare the information reviewed by the JCI’s chief operating decision makers are the same as those described in the summary of significant accounting policies. JCI evaluates performance based on segment operating income, excluding reorganization and restructuring charges, unusual gains and losses, and amortization of goodwill and intangibles. Consistent with the information reviewed by the JCI’s chief operating decision makers, corporate costs, foreign exchange gains and losses, interest expense, other nonoperating income or expense, and income taxes are not allocated to operating segments. The effects of intersegment sales (net sales and related gross profit) are excluded from the computation of segment operating income. Gross profit from affiliates and notes and accounts receivable from affiliates (primarily in Mexico and South America) are included in the following table under the caption “Corporate, Unallocated and Other.”

                                                 
Corporate,
United All Total Unallocated Consolidated
Dollars in thousands States Europe(1) Others Segments and Other Total







Year ended December 31, 2002
                                               
Net sales
  $ 92,143     $ 26,932     $ 6,124     $ 125,199     $ 15,817     $ 141,016  
Operating profit (loss)
    15,620       1,224       (89 )     16,755       2,045       18,800  
Depreciation and amortization
    2,631       382       218       3,231             3,231  
Capital expenditures
    6,298       174       197       6,669             6,669  
Segment assets
    82,532       18,414       2,541       103,487       36,302       139,789  
Goodwill
    32,188       5,300             37,488             37,488  
Year ended December 31, 2001
                                               
Net sales
    79,611       26,295       4,321       110,227       13,442       123,669  
Operating profit (loss)
    11,580       2,143       (768 )     12,955       6,819       19,774  
Depreciation and amortization
    2,709       601       174       3,484             3,484  
Capital expenditures
    4,529       230       332       5,091             5,091  
Segment assets
    67,792       17,522       3,198       88,512       27,535       116,047  
Year ended December 31, 2000
                                               
Net sales
    74,137       26,680       1,450       102,267       14,297       116,564  
Operating profit (loss)
    10,709       876       (790 )     10,795       2,432       13,227  
Depreciation and amortization
    2,111       883       20       3,014             3,014  
Capital expenditures
    3,662       90       666       4,418             4,418  
Segment assets
  $ 68,843     $ 17,650     $ 2,102     $ 88,595     $ 32,547     $ 121,142  


(1)  excludes Poland, an indirect wholly-owned subsidiary of the Parent, an affiliate of JCI.

80


Table of Contents

JAFRA COSMETICS INTERNATIONAL, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

      Additional business segment information regarding product lines is as follows:

                                                     
2002 2001 2000



Sales by Percentage Sales by Percentage Sales by Percentage
Product of Total Product of Total Product of Total
Line Sales Line Sales Line Sales






(in millions) (in millions) (in millions)
Skin care
  $ 35.2       29.4 %   $ 36.2       34.3 %   $ 34.3       34.9 %
Color cosmetics
    21.6       18.0       18.7       17.7       17.9       18.2  
Fragrances
    26.2       21.9       22.1       21.0       20.5       20.9  
Body care and personal care
    18.0       15.0       12.5       11.9       12.0       12.2  
Other(1)
    18.8       15.7       15.9       15.1       13.6       13.8  
     
     
     
     
     
     
 
 
Subtotal before shipping, other fees and sales to affiliates, less commissions
    119.8       100.0 %     105.4       100.0 %     98.3       100.0 %
             
             
             
 
Shipping and other fees, less commissions
    5.4               4.8               4.0          
Sales to affiliates
    15.8               13.5               14.3          
     
             
             
         
   
Total
  $ 141.0             $ 123.7             $ 116.6          
     
             
             
         


(1)  Includes sales aids (e.g.; party hostess gifts, demonstration products, etc.) and promotional materials, which typically do not qualify for commissions or overrides.

(12) Commitments and Contingencies

      The Company leases office and warehouse facilities as well as manufacturing, transportation and data processing equipment under operating leases which expire at various dates through 2007. The leases contain certain renewal options and require payment of property taxes, utilities, common area maintenance and insurance and rent escalation clauses based upon consumer price indices. Future minimum lease payments under noncancelable operating leases as of December 31, 2002 are (in thousands):

         
2003
  $ 1,186  
2004
    1,127  
2005
    967  
2006
    712  
2007
    601  
     
 
    $ 4,593  
     
 

      Rental expense was $1,058,000, $1,453,000 and $1,617,000 for the years ended December 31, 2002, 2001 and 2000, respectively.

      In connection with the issuance of the Parent’s Common Stock, the Parent has guaranteed loans for some members of JCI’s management. As of December 31, 2002, approximately $2,145,000 of loans were outstanding and guaranteed by the Parent.

      During 2002, JCI initiated product replacement for a certain product sold in 2001 and 2002. The total cost of the product replacement is approximately $400,000. However, management believes that the majority the cost will be recovered pursuant to contractual obligations with the third-party manufacturer. (See Note 14).

81


Table of Contents

JAFRA COSMETICS INTERNATIONAL, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

      In accordance with FASB Statement No. 144, “Accounting for the Impairment or Disposal of Long-Lived Assets,” JCI recorded impairment losses on long-lived assets used in operations when events and circumstances indicate that long-lived assets might be impaired and undiscounted cash flows estimated to be generated by those assets are less than the carrying amounts of those assets. Subsequent to December 31, 2002, JCI is considering strategic decisions to exit certain non-core markets in Thailand and some or all of Europe through sale or discontinuance of these operations. As of December 31, 2002, no decision had been made on these non-core markets and the undiscounted cash flows indicated that such carrying amounts were expected to be recovered. It is reasonably possible that the estimate of undiscounted cash flows may change in the near term resulting in a need to write down those assets to fair value. In accordance with FASB 142, Goodwill and Other Intangible Assets, the transitional and annual impairment test indicated that fair value of the reporting units associated with the non-core markets exceeded the carrying value, including goodwill, at December 31, 2002.

      JCI is involved from time to time in routine legal matters incidental to its business. JCI believes that the resolution of such matters will not have a material adverse effect on JCI’s business, financial condition or results of operations.

(13) Management Incentive Arrangements

Company Plan

      Effective 1998, the Parent adopted a stock incentive plan (the “Stock Incentive Plan”), which provides for the sale to members of senior management of up to 52,141 shares of common stock of the Parent and the issuance of options to purchase up to 104,282 additional shares of common stock. The Parent reserved 156,423 shares for issuance under the Stock Incentive Plan, and as of December 31, 2002, 42,121 shares and 84,242 options were outstanding. A summary of the status and activity of shares purchased under the Stock Incentive Plan is as follows:

                 
Number of Price Per
Shares Share


Shares outstanding at December 31, 1999
    38,392          
Shares issued in 2000
    4,424       206  
Options exercised in 2000
    158       100  
Shares repurchased in 2000
    (948 )   $ 210  
     
         
Shares outstanding at December 31, 2000
    42,026          
Shares issued in 2001
    474       210  
Options exercised in 2001
    210       150  
Shares repurchased in 2001
    (589 )   $ 250  
     
         
Shares outstanding at December 31, 2001
    42,121          
Shares issued in 2002
           
Options exercised in 2002
           
Shares repurchased in 2002
           
     
         
Shares outstanding at December 31, 2002
    42,121          
     
         

      The purchase price of shares issued in 2000 and 2001 and options exercised in 2000 and 2001 represented the estimated fair value at the respective dates of issuance and exercise, except as discussed below. In 2000, 316 shares were issued at a price below fair value, and the Parent recognized compensation expense of approximately $19,000. In 2001, 210 shares were issued at a price below fair value, and the Company recognized compensation expense of approximately $21,000. Under certain circumstances, the management

82


Table of Contents

JAFRA COSMETICS INTERNATIONAL, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

stockholders can require the Parent to repurchase their shares, subject to a holding period of at least seven months from the date such shares were acquired, for an amount not to exceed fair value.

      In connection with the purchase of common stock of the Parent, certain members of senior management were granted options to purchase two additional shares of common stock for each share purchased at an exercise price equal to the fair value at the date of grant under the Stock Incentive Plan. The options have a life of ten years from the date of grant. Fifty percent of the options granted are expected to vest in three equal installments on each of the first three anniversaries of the date of grant, subject to the continuous employment of the grantee (“Option Type 1”). The remaining fifty percent of the options become vested as follows, subject to the continuous employment of the grantee: (a) up to one-third of the options become vested as of each of the first three anniversaries of the date of grant if the Parent achieves at least 85% of its EBITDA target for the immediately preceding fiscal year, (b) if less than one-third of the total number of options shall have become vested as provided in clause (a) above, the portion that has not become so vested shall become vested as of the first day of the fiscal year following the fiscal year, if any, that the Parent achieves its cumulative EBITDA target, and (c) any options that do not become vested as provided above will become vested on the ninth anniversary of the date of grant (“Option Type 2”). A summary of the status and activity of the options under the Stock Incentive Plan is as follows:

                                                 
2002 2001 2000



Weighted Weighted Weighted
Average Average Average
Exercise Exercise Exercise
Shares Price Shares Price Shares Price






Outstanding at beginning of year
    84,242     $ 112.36       84,052     $ 111.69       76,784     $ 101.03  
Granted
                948       210.00       8,848       205.71  
Exercised
                (210 )     150.00       (158 )     100.00  
Canceled
                (548 )     163.80       (1,422 )     122.22  
     
             
             
         
Outstanding at year-end
    84,242     $ 112.36       84,242     $ 112.36       84,052     $ 111.69  
     
             
             
         
Options exercisable at year-end
    66,615     $ 109.92       63,528     $ 105.32       37,655     $ 100.70  
Options available for grant
    19,093             19,093             19,493        

      The following table summarizes information about options outstanding as of December 31, 2002:

                                             
Outstanding Exercisable


Weighted
Average Weighted Weighted
Remaining Average Average
Exercise Number Contractual Exercise Number Exercise
Price of Options Life (Yrs.) Price of Options Price






$ 100.00       74,256       5.75     $ 100.00       60,117     $ 100.00  
$ 150.00       948       6.92       150.00       902       150.00  
$ 210.00       9,038       7.63       210.00       5,596       210.00  
         
                     
         
          84,242       5.96     $ 112.36       66,615     $ 109.92  
         
                     
         

      JCI applies Accounting Principles Board Opinion No. 25, “Accounting for Stock Issued to Employees,” and related Interpretations in accounting for these options. As the options were granted with exercise prices equal to the fair value at the date of grant, no compensation cost was recognized by JCI upon issuance of such options. The fair value of each option granted by JCI was estimated using the minimum value option pricing

83


Table of Contents

JAFRA COSMETICS INTERNATIONAL, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

model. The assumptions used in this pricing model and the weighted average fair value of options granted during 2001 and 2000 are summarized as follows:

                                 
2001 2000


Option Option Option Option
Type 1 Type 2 Type 1 Type 2




Risk-free interest rate
    5.80 %     5.80 %     6.30 %     6.30 %
Expected option life (in years)
    5.0       7.0       5.0       7.0  
Expected volatility
    0.0 %     0.0 %     0.0 %     0.0 %
Expected dividend yield
    0.0 %     0.0 %     0.0 %     0.0 %
Weighted average fair value per option
  $ 52.20     $ 69.28     $ 56.00     $ 73.97  

Pro Forma Compensation Cost

      Had JCI recorded compensation cost based on the fair value of options granted at the grant date, as prescribed by FASB Statement No. 123, “Accounting for Stock Based Compensation,” pro forma net income would have been as follows (in thousands):

                         
Years Ended December 31,

2002 2001 2000



Net income, as reported
  $ 8,625     $ 6,512     $ 2,214  
Pro forma compensation cost
    83       319       609  
     
     
     
 
Pro forma net income
  $ 8,542     $ 6,193     $ 1,605  
     
     
     
 

Employment Agreements

      Certain senior executive officers have employment agreements which provide for annual bonuses if the Parent achieves the performance goals established under its annual incentive plan for executives.

      JCI has a bonus plan for U.S. based employees which provides that 50% of the bonus earned by any Vice President or Director shall be deferred and shall vest in three equal annual installments. As of December 31, 2002 and 2001, $415,000 and $372,000 of bonuses were deferred, respectively. JCI recognizes compensation expense as the vesting requirements are met.

(14) Manufacturing Agreement

      JCI and a third-party contractor (the “Contractor”) entered into a manufacturing agreement, dated June 10, 1999, (the “Manufacturing Agreement”). Subject to the terms and conditions of the Manufacturing Agreement, the Contractor has agreed to manufacture all of the JCI’s requirements for certain cosmetic and skin care products for an initial term of five years. Following the expiration of the initial five-year term, the Manufacturing Agreement will be automatically extended for additional one-year terms unless terminated by six months’ prior written notice by either party. The Manufacturing Agreement provides for price renegotiations by the Contractor if JCI’s quarterly or annual purchase volume falls below specified minimums. The Manufacturing Agreement requires the Contractor to maintain insurance to cover costs associated with any product liability or product recall caused by the acts or omissions of the Contractor. In addition, JCI is obligated to purchase materials acquired by the Contractor based upon product forecasts provided by JCI if the Contractor is unable to sell such materials to a third-party. There have been no such repurchases to date. The Contractor is solely responsible for obtaining the inventories, manufacturing the inventories at its current location in Chino, California, complying with applicable laws and regulations, and performing quality assurance functions.

84


Table of Contents

JAFRA COSMETICS INTERNATIONAL, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

      During the fourth quarter of 2000, the Contractor obtained $1,000,000 of advances from JCI in exchange for an unsecured promissory note. The note bears interest at an annual rate of 9% and is payable in monthly installments commencing on February 15, 2001. On April 15, 2002, the unsecured promissory note was amended to advance an additional $320,000 to the contractor. At December 31, 2002 and 2001, approximately $101,000 and $349,000, of the note was outstanding and was included in receivables in the accompanying consolidated balance sheets, respectively.

85


Table of Contents

INDEPENDENT AUDITORS’ REPORT

To the Board of Directors and Stockholders of

Jafra Cosmetics International, S.A. de C.V.
Mexico City, Mexico D.F.

      We have audited the accompanying consolidated balance sheets of Jafra Cosmetics International, S.A. de C.V. and subsidiaries (the “Company”), an indirect, wholly owned subsidiary of CDRJ Investments (Lux) S.A., as of December 31, 2001, and the related consolidated statements of income, stockholders’ equity, and cash flows for each of the two years in the period ended December 31, 2001. These financial statements and the financial statement schedule are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements and the financial statement schedule based on our audits.

      We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

      In our opinion, such consolidated financial statements referred to above present fairly, in all material respects, the financial position of Jafra Cosmetics International, S.A. de C.V. and subsidiaries as of December 31, 2001, and the results of their operations and their cash flows for each of the two years in the period ended December 31, 2001, in conformity with accounting principles generally accepted in the United States of America. Also, in our opinion, the financial statement schedule referred to above, when considered in relation to the basic consolidated financial statements taken as a whole, presents fairly in all material respects the information set forth therein.

DELOITTE & TOUCHE, LLP

Mexico City, Mexico

March 6, 2002 (February 24, 2003, as to
paragraphs 19 and 20 of Note 2)

86


Table of Contents

INDEPENDENT AUDITORS’ REPORT

To the Board of Directors and Stockholders of

Jafra Cosmetics International, S.A. de C.V.
Mexico City, Mexico D.F.

      We have audited the accompanying consolidated balance sheets of Jafra Cosmetics International, S.A. de C.V. and subsidiaries (the “Company”), an indirect, wholly owned subsidiary of CDRJ Investments (Lux) S.A., as of December 31, 2002, and the related consolidated statement of income, stockholders’ equity, and cash flows for the year then ended. Our audit also included the financial statement schedule for the year ended December 31, 2002 listed at Item 15(a)(2). These financial statements and schedule are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements and schedule based on our audit.

      We conducted our audits in accordance with auditing standards generally accepted in the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

      In our opinion, such consolidated financial statements present fairly, in all material respects, the financial position of Jafra Cosmetics International, S.A. de C.V. and subsidiaries as of December 31, 2002, and the results of their operations and their cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States. Also, in our opinion, the related financial statement schedule for the year ended December 31, 2002, when considered in relation to the basic financial statements taken as a whole, presents fairly in all material respects the information set forth therein.

      As discussed in Note 2 to the consolidated financial statements, effective January 1, 2002, the Company adopted Statement of Financial Accounting Standards No. 142.

  /S/ ERNST & YOUNG, LLP

Mexico City, Mexico

February 21, 2003

87


Table of Contents

JAFRA COSMETICS INTERNATIONAL, S.A. DE C.V. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(In thousands, except share amounts)

ASSETS

                     
December 31,

2002 2001


Current assets:
               
 
Cash and cash equivalents
  $ 13,394     $ 920  
 
Receivables, less allowances for doubtful accounts of $7,161 in 2002 and
$4,952 in 2001.
    33,518       34,430  
 
Inventories
    21,200       29,622  
 
Receivables from affiliates
    17,675       5,938  
 
Prepaid expenses and other current assets
    2,130       5,514  
     
     
 
   
Total current assets
    87,917       76,424  
Property and equipment, net
    33,809       36,121  
Other assets:
               
 
Goodwill
    28,548       32,401  
 
Trademarks
    44,408       50,402  
 
Deferred financing fees, net
    395       1,270  
 
Other
    1,227       2,699  
     
     
 
   
Total
  $ 196,304     $ 199,317  
     
     
 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
               
 
Current portion of long-term debt
  $ 2,489     $ 3,188  
 
Accounts payable
    11,966       20,205  
 
Accrued liabilities
    31,469       27,299  
 
Income taxes payable
    4,097       6,122  
 
Payables to affiliates
    21,894       21,373  
 
Deferred income taxes
    1,430       4,094  
     
     
 
   
Total current liabilities
    73,345       82,281  
Long-term debt
    30,786       33,993  
Deferred income taxes
    16,515       16,958  
     
     
 
   
Total liabilities
    120,646       133,232  
     
     
 
Commitments and contingencies
           
Stockholders’ equity:
               
 
Series B common stock, no par value; authorized, issued and outstanding, 151 shares in 2002 and 2001.
           
 
Additional paid-in capital
    34,184       34,184  
 
Retained earnings
    49,046       32,194  
 
Accumulated other comprehensive loss
    (7,572 )     (293 )
     
     
 
   
Total stockholders’ equity
    75,658       66,085  
     
     
 
   
Total
  $ 196,304     $ 199,317  
     
     
 

See accompanying notes to consolidated financial statements.

88


Table of Contents

JAFRA COSMETICS INTERNATIONAL, S.A. DE C.V. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME

(In thousands)
                           
Years Ended December 31,

2002 2001 2000



Net sales to third parties
  $ 251,545     $ 247,514     $ 199,777  
Sales to affiliates
    14,994       11,583       10,538  
     
     
     
 
 
Net sales
    266,539       259,097       210,315  
Cost of sales
    74,542       68,654       61,208  
     
     
     
 
 
Gross profit
    191,997       190,443       149,107  
Selling, general and administrative expenses
    124,535       119,490       90,951  
Management fee expense to affiliate
    7,224       8,498       8,164  
Gain on sale of assets
    (77 )            
 
Royalty expense to affiliates, net
    19,775       20,098       14,811  
     
     
     
 
 
Income from operations
    40,540       42,357       35,181  
Other income (expense):
                       
 
Exchange loss, net
    (7,184 )     (9,183 )     (11,295 )
 
Interest expense, net
    (4,883 )     (6,111 )     (7,789 )
 
Other, net
    (123 )     (23 )     1,586  
     
     
     
 
Income before income taxes, extraordinary item and cumulative effect of accounting change
    28,350       27,040       17,683  
Income tax expense
    11,498       11,202       6,805  
     
     
     
 
Income before extraordinary item and cumulative effect of accounting change
    16,852       15,838       10,878  
Extraordinary loss on early extinguishment of debt, net of income tax benefit of $75.
                110  
     
     
     
 
Income before cumulative effect of accounting change
    16,852       15,838       10,768  
Cumulative effect of accounting change, net of income tax expense of $82.
          126        
     
     
     
 
Net income
  $ 16,852     $ 15,964     $ 10,768  
     
     
     
 

See accompanying notes to consolidated financial statements.

89


Table of Contents

JAFRA COSMETICS S.A. DE C.V. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(In thousands, except for shares)
                                                     
Years Ended December 31,

2002 2001 2000



Shares Amount Shares Amount Shares Amount






Capital Stock:
                                               
 
Balance, beginning of year
    151             151             151        
     
     
     
     
     
     
 
 
Balance, end of year
    151             151             151        
     
     
     
     
     
     
 
Additional Paid-in Capital:
                                               
 
Balance, beginning of year
          $ 34,184             $ 34,184             $ 34,184  
             
             
             
 
 
Balance, end of year
            34,184               34,184               34,184  
             
             
             
 
Retained Earnings:
                                               
Balance, beginning of year
            32,194               27,030               16,262  
 
Net income
            16,852               15,964               10,768  
 
Dividends paid to parent
                          (10,800 )              
             
             
             
 
 
Balance, end of year
            49,046               32,194               27,030  
             
             
             
 
Accumulated Other Comprehensive Loss:
                                               
 
Balance, beginning of year
            (293 )             (1,458 )             (309 )
 
Net unrealized and deferred realized losses on derivatives
            (264 )             (3,746 )              
 
Tax benefit on unrealized and deferred realized losses on derivatives
            92               1,311                
 
Currency translation adjustments
            (7,107 )             3,600               (1,149 )
             
             
             
 
 
Balance, end of year
            (7,572 )             (293 )             (1,458 )
     
     
     
     
     
     
 
   
Total Stockholders’ Equity
    151     $ 75,658       151     $ 66,085       151     $ 59,756  
     
     
     
     
     
     
 
Comprehensive Income:
                                               
 
Net income
          $ 16,852             $ 15,964             $ 10,768  
 
Unrealized and deferred realized losses on derivatives
            (4,192 )             (5,504 )              
 
Reclassified to exchange loss
            1,167               797                
 
Reclassified to cost of sales
            2,761               961                
 
Tax benefit on unrealized and deferred realized losses on derivatives
            92               1,311                
 
Currency translation adjustments
            (7,107 )             3,600               (1,149 )
             
             
             
 
   
Total Comprehensive Income
          $ 9,573             $ 17,129             $ 9,619  
             
             
             
 

See accompanying notes to consolidated financial statements.

90


Table of Contents

JAFRA COSMETICS INTERNATIONAL, S.A. DE C.V. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)
                                 
Years Ended December 31,

2002 2001 2000



Cash flows from operating activities:
                       
 
Net income
  $ 16,852     $ 15,964     $ 10,768  
 
Extraordinary loss on early extinguishment of debt, net of taxes
                110  
 
Cumulative effect of accounting change, net of taxes
          (126 )      
     
     
     
 
 
Income before extraordinary item and cumulative effect of accounting change
    16,852       15,838       10,878  
 
Adjustments to reconcile income before extraordinary item and cumulative effect of accounting change to net cash provided by operating activities:
                       
   
Gain on sale of property and equipment
    (77 )     (24 )      
   
Depreciation and amortization
    2,121       3,908       4,231  
   
Amortization of deferred financing fees
    776       805       797  
   
Provision for uncollectible accounts receivable
    11,033       7,681       4,956  
   
Unrealized foreign exchange and derivative losses
    4,667       (994 )     2,669  
   
Deferred realized derivative losses
    181       (827 )      
   
Deferred income taxes
    (1,429 )     1,506       2,539  
   
Changes in operating assets and liabilities:
                       
     
Receivables
    (14,010 )     (13,795 )     (10,655 )
     
Inventories
    5,249       (3,021 )     (6,047 )
     
Prepaid expenses and other current assets
    744       (1,126 )     (1,108 )
     
Value-added tax receivables and payables
    5,890       3,057       103  
     
Intercompany receivables and payables
    (11,628 )     17,980       15  
     
Other assets
    1,232       154       (1,728 )
     
Accounts payable and accrued liabilities
    1,107       330       13,581  
     
Income taxes payable/prepaid
    (960 )     6,688       11,667  
     
     
     
 
       
Net cash provided by operating activities
    21,748       38,160       31,898  
     
     
     
 
Cash flows from investing activities:
                       
 
Proceeds from sale of property and equipment
    225       93        
 
Purchases of property and equipment
    (4,124 )     (6,024 )     (2,262 )
     
     
     
 
       
Net cash used in investing activities
    (3,899 )     (5,931 )     (2,262 )
     
     
     
 
Cash flows from financing activities:
                       
 
Repurchase of subordinated debt
                (4,239 )
 
Repayments under term loan facility
    (3,125 )     (2,000 )     (1,500 )
 
Net borrowings under revolving credit facility
                (500 )
 
Net (repayments) borrowings under bank debt
    (781 )     1,263       346  
 
Payment of note payable to affiliate
          (20,756 )     (22,946 )
 
Payment of dividends
          (10,800 )      
     
     
     
 
       
Net cash used in financing activities
    (3,906 )     (32,293 )     (28,839 )
     
     
     
 
Effect of exchange rate changes on cash
    (1,469 )     423       (239 )
     
     
     
 
Net increase in cash and cash equivalents
    12,474       359       558  
Cash and cash equivalents at beginning of year
    920       561       3  
     
     
     
 
Cash and cash equivalents at end of year
  $ 13,394     $ 920     $ 561  
     
     
     
 
Supplemental disclosure of cash flow information
                       
 
Cash paid (received) during the year for:
                       
       
Interest
  $ 4,305     $ 4,786     $ 5,652  
       
Income Taxes
    7,213       2,734       (7,401 )

      At December 31, 2002, Jafra S.A. had deferred net gains of $0.4 million on foreign currency option contracts recorded as other comprehensive loss and other receivables. At December 31, 2001, Jafra S.A. had deferred losses of $2.9 million on foreign currency forward contracts recorded in accrued liabilities and other comprehensive income. Additionally, the related deferred income tax benefit of $1.3 million related to the deferred losses was recorded as a component of net deferred tax liability and other comprehensive income.

See accompanying notes to consolidated financial statements.

91


Table of Contents

JAFRA COSMETICS INTERNATIONAL, S.A. DE C.V. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(1) Basis of Presentation and Description of Business

Basis of Presentation

      Jafra Cosmetics International, S.A. de C.V., a sociedad anónima de capital variable, organized under the laws of the United Mexican States (“Jafra S.A.”) is owned by five indirect wholly owned subsidiaries of CDRJ Investments (Lux) S.A., a Luxembourg société anonyme (the “Parent”). Jafra S.A., its subsidiaries, and certain other subsidiaries of the Parent were organized by Clayton, Dubilier & Rice Fund V Limited Partnership, a Cayman Islands exempted limited partnership managed by Clayton, Dubilier & Rice, Inc. (“CD&R”) to acquire (the “Acquisition”) the worldwide Jafra Cosmetics business (the “Jafra Business”) from The Gillette Company (“Gillette”).

      The accompanying consolidated financial statements for the years ended December 31, 2002, 2001 and 2000 reflect the operations of Jafra S.A. and its subsidiaries (collectively, “Jafra S.A.”). All significant intercompany accounts and transactions between entities have been eliminated in consolidation.

      In connection with the Acquisition, Jafra S.A. and an affiliated company, Jafra Cosmetics International, Inc. (“JCI”) (the indirect, wholly owned United States subsidiary of the Parent) issued $100 million aggregate principal amount of 11.75% Subordinated Notes due 2008 (the “Notes”). See Note 6. The Notes represent several obligations of Jafra S.A. and JCI, with each participating on a pro rata basis upon redemption. Jafra S.A. and JCI have fully and unconditionally guaranteed the obligations under the Notes of the other on a senior subordinated basis, subject to a 30-day standstill period prior to enforcement of such guarantees. As the cross-guarantee of Jafra S.A. and JCI is subject to a 30-day standstill period, the Parent is filing these separate financial statements of Jafra S.A. as a schedule to its Annual Report on Form 10-K for the year ended December 31, 2002.

Description of Business

      Jafra S.A. is a marketer of premium skin and body care products, color cosmetics, fragrances, and other personal care products in Mexico through a direct selling, multilevel distribution system comprised of self-employed salespersons (known as “consultants”). In addition, Jafra S.A. manufactures color cosmetics and fragrance products for its own use as well as for distribution to the international subsidiaries of the Parent (referred to herein as the “affiliates”).

(2) Summary of Significant Accounting Policies

      Use of Estimates. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

      Cash and Cash Equivalents. Cash and cash equivalents include cash, time deposits and all highly liquid debt instruments purchased with a maturity of three months or less.

      Inventories. Inventories are stated at the lower of cost, as determined by the first-in, first-out basis, or market.

      Property and Equipment. Property and equipment are stated at cost. Depreciation of property and equipment is provided for over the estimated useful lives of the respective assets using the straight-line method. Estimated useful lives are 20 years for buildings, the lesser of 20 years or the term of the lease for improvements, 5 to 10 years for machinery and equipment and 3 years for hardware and software. Maintenance and repairs, including cost of minor replacements, are charged to operations as incurred. Costs of

92


Table of Contents

JAFRA COSMETICS INTERNATIONAL, S.A. DE C.V. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

additions and betterments are added to property and equipment accounts provided that such expenditures increase the useful life or the value of the asset.

      Intangible Assets. Intangible assets principally consist of goodwill and trademarks. On January 1, 2002, Jafra S.A. adopted Statement of Financial Accounting Standards (“SFAS”) No. 142, “Goodwill and other Intangible Assets” which requires the Company to not amortize goodwill and other intangible assets, but to test those intangible assets for impairment at least annually. Prior to adoption of SFAS No. 142, goodwill and other intangible assets were amortized using the straight-line method over a period of 40 years. The book value of goodwill and trademarks was $28,548,000 and $44,408,000 at December 31, 2002, respectively. (See “New Accounting Standards”).

      Deferred Financing Costs. In connection with the acquisition of the Jafra Business, Jafra S.A. incurred approximately $4.8 million of costs related to the 11.75% Senior Subordinated Notes due 2008 (the “Notes”), the revolving credit facility and the term loan facility (see Note 6). Such costs are being amortized on a basis that approximates the interest method over the expected term of the related debt. Accumulated amortization at December 31, 2002 and 2001 was $3,425,000 and $3,066,000, respectively.

      Impairment of Long-Lived Assets and Goodwill. Long-lived assets are reviewed for impairment based on undiscounted cash flows, whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. If this review indicates that the carrying amount of the long-live assets is not recoverable, Jafra S.A. will recognize an impairment loss, measured by the future discounted cash flow method. Goodwill is tested for impairment annually, or whenever events or changes in circumstances indicate that the carrying amount of goodwill may not be recoverable based on the provisions of SFAS No. 142 (see “new Accounting Standards”).

      Foreign Currency Forward and Option Contracts. During 2002 and 2001, Jafra S.A. entered into foreign currency forward contracts, In 2002, Jafra S.A. entered into forward currency option contracts. Jafra S.A. enters into these contracts to reduce the effect of potentially adverse exchange rate fluctuations in the exchange rate of the Mexican peso to the U.S. dollar. Effective January 1, 2001, Jafra S.A. adopted SFAS No. 133, “Accounting for Derivative Instruments and Hedging Activities.” SFAS No. 133, as amended and interpreted, establishes accounting and reporting standards for derivative instruments and hedging activities and requires that all derivative instruments be recorded based on fair value. In connection with the adoption of SFAS No. 133, at January 1, 2001, Jafra S.A. recorded a net gain of $126,000 (net of a tax effect of $82,000) as a cumulative transition adjustment to earnings. This adjustment relates to derivatives not designated as hedges prior to adoption of SFAS No. 133, and represents the difference between the carrying value and the fair value of such instruments.

      As a matter of policy, Jafra S.A. does not hold or issue foreign currency forward contracts or foreign currency option contracts for trading or speculative purposes. The forward contracts utilized by Jafra S.A. did not qualify for hedge accounting under the applicable accounting standards prior to adoption of SFAS No. 133 on January 1, 2001, and accordingly such instruments were marked-to-market each month based upon the change in the spot rate from the date of contract inception to the balance sheet date. The premium on such contracts was amortized to expense over the life of the contracts. However, under SFAS No. 133, Jafra S.A.’s use of forward contracts and option contracts to hedge certain forecasted transactions qualifies for hedge accounting. Gains and losses from qualifying hedged derivative instruments are deferred as a separate component of other comprehensive loss, and are recognized in income at the same time that the underlying hedged exposure is recognized in income. This accounting treatment results in the matching of gains and losses from such forward contracts and option contracts with the corresponding gains and losses generated by the underlying hedged transactions. Under SFAS No. 133, certain of Jafra S.A.’s foreign currency forward and option contracts do not qualify for hedge accounting and therefore, are remeasured based on fair value, with gains and losses included as a component of net income. At December 31, 2001, the carrying value of the forward contracts was $5,540,000 and was included in accrued liabilities in the accompanying consolidated

93


Table of Contents

JAFRA COSMETICS INTERNATIONAL, S.A. DE C.V. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

balance sheets, At December 31, 2002, the carrying value of the option contracts was $402,000 and was included in other receivables in the accompanying consolidated balance sheets.

      Fair Value of Financial Instruments. The carrying amounts of cash and cash equivalents, accounts receivable, and accounts payable approximate fair value because of the short-term maturities of these instruments. The fair value of the Notes and other fixed rate long-term debt at December 31, 2002 and 2001 was $31,652,000 and $33,786,000, respectively, based upon discussions with one of Jafra S.A.’s largest bondholders and an analysis of current market interest rates and the Company’s credit rating. As Jafra S.A.’s Revolving Credit Facility and the Term Loan are variable rate debt, and the interest rate spread paid by Jafra S.A. is adjusted for changes in certain financial ratios of the Parent, the fair value of the Revolving Credit Facility and the Term Loan approximated their carrying amounts at December 31, 2002 and 2001.

      Revenue Recognition. Jafra S.A. recognizes revenue when title passes at shipment in accordance with its shipping terms. Amounts billed to consultants for shipping and handling costs are included in net sales. Sales are reduced by commissions paid to consultants on their personal sales.

      Shipping and Handling Costs. Shipping and handling costs of $17,442,000, $15,182,000 and $10,651,000 for the years ended December 31, 2002, 2001 and 2000, respectively, are included in selling, general and administrative expenses.

      Income Taxes. Jafra S.A. accounts for income taxes under the balance sheet approach that requires the recognition of deferred income tax assets and liabilities for the expected future consequences of events that have been recognized in the financial statements or income tax returns. Management provides a valuation allowance for deferred income tax assets when it is more likely than not that a portion of such deferred income tax assets will not be realized.

      Foreign Currency Translation. The functional currency for Jafra S.A. is the Mexican peso. For presentation purposes, assets and liabilities are translated into U.S. dollars at current exchange rates, and related revenues and expenses are translated at average exchange rates in effect during the period. Resulting translation adjustments are recorded as a component of other comprehensive loss.

      Mexico has historically experienced periods of hyperinflation, and the value of the peso has been subject to significant fluctuations with respect to the U.S. dollar. Jafra S.A. had outstanding U.S. dollar-denominated debt of $32,447,000 and $35,572,000 at December 31, 2002 and 2001, respectively. This debt is remeasured at each reporting date, subjecting Jafra S.A. to additional foreign exchange risk.

      New Accounting Standards. Effective January 1, 2001, Jafra S.A. adopted SFAS No. 133, “Accounting for Derivative Instruments and Hedging Activities.” SFAS No. 133, as amended and interpreted, established accounting and reporting standards for derivative instruments, including certain derivative instruments embedded in other contracts, and for hedging activities. All derivatives, whether designated in hedging relationships or not, are required to be recorded on the balance sheet at fair value. If the derivative is designated in a fair-value hedge, the changes in the fair value of the derivative and the underlying hedged item are recognized concurrently in earnings. If the derivative is designated in a cash-flow hedge, changes in the fair value of the derivative are recorded in other comprehensive income (loss) (“OCI”) and are recognized in the statement of income when the hedged item affects earnings. SFAS No. 133 defined new requirements for designation and documentation of hedging relationships as well as ongoing effectiveness assessments in order to use hedge accounting. For a derivative that does not qualify as a hedge, changes in fair value are recognized concurrently in earnings. As of January 1, 2001, Jafra S.A. recorded a net gain of $126,000 (net of a tax effect of $82,000) as a cumulative transition adjustment to earnings. This adjustment relates to derivatives not designated as hedges prior to adoption of SFAS No. 133, and represents the difference between the carrying value as measured by the difference in the spot rate to the forward rate and the fair value as determined by forward rates of such instruments at January 1, 2001.

94


Table of Contents

JAFRA COSMETICS INTERNATIONAL, S.A. DE C.V. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

      In June 2001, the Financial Accounting Standards Board (“FASB”) approved two new statements: SFAS No. 141, “Business Combinations” and SFAS No. 142, “Goodwill and Other Intangible Assets.” SFAS No. 141 requires business combinations entered into after June 30, 2001 to be accounted for using the purchase method of accounting. SFAS No. 142 requires that goodwill not be amortized, but be tested for impairment at least annually. SFAS No. 142 was effective for fiscal years beginning after December 15, 2001 to all goodwill and other intangible assets recognized in an entity’s statement of financial position at that date, regardless of when those assets were initially recognized. Jafra S.A. adopted SFAS No. 142 on January 1, 2002. In accordance with such adoption, the Company identified all reporting units in conjunction with the provisions of SFAS No. 142 and allocated all goodwill accordingly. During the year ended December 31, 2002, Jafra S.A. completed the transitional goodwill impairment test required by SFAS No. 142. Based on the transitional and annual impairment test, Jafra S.A. determined that there was no impairment to goodwill. There were no changes, except for translation effects, to the carrying amount of goodwill for the year ended December 31, 2002.

      Jafra S.A.’s other intangible assets consist of trademarks. During the year ended December 31, 2002, Jafra S.A. determined trademarks to have an indefinite life and performed the transitional impairment test as required under SFAS No. 142. Based upon the transitional and annual test, Jafra S.A. determined that there was no impairment of trademarks. The carrying value of trademarks was $44,408,000 at December 31, 2002 on the accompanying consolidated balance sheets.

      In accordance with SFAS No. 142, Jafra S.A. discontinued amortization of goodwill and other intangible assets with an indefinite life. A reconciliation of previously reported net income to amounts adjusted for the exclusion of goodwill and trademark amortization, net of the related income tax effects, where applicable, is as follows (in thousands):

                         
Years Ended December 31,

2002 2001 2000



Net income
  $ 16,852     $ 15,964     $ 10,768  
Goodwill amortization
          870       859  
Trademark amortization, net of tax
          796       825  
     
     
     
 
Adjusted net income
  $ 16,852     $ 17,630     $ 12,452  
     
     
     
 

      In November 2001, the Emerging Issues Task Force (“EITF”) issued EITF Issue No. 01-9, “Accounting for Consideration Given by a Vendor to a Customer or a Reseller of the Vendor’s Products.” This new guidance provides that consideration from a vendor to a reseller is generally presumed to be a reduction of the selling prices of the vendor’s products, and, therefore, should be characterized as a reduction of revenue when recognized in the vendor’s income statement. On January 1, 2002, Jafra S.A. adopted EITF Issue No. 01-9 and reclassified commissions paid to consultants of $2,260,000 and $1,948,000 on their personal sales, previously as a component of selling, general and administrative expenses, as a reduction in net sales and selling, general and administrative expenses for the years ended December 31, 2001 and 2000, respectively.

      On January 1, 2002, the Jafra S.A. adopted SFAS No. 144, “Accounting for the Impairment or Disposal of Long-Lived Assets.” SFAS No. 144 supersedes SFAS No. 121, “Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to be Disposed of.” SFAS No. 144 retains substantially all of the requirements of SFAS No. 121, while resolving certain implementation issues and addressing the accounting for a component of a business accounted for as a discontinued operation. SFAS No. 144 was adopted with no significant impact on the financial position or results of operations of Jafra S.A.

      In April 2002, the FASB issued SFAS No. 145, “Rescission of FASB Statements No. 4, 44, and 64, Amendment of FASB Statement No. 13, and Technical Corrections.” This Statement rescinds or modifies existing authoritative pronouncements including SFAS No. 4 “Reporting Gains and Losses from Extinguish-

95


Table of Contents

JAFRA COSMETICS INTERNATIONAL, S.A. DE C.V. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

ment of Debt.” As a result of the issuance of SFAS No. 145, gains and losses from extinguishment of debt should be classified as extraordinary items only if they meet the criteria in Accounting Principles Board (“APB”) Opinion 30. “Reporting the Results of Operations-Reporting the Effects of Disposal of a Segment of a Business, and Extraordinary, Unusual and Infrequently Occurring Events and Transactions.“Applying the provisions of APB Opinion 30 will distinguish transactions that are part of an entity’s recurring operations from those that are unusual or infrequent or that meet the criteria for classification as an extraordinary item. The provisions of this Statement related to the rescission of SFAS No. 4 shall be applied in fiscal years beginning after May 15, 2002. Any gain or loss on extinguishment of debt that was classified as an extraordinary item in prior periods presented that does not meet the criteria in APB Opinion 30 for classification as an extraordinary item shall be reclassified. Jafra S.A. is currently evaluating the impact that this statement may have on any potential future extinguishments of debt. Upon adoption of SFAS No. 145, Jafra S.A. will reclassify items previously reported as extraordinary items as a component of operating income on the accompanying statements of income.

      In June 2002, the FASB approved SFAS No. 146, “Accounting for Costs Associated with Exit or Disposal Activities.” This statement addresses financial accounting and reporting for costs associated with exit or disposal activities and nullifies EITF Issue No. 94-3, “Liability Recognition for Certain Employee Termination Benefits and Other Costs to Exit an Activity.” The provisions of this statement are effective for exit or disposal activities that are initiated after December 31, 2002, with early application encouraged. Jafra S.A. is currently evaluating the impact that this statement may have on any potential future exit or disposal activities.

      Reclassifications. Certain reclassifications were made to the prior year financial statements to conform to current year presentation.

(3) Inventories

      Inventories consist of the following at December 31, 2002 and 2001 (in thousands):

                 
2002 2001


Raw materials and supplies
  $ 4,858     $ 5,717  
Finished goods
    16,342       23,905  
     
     
 
Total inventories
  $ 21,200     $ 29,622  
     
     
 

(4) Property and Equipment

      Property and equipment consist of the following at December 31, 2002 and 2001 (in thousands):

                 
2002 2001


Land
  $ 10,260     $ 11,645  
Buildings and improvements
    10,311       11,703  
Machinery, equipment and other
    18,726       17,532  
     
     
 
      39,297       40,880  
Less accumulated depreciation
    5,488       4,759  
     
     
 
Property and equipment, net
  $ 33,809     $ 36,121  
     
     
 

96


Table of Contents

JAFRA COSMETICS INTERNATIONAL, S.A. DE C.V. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(5) Accrued Liabilities

      Accrued liabilities consist of the following at December 31, 2002 and 2001 (in thousands):

                 
2002 2001


Sales promotions, commissions and overrides
  $ 12,048     $ 10,936  
Accrued interest
    618       618  
Compensation and other benefit accruals
    3,503       3,755  
State and local sales taxes and other taxes
    11,407       3,399  
Unrealized losses on forward contracts
          5,540  
Other
    3,893       3,051  
     
     
 
Total accrued liabilities
  $ 31,469     $ 27,299  
     
     
 

(6) Debt

      Debt consists of the following at December 31, 2002 and 2001 (in thousands):

                 
2002 2001


Subordinated Notes, U.S. dollar-denominated, unsecured, interest payable semi-annually at 11.75% due in 2008
  $ 30,072     $ 30,072  
Term loan, secured, U.S. dollar-denominated, principal and interest due in quarterly installments through April 30, 2004, interest rates at 3.1% and 4.3% at December 31, 2002 and 2001, respectively
    2,375       5,500  
Unsecured bank loan agreement, principal and interest due in monthly installments through January 25, 2005, weighted average interest rates of 18.5% and 18.7% at December 31, 2002 and 2001, respectively
    828       1,609  
     
     
 
Total debt
    33,275       37,181  
Less current maturities
    2,489       3,188  
     
     
 
Long-term debt
  $ 30,786     $ 33,993  
     
     
 

      Jafra S.A.’s long-term debt matures as follows (in thousands): $2,489 in 2003, $714 in 2004, $0 in 2005, 2006 and 2007, and $30,072 thereafter.

      On April 30, 1998, Jafra S.A. and JCI borrowed $125 million by issuing $100 million aggregate principal amount of 11.75% Subordinated Notes due 2008 (the “Notes”) pursuant to an Indenture dated April 30, 1998 (the “Indenture”) and $25 million under a senior credit agreement.

      At the date of issuance, the Notes represented several obligations of Jafra S.A. and JCI in the amount of $40 million and $60 million, respectively, participating on a pro rata basis upon redemption. The Notes mature in 2008 and bear a fixed interest rate of 11.75% payable semi-annually.

      Jafra S.A. and JCI are indirect, wholly owned subsidiaries of the Parent and have fully and unconditionally guaranteed the obligations under the Notes of the other on a senior subordinated basis, subject to a 30-day standstill period prior to enforcement of such guarantees. In addition, the Parent has fully and unconditionally guaranteed the Notes on a senior subordinated basis. Each existing subsidiary of Jafra S.A. fully and unconditionally guarantees the Notes jointly and severally, on a senior subordinated basis, and each subsequently acquired or organized subsidiary of Jafra S.A. will fully and unconditionally guarantee the Notes jointly and severally, on a senior subordinated basis. JCI currently has no U.S. subsidiaries. Each acquired or organized U.S. subsidiary of JCI will also be required to fully and unconditionally guarantee the Notes jointly and severally, on a senior subordinated basis. The nonguarantor entities are the Parent’s indirect European subsidiaries in Austria, Germany, Italy, the Netherlands, Poland, and Switzerland; its indirect South

97


Table of Contents

JAFRA COSMETICS INTERNATIONAL, S.A. DE C.V. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

American subsidiaries in Argentina, Brazil, Chile, Colombia, Peru, and Venezuela; and its indirect subsidiaries in the Dominican Republic and Thailand. All guarantor and nonguarantor entities are either direct or indirect wholly owned subsidiaries of the Parent. The Notes were registered in a registered exchange offer, effective as of January 25, 1999, under the Securities Act of 1933, as amended.

      The Notes are unsecured and are generally non-callable for five years. Thereafter, the Notes will be callable at premiums declining to par in the eighth year.

      Consents and waivers, dated June 30, 2001 and November 19, 1999, to the senior credit agreement, as described below, allow Jafra S.A. and JCI to repurchase the Notes in the open market from time to time, with the aggregate purchase price for all such Notes repurchased not to exceed $50 million. Aggregate repurchases as of December 31, 2002 were $24.8 million. During 2000, Jafra S.A. retired notes, prior to maturity, with a face value of $4.3 million. The debt repurchases in 2000 resulted in an extraordinary loss of $110,000, net of an income tax benefit of $75,000. In connection with the early retirement of the Notes as described above, a portion of the unamortized deferred financing costs was written off and included in the determination of the extraordinary loss on early extinguishment of debt. In 2000, $274,000 of the unamortized deferred financing fees were written off.

      In addition, Jafra S.A. and JCI entered into a senior credit agreement that provides for senior secured credit facilities in an aggregate principal amount of $90 million, consisting of a multicurrency revolving credit facility of $65 million and a term loan facility of $25 million. Borrowings under the term loan facility are payable in quarterly installments of principal and interest over 6 years through April 30, 2004. Borrowings under the revolving credit facility mature on April 30, 2004. Borrowings under the senior credit agreement currently bear interest at an annual rate of LIBOR plus a margin of 1.625% or an alternate base rate (the higher of the prime rate or federal funds rate plus 0.5%, plus an applicable margin of 0.625%). The interest rate in effect at December 31, 2002 was approximately 3.1% for the LIBOR-based borrowings. Borrowings under the senior credit agreement are secured by substantially all of the assets of Jafra S.A. and JCI. No amounts were outstanding under the revolving credit facility at December 31, 2002.

      Both the Indenture and the senior credit agreement contain certain covenants that limit the Jafra S.A.’s ability to incur additional indebtedness, pay cash dividends and make certain other payments. These debt agreements also require the Parent to maintain certain financial ratios including a minimum EBITDA to cash interest expense coverage ratio and a maximum debt to EBITDA ratio.

      During the year ended December 31, 2001, Jafra S.A. repaid the balance remaining under a one-year term loan originally due on August 16, 2001, and entered into an unsecured bank loan agreement. Under this agreement, Jafra S.A. had the peso equivalent of $828,000 outstanding at December 31, 2002 at a weighted average fixed interest rate of 18.5%. Principal and interest payments are due monthly through January 25, 2005.

      As of December 31, 2002, Jafra S.A. has irrevocable standby letters of credit outstanding, totaling $2.8 million. These letters of credit, expiring on February 17, 2003 collateralize the Company’s obligation to a third-party in connection with certain lease agreements.

98


Table of Contents

JAFRA COSMETICS INTERNATIONAL, S.A. DE C.V. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(7) Income Taxes

      Actual income tax expense differs from the “expected” tax expense (computed by applying the Mexican federal corporate rate of 35% to income before income taxes) as a result of the following (in thousands):

                         
Years Ended December 31,

2002 2001 2000



Provision for income taxes at statutory rate
  $ 9,923     $ 9,464     $ 6,189  
Permanent differences, principally effect of inflation upon taxable income
    829       1,116       616  
Change in net deferred income tax liabilities due to enactment of changes of Mexico’s future statutory rate
    (1,169 )            
Other
    1,915       622        
     
     
     
 
Income tax expense
  $ 11,498     $ 11,202     $ 6,805  
     
     
     
 

      The components of the provision for income taxes are as follows (in thousands):

                             
Years Ended December 31,

2002 2001 2000



Current
  $ 14,605     $ 11,007     $ 4,266  
Deferred
    (4,326 )     1,506       2,539  
Deferred allocated to other comprehensive income
    1,219       (1,311 )      
     
     
     
 
 
Total deferred
    (3,107 )     195       2,539  
     
     
     
 
Total income taxes on income before income taxes, extraordinary item and cumulative effect
    11,498       11,202       6,805  
Income tax benefit on early extinguishment of debt
                (75 )
Income tax expense on cumulative effect of accounting change
          82        
     
     
     
 
   
Total income tax expense
  $ 11,498     $ 11,284     $ 6,730  
     
     
     
 

      The components of deferred income tax assets and deferred income tax liabilities at December 31, 2002 and 2001 are as follows (in thousands):

                     
2002 2001


Deferred income tax assets:
               
 
Accounts receivable
  $ 2,435     $ 1,733  
 
Net operating loss carryforward of subsidiaries
    199       814  
 
Asset tax credit carryforward
    122       2,687  
 
Accrued bonuses
    33       301  
 
Accrued sales promotions
    1,977       2,273  
 
Other accrued liabilities
    5,053       1,632  
 
Other
    348       2,849  
     
     
 
   
Total deferred income tax assets
    10,167       12,289  

99


Table of Contents

JAFRA COSMETICS INTERNATIONAL, S.A. DE C.V. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

                     
2002 2001


Deferred income tax liabilities:
               
 
Transaction and deferred financing costs
    (130 )     (445 )
 
Property and equipment
    (2,399 )     (2,592 )
 
Trademark and goodwill
    (14,655 )     (17,641 )
 
Inventories
    (7,653 )     (12,469 )
 
Prepaid purchases and expenses
    (3,163 )      
 
Other
    (112 )     (194 )
     
     
 
   
Total deferred income tax liabilities
    (28,112 )     (33,341 )
     
     
 
   
Net deferred income tax liabilities
  $ (17,945 )   $ (21,052 )
     
     
 

      At December 31, 2002 and 2001, Jafra S.A.’s deferred income tax assets included $199,000 and $814,000, respectively, for operating loss carryforwards. The tax loss and asset credit carryforwards expire in varying amounts through 2012. Although realization is not assured, management believes it is more likely than not that the net carrying value of the income tax loss and credit carryforwards will be realized.

      Income tax expense for the year ended December 31, 2002 was reduced by $1,169,000 as the result of the enactment of changes in the Mexico corporate statutory tax rate and the related impact on Jafra S.A.’s net deferred income tax liabilities. The enactment in Mexico will reduce the Mexico corporate income tax rate annually in one-percent increments from 35% to 32% beginning January 1, 2003 through 2005

(8) Benefit Plans

      Under Mexican labor laws, employees of Jafra S.A. and its subsidiaries are entitled to a payment when they leave Jafra S.A. if they have fifteen or more years of service. In addition, Jafra S.A. makes government mandated employee profit sharing distributions equal to ten percent of the taxable income of the subsidiary in which they are employed. Total expense under these programs was $1,222,000, $995,000 and $345,000 for the years ended December 31, 2002, 2001 and 2000, respectively. The total liability was approximately $1,724,000 and $1,010,000 at December 31, 2002 and 20001 respectively, and is classified as a noncurrent liability in the accompanying consolidated balance sheets.

(9) Related Party Transactions

      Jafra S.A. manufactures and distributes color cosmetics and fragrance products to other subsidiaries of the Parent (“affiliates”). Sales to affiliates, primarily in the United States and Germany, were $14,994,000, $11,538,000 and $10,538,000 for the years ended December 31, 2002, 2001 and 2000, respectively. These sales were made at cost plus a markup ranging from 0 to 11%. Jafra S.A. also purchases skin and body products from the Parent’s United States affiliate. Purchases were $14,483,000, $12,044,000 and $12,331,000 for the years ended December 31, 2002, 2001 and 2000, respectively.

      In addition, Jafra S.A. is provided with certain management services, such as legal, accounting and treasury, management oversight, and other administrative functions from an affiliate. The cost of these services is included in management fee expense to affiliate in the accompanying consolidated statements of income. JCI charges out a portion of these management expenses to its affiliates based principally upon a formula using the percentage of revenues of each affiliate to the total consolidated revenues of the Parent. Jafra S.A. believes the amounts and methods of allocations are reasonable and approximate the cost of the actual services received. The management fee expense charged by JCI to Jafra S.A. was $7,224,000, $8,498,000 and $8,164,000, for the years ended December 31, 2002, 2001 and 2000 respectively.

      During 1999, Jafra S.A. purchased U.S. and German trademarks from JCI. Jafra S.A. charges JCI a royalty for the right to use the Jafra trademark in the United States and Europe. The total royalty income

100


Table of Contents

JAFRA COSMETICS INTERNATIONAL, S.A. DE C.V. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

charged by Jafra S.A. to JCI was $2,443,000, $1,639,000 and $1,126,000 for the years ended December 31, 2002, 2001 and 2000, respectively, and is offset against royalty expense to affiliates in the accompanying consolidated statements of income.

      JCI owns the worldwide rights to its multi-level sales know-how (referred to as the “Jafra Way”). The Jafra Way was initially developed in the United States for lineage, training, and compensation of consultants. JCI charges Jafra S.A. a royalty for the use of the Jafra Way. The royalty fees charged by JCI were $22,218,000, $21,737,000, and $15,746,000 for the years ended December 31, 2002, 2001 and 2000, and were based on a percentage of Jafra S.A.’s sales.

      In prior years, Jafra S.A. obtained loans from certain affiliates at annual interest rates ranging from 6% to 9%. Such loans are due to be repaid five years from the date of grant, with no prepayment penalty. At December 31, 2002 and 2001, Jafra S.A. did not have any notes payable to affiliates outstanding. Additionally, in 2002, Jafra S.A. began charging interest to affiliates on aging payables. Net interest income from affiliates was $9,000 for the year ended December 31, 2002 and net interest expense to affiliates, primarily JCI, was $257,000 and $1,780,000 for the years ended December 31, 2001 and 2000, respectively. Interest income and expense relating to affiliates is included in interest expense, net, in the accompanying consolidated statements of income.

(10) Financial Reporting for Business Segments

      Segment information has been prepared in accordance with SFAS No. 131, “Disclosure about Segments of an Enterprise and Related Information”. SFAS No. 131 requires disclosure of certain information regarding operating segments, products and services, geographic areas of operations and major customers. The Parent’s business is comprised of one industry segment, direct selling, with worldwide operations. The Parent is organized into geographical business units that each sell the full line of Jafra cosmetics, skin care, body care, fragrances, and other products. Jafra S.A. is one of the Parent’s reportable business segments, and as such, the only additional business segment information presented is the following breakdown of sales by product lines:

                                                     
2002 2001 2000



Sales by Percentage Sales by Percentage Sales by Percentage
Product of Total Product of Total Product of Total
Line Sales Line Sales Line Sales






(in millions) (in millions) (in millions)
Skin care
  $ 29.5       12.0 %   $ 27.7       11.5 %   $ 25.7       13.0 %
Color cosmetics
    75.3       30.8       72.1       29.8       60.8       30.9  
Fragrances
    96.4       39.4       99.3       41.1       79.6       40.4  
Body care and personal care
    21.8       8.9       21.4       8.9       14.7       7.5  
Other(1)
    21.8       8.9       21.0       8.7       16.1       8.2  
     
     
     
     
     
     
 
 
Subtotal before shipping fees, and sales to affiliates less commissions
    244.8       100.0 %     241.5       100.0 %     196.9       100.0 %
             
             
             
 
Shipping fees less commissions
    6.7               6.0               2.9          
Sales to affiliates
    15.0               11.6               10.5          
     
             
             
         
   
Total
  $ 266.5             $ 259.1             $ 210.3          
     
             
             
         

(1)  Includes sales aids (e.g., party hostess gifts, demonstration products, etc.) and promotional materials, which typically do not qualify for commissions or overrides.

101


Table of Contents

JAFRA COSMETICS INTERNATIONAL, S.A. DE C.V. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(11) Commitments and Contingencies

      Jafra S.A. leases office and warehouse facilities as well as manufacturing, transportation and data processing equipment under operating leases which expire at various dates through 2008. The leases contain certain renewal options and require payment of property taxes, utilities, common area maintenance and insurance and contain rent escalation clauses based upon consumer price indices. Future minimum lease payments under noncancelable operating leases as of December 31, 2002 are (in thousands):

         
2003
  $ 2,037  
2004
    2,108  
2005
    2,176  
2006
    2,243  
2007
    2,310  
2008
    167  
     
 
    $ 11,041  
     
 

      Rental expense was $1,939,000, $1,507,000 and $3,624,000 for the years ended December 31, 2002, 2001 and 2000, respectively.

      Other income for 2000 included approximately $1.4 million of income related to a recovery of the effect of inflation from a receivable due from the Mexican government related to taxes.

      Jafra S.A. is involved from time to time in routine legal matters incidental to its business. Jafra S.A. believes that the resolution of such matters will not have a material adverse effect on Jafra S.A.’s business, financial condition or results of operations.

(12) Management Incentive Arrangements

      Effective as of the closing of the Acquisition, the Parent adopted a stock incentive plan (the “Stock Incentive Plan”), which provides for the sale of up to 52,141 shares of common stock of the Parent and the issuance of options to purchase up to 104,282 additional shares of common stock to members of senior management of certain of the Parent’s subsidiaries. Four employees of Jafra S.A. participate in the Stock Incentive Plan. These employees currently hold 3,761 shares of the Parent’s stock, and hold options to purchase an additional 7,522 shares. The activity related to these employees’ holdings under the Stock Incentive Plan is not significant to Jafra S.A. Jafra S.A. applies Accounting Principles Board Opinion No. 25, “Accounting for Stock Issued to Employees” and related interpretations in accounting for these options. As the options were granted with exercise prices equal to the fair value at the date of grant, no compensation expense was recognized by Jafra S.A. upon issuance of such options.

      Certain senior executive officers have employment agreements which provide for annual bonuses if Jafra S.A. and the Parent achieve the performance goals established under its annual incentive plan for executives.

(13) Foreign Currency Forward and Option Contracts

      Jafra S.A. is exposed to currency risk relating to its forecasted U.S. dollar-denominated expenditures. As part of its overall strategy to reduce the risk of adverse potential exchange rate fluctuations, Jafra S.A. enters into foreign currency exchange contracts. Prior to March 2002, Jafra S.A. purchased forward exchange contracts (“forward contracts” or “forwards”) to hedge its foreign currency exposures to the Mexican peso. In March 2002, in accordance with previously approved policies, Jafra S.A. modified its hedging program to include the use of foreign currency option contracts (“option contracts”). Jafra S.A. places forward contracts or option contracts based on its forecasted U.S. dollar cash outflows over a rolling 12 month period and does

102


Table of Contents

JAFRA COSMETICS INTERNATIONAL, S.A. DE C.V. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

not hedge transactions that are not included in the 12 month forecast on the date the forward contract is initiated. As a matter of policy, Jafra S.A. does not hold or issue forward contracts for trading or speculative purposes nor does it enter into contracts or agreements containing “embedded” derivative features. Prior to entering into forward contracts or option contracts, Jafra S.A. evaluates the counter parties’ credit ratings. Credit risk represents the accounting loss that would be recognized at the reporting date if counter parties failed to perform as contracted. Jafra S.A. does not currently anticipate non-performance by such counter parties.

      Effective January 1, 2001, Jafra S.A. adopted SFAS No. 133, “Accounting for Derivative Instruments and Hedging Activities.” SFAS No. 133, as amended and interpreted, establishes accounting and reporting standards for derivative instruments and hedging activities and requires that all derivative instruments be recorded based on fair value. In connection with the adoption of SFAS No. 133, at January 1, 2001, the Company recorded a net gain of $126,000 (net of a tax effect of $82,000) as a cumulative transition adjustment to earnings. This adjustment relates to derivatives not designated as hedges prior to adoption of SFAS No. 133, and represents the difference between the carrying value and the fair value of such instruments. Under SFAS No. 133, Jafra S.A.’s use of forward contracts or option contracts to hedge certain forecasted transactions does qualify for hedge accounting. Gains and losses from such derivatives are deferred as a separate component of other comprehensive loss, and are recognized in income at the same time that the underlying hedged exposure is recognized in income. This accounting treatment results in the matching of gains and losses from such forward contracts or option contracts with the corresponding gains and losses generated by the underlying hedged transactions. Contracts that do not qualify for hedge accounting under SFAS No. 133 are remeasured based on fair value and the gains and losses are included as a component of net income.

      The forward contracts utilized by Jafra S.A. did not qualify for hedge accounting under the applicable accounting standards prior to adoption of SFAS No. 133 on January 1, 2001, and accordingly such instruments were marked-to-market with gains and losses included as a component of exchange loss in the accompanying consolidated statements of income for the year ended December 31, 2000.

      Jafra S.A. currently designates certain of its forward contracts and option contacts as cash flow hedges of forecasted U.S. dollar-denominated inventory purchases, forecasted U.S. dollar-denominated intercompany charges from JCI, forecasted management fee charges from JCI, and U.S. dollar-denominated interest payments. On the date Jafra S.A. enters into a derivative contract, management designates the derivative as a hedge of the identified exposure. Jafra S.A. formally documents all relationships between hedging instruments and hedged items, as well as its risk-management objective and strategy for undertaking various hedge transactions. In this documentation, Jafra S.A. specifically identifies the forecasted transaction that has been designated as a hedged item and states how the hedging instrument is expected to hedge the risks related to the hedged item. Jafra S.A. formally measures effectiveness of its hedging relationships both at the hedge inception and on an ongoing basis in accordance with its risk management policy. For all qualifying and highly effective cash flow hedges, the changes in the fair value of the derivative are deferred as a component of other comprehensive loss. Such amounts will be reclassified from other comprehensive loss into net income when the underlying hedged exposure is recognized in income. For U.S. dollar-denominated inventory purchases, this will occur upon sale to an outside party of the related inventory. For intercompany charges and interest, this will occur at the date such charges are recorded by Jafra S.A.

      During the year ended December 31, 2002, Jafra S.A. recognized losses of approximately $2,605,000 on forward contracts and gains of approximately $886,000 on option contracts (including reclassification of other comprehensive loss) as a component of exchange loss in the accompanying consolidated statements of income. During the year ended December 31, 2001, Jafra S.A. recognized approximately $12,188,000 of losses on forward contracts as a component of exchange loss in the accompanying consolidated statements of income. During the year ended December 31, 2000, the Company recognized approximately $10,050,000 of

103


Table of Contents

JAFRA COSMETICS INTERNATIONAL, S.A. DE C.V. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

losses as a component of exchange loss on forward contracts that did not qualify for hedge accounting under accounting standards prior to the adoption of SFAS No. 133.

      Additionally, during the year ended December 31, 2001, Jafra S.A. deferred as a component of other comprehensive loss $5,504,000 of losses on forward contracts qualifying for hedge accounting under SFAS No. 133. Of this amount, approximately $797,000 was reclassified as exchange loss and $961,000 was reclassified as cost of sales upon recognition of the underlying hedged exposure prior to December 31, 2001. As of December 31, 2001, Jafra S.A. had deferred as a component of other comprehensive loss $3,746,000 of losses on forward contracts.

      During the year ended December 31, 2002, Jafra S.A. deferred approximately an additional $1,782,000 of losses on forward contracts qualifying for hedge accounting under SFAS No. 133, Of the total amount deferred, during the year ended December 31, 2002, approximately $1,650,000 of other comprehensive loss was reclassified into exchange loss and approximately $3,139,000 was reclassified into cost of sales upon the recognition of the underlying hedged exposure. Jafra S.A. expects that substantially all of the remaining loss of $739,000, deferred as a component of other comprehensive loss, will be recognized into income within the next twelve months.

      During the year ended December 31, 2002, Jafra S.A. deferred as a component of other comprehensive loss $1,336,000 of gains on option contracts qualifying for hedge accounting under SFAS No. 133. Of this amount, approximately $483,000 was reclassified to exchange loss and approximately $378,000 was reclassified as an offset to cost of sales upon the recognition of the underlying hedged exposure. Jafra S.A. expects substantially all of the remaining gain of approximately $475,000, deferred as a component of other comprehensive loss, to be recognized into income within the next twelve months.

      The fair value of the forward contacts at December 31, 2001 represented an unrealized loss of $5,540,000 consisting of $2,920,000 of unrealized losses recorded as a component of other comprehensive loss for qualifying hedges and $2,620,000 of unrealized losses recorded as a component of exchange loss for non-qualifying hedges under SFAS No. 133. As of December 31, 2002, Jafra S.A. had no outstanding forward contracts. The fair value of the option contracts at December 31, 2002 represented an unrealized gain of approximately $402,000, consisting of $382,000 of unrealized gains of recorded as a component of other comprehensive loss for qualifying hedges and $21,000 of unrealized gains for non-qualifying hedges under SFAS No. 133.

      During the year ended December 31, 2002, the ineffectiveness generated by the Jafra S.A.’s forward contracts and option contracts designated as hedges was insignificant. Certain hedged forecasted transactions do not appear probable of occurring due to timing differences between the original and current forecasts, and accordingly $164,000 of gains were reclassified into earnings.

      The outstanding option contracts had a notional value denominated in Mexican pesos of $523,000,000 in put and call positions at December 31, 2002 and mature at various dates through December 31, 2003. The outstanding forward contracts had notional values denominated in Mexican pesos of $688,873,000 at December 31, 2001 and matured in 2002. Notional amounts do not quantify market or credit exposure or represent assets or liabilities of the Company, but are used in the calculation of cash settlements under the contracts.

104


Table of Contents

JAFRA COSMETICS INTERNATIONAL, S.A. DE C.V. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

      The following table provides information about the details of Jafra S.A.’s option contracts as of December 31, 2002 (in thousands):

At December 31, 2002:

                                 
Coverage in
Mexican Average Fair Value in
Foreign Currency Pesos Strike Price U.S. Dollars(1) Maturity Date





Purchased Puts (Company may sell Peso/buy USD) Mexican Peso
  $ 149,000       10.31-10.48     $ (113 )     Jan.-Mar. 2003  
Mexican Peso
    100,000       11.05-12.19       77       Apr.-June 2003  
Mexican Peso
    150,000       11.76-12.79       131       July-Aug 2003  
Mexican Peso
    124,000       12.51-12.91       21       Oct.-Dec. 2003  
     
             
         
    $ 523,000             $ 116          
     
             
         
Written Calls (Counterparty may buy Peso/sell USD) Mexican Peso
  $ 149,000       9.01-9.02     $ (207 )     Jan.-Mar. 2003  
Mexican Peso
    100,000       9.50-9.84       (144 )     Apr.-June 2003  
Mexican Peso
    150,000       9.69-10.19       (112 )     July-Aug 2003  
Mexican Peso
    124,000       10.15-10.19       (55 )     Oct.-Dec. 2003  
     
             
         
    $ 523,000             $ (518 )        
     
             
         


(1)  The fair value of the option contracts presented above, an unrealized gain of $402,000 at December 31, 2002, represents the carrying value and has been recorded in other receivables in the accompanying consolidated balance sheets.

105


Table of Contents

JAFRA COSMETICS INTERNATIONAL, S.A. DE C.V. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

      The tables below describe the forward contracts that were outstanding at December 31, 2001 (in thousands):

December 31, 2001:

                                 
Weighted
Forward Average Fair
Position In Maturity Contract Value in
Foreign Currency Mexican Pesos(1) Date Rate U.S. Dollars(1)





Buy US Dollar/sell Mexican Peso
  $ 108,715       1/31/02       10.19     $ 1,128  
Sell Mexican Peso/buy US Dollar
    (20,000 )     1/31/02       9.35       (34 )
Buy US Dollar/sell Mexican Peso
    71,787       2/28/02       10.26       756  
Sell Mexican Peso/buy US Dollar
    (20,000 )     2/28/02       9.47       (48 )
Buy US Dollar/sell Mexican Peso
    94,371       3/27/02       10.46       1,102  
Sell Mexican Peso/buy US Dollar
    (40,000 )     3/27/02       9.48       (80 )
Buy US Dollar/sell Mexican Peso
    85,000       4/30/02       10.23       748  
Sell Mexican Peso/buy US Dollar
    (30,000 )     4/30/02       9.62       (84 )
Buy US Dollar/sell Mexican Peso
    81,000       5/31/02       10.11       559  
Sell Mexican Peso/buy US Dollar
    (25,000 )     5/31/02       9.71       (75 )
Buy US Dollar/sell Mexican Peso
    80,000       6/28/02       9.95       375  
Sell Mexican Peso/buy US Dollar
    (30,000 )     6/28/02       9.78       (88 )
Buy US Dollar/sell Mexican Peso
    48,000       7/31/02       10.07       242  
Buy US Dollar/sell Mexican Peso
    100,000       8/30/02       10.05       410  
Buy US Dollar/sell Mexican Peso
    45,000       9/30/02       10.09       169  
Buy US Dollar/sell Mexican Peso
    110,000       10/31/02       10.09       338  
Buy US Dollar/sell Mexican Peso
    30,000       11/29/02       10.27       122  
     
                     
 
    $ 688,873                     $ 5,540 (1)
     
                     
 

(1)  The Fair Value of the forward positions presented above, an unrealized loss of $5,540,000 at December 31, 2001 represents the carrying value of the forward contracts and has been recorded in accrued liabilities in the accompanying consolidated balance sheets.

(14) Fourth Quarter Adjustments

      During the fourth quarter of 2001, Jafra S.A. recorded a total of approximately $3,809,000 to bad debt expense due to declining consultant liquidity as a result of the general slowdown of the economy in Mexico. During the fourth quarter of 2000, Jafra S.A. recorded certain adjustments related to changes in cost accounting estimates, which resulted in an increase to cost of sales of approximately $3,000,000.

106


Table of Contents

SCHEDULE II — VALUATION AND QUALIFYING ACCOUNTS

(in thousands)

CDRJ Investments (Lux) S.A. and Subsidiaries:

                                   
Charged
Balance to Balance
at beginning costs and Deductions- at end
Descriptions of period expenses recoveries of period





Accounts Receivable:
                               
 
2002
  $ 7,267     $ 12,376     $ 11,247     $ 8,396  
 
2001
    3,553       9,464       5,750       7,267  
 
2000
    3,087       5,958       5,492       3,553  
Inventories:
                               
 
2002
    2,821       2,635       2,807       2,649  
 
2001
    2,462       1,879       1,520       2,821  
 
2000
  $ 2,442     $ 1,973     $ 1,953     $ 2,462  

Jafra Cosmetics International, Inc. and Subsidiaries:

                                   
Charged
Balance to Balance
at beginning costs and Deductions- at end
Descriptions of period expenses Recoveries of period





Accounts Receivable:
                               
 
2002
  $ 523     $ 680     $ 590     $ 613  
 
2001
    536       559       572       523  
 
2000
    800       898       1,162       536  
Inventories:
                               
 
2002
    1,479       1,108       887       1,700  
 
2001
    1,404       692       617       1,479  
 
2000
  $ 2,084     $ 532     $ 1,212     $ 1,404  

Jafra Cosmetics International, S.A. de C.V. and Subsidiaries:

                                   
Charged
Balance to Balance
at beginning costs and Deductions- at end
Descriptions of period expenses Recoveries of period





Accounts Receivable:
                               
 
2002
  $ 4,952     $ 11,033     $ 8,824     $ 7,161  
 
2001
    2,117       7,681       4,846       4,952  
 
2000
    1,956       4,956       4,795       2,117  
Inventories:
                               
 
2002
    1,057       1,502       1,705       854  
 
2001
    894       1,035       872       1,057  
 
2000
  $ 269     $ 1,337     $ 712     $ 894  

107


Table of Contents

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

      On June 25, 2002, Deloitte & Touche LLP (“Deloitte”) advised the Company that, because of an independence issue between Deloitte and Riverwood Holding, Inc., an entity in which the Company’s majority shareholder holds an approximately 29.7% common stock interest, Deloitte no longer considered itself independent with respect to the Company. In light of this determination by Deloitte, at a meeting held on July 10, 2002, upon the recommendation of the Audit Committee, the Board of Directors of the Company determined to dismiss Deloitte as the Company’s auditors, subject to the approval of the Company’s shareholders. On July 15, 2002, the Audit Committee, pursuant to the authorization of the Board of Directors, recommended that the Company appoint Ernst & Young LLP (“Ernst & Young”) as the Company’s independent auditor for the fiscal year ending December 31, 2002 and for each fiscal year thereafter through the fiscal year ending December 31, 2007. On July 30, 2002, a majority of the Company’s shareholders approved the dismissal of Deloitte and the selection of Ernst & Young, as the Company’s independent auditor.

      Deloitte’s determination with respect to its independence does not affect its reports on the Company’s consolidated financial statements for any past fiscal year or its reviews of the Company’s interim condensed consolidated financial statements for any previous quarterly period. Deloitte’s report on the Company’s consolidated financial statements for each of the past two fiscal years did not contain an adverse opinion or disclaimer of opinion, and was not qualified or modified as to uncertainty, audit scope or accounting principles.

      During each of the Company’s two most recent fiscal years and the subsequent interim period through July 10, 2002, (i) there was no disagreement with Deloitte on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreement, if not resolved to the satisfaction of Deloitte, would have caused Deloitte to make reference to the subject matter of the disagreement in connection with its reports on the Company’s consolidated financial statements for such years; (ii) the Company did not consult Ernst & Young regarding the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s consolidated financial statements, or any other matter or reportable event as set forth in Items 304(a)(2)(i) and (ii) of Regulation S-K; and (iii) no reportable event as defined in Item 304(a)(1)(v) of Regulation S-K.

108


Table of Contents

PART III

Item 10. Directors, Executive Officers and Significant Employees of the Company

      The names, ages and positions of the executive officers, significant employees and directors of the Company as of March 15, 2003 are set forth below.

             
Name Age Position



Ronald B. Clark
    67     Chairman and Chief Executive Officer; Director
Gonzalo R. Rubio
    59     President and Chief Operating Officer; Director
Ralph S. Mason, III
    51     Vice Chairman, Executive Vice President and General Counsel
Michael A. DiGregorio
    48     Senior Vice President and Chief Financial Officer
Alan Fearnley
    52     Senior Vice President of Strategic Planning and Business Development
Jaime Lopez Guirao
    55     President of Global Operations
Eugenio Lopez Barrios
    61     President of Mexican Operations
Jose Luis Peco
    57     President of European Operations
Ademar Serodio
    58     President of South American Operations
Beatriz Gutai
    42     General Manager of U.S. Operations — Hispanic Division
Dyan Lucero
    53     General Manager of U.S. Operations — General Division
Donald J. Gogel
    54     Director
Steven D. Goldstein
    51     Director
Thomas E. Ireland
    53     Director
Siri Marshall
    54     Director
David A. Novak
    34     Director
Ann Reese
    49     Director
Edward H. Rensi
    58     Director
Kenneth D. Taylor
    68     Director

      None of the Company’s officers has any family relationship with any director or other officer. “Family relationship” for this purpose means any relationship by blood, marriage or adoption, not more remote than first cousin. The business experience during the past five years of each of the directors and executive officers listed above is as follows:

      Ronald B. Clark has served as a director and the Chairman and Chief Executive Officer since joining the Company in May 1998. From 1997 to 1998, Mr. Clark served as President, Richmont Europe (Mary Kay Holding Company). Prior to 1997, he was President of Mary Kay Europe, Executive Vice President of Primerica Corp., President of Jafra Cosmetics International, Inc., and Vice President of Avon Products, Inc. Mr. Clark’s employment agreement provides that he shall be a director of CDRJ Investments (Lux) S.A. during the term of his employment.

      Gonzalo R. Rubio has served as a director and the President and Chief Operating Officer since joining the Company in May 1998. Mr. Rubio served from prior through 1997 as Area Vice President and later President of the European operations of Mary Kay Inc. Prior to that, Mr. Rubio was employed by Avon Products Inc., serving alternately as Area Director for Europe, International Operations Director and Area Director for Latin America. Mr. Rubio’s employment agreement provides that he shall be a director of CDRJ Investments (Lux) S.A. during the term of his employment.

      Ralph S. Mason, III has served as the Company’s Vice Chairman, Executive Vice President and General Counsel since joining the Company in May 1998. For more than the prior five years, Mr. Mason was the senior and founding partner at Mason, Taylor & Colicchio, a law firm in Princeton, New Jersey.

      Michael A. DiGregorio has served as Senior Vice President and Chief Financial Officer of the Company since June of 1999. In his eight years with the Company, his previous responsibilities included Financial

109


Table of Contents

Director and General Manager of the Mexico operations and President of U.S. Operations. In addition, Mr. DiGregorio has been the CFO of two other public companies, and spent a total of fourteen years with the Gillette Company.

      Alan Fearnley has served as Senior Vice President of Strategic Planning and Business Development of the Company since July of 2001. From 1998 to 2001, Mr. Fearnley served as Senior Vice President of Global Marketing of the Company. From 1997 to 1998, Mr. Fearnley served as Vice President of Marketing for Dermatologica. Prior to that, Mr. Fearnley took a year’s sabbatical to attend the Sloan Fellowship Masters Program at the London Business School. During this sabbatical, Mr. Fearnley also served as consultant to various companies.

      Jaime Lopez Guirao has served as President, Global Operations since joining the Company in June 1998. For more than the prior five years, Mr. Guirao was employed by Avon Products, Inc., holding several operational, management and Country President positions in Europe and the Americas.

      Eugenio Lopez Barrios has served as President of Mexican Operations since joining the Company in June 1998. From prior to 1998, Mr. Barrios was President of Mary Kay Mexico.

      Jose Luis Peco has served as President of European Operations of the Company since joining the Company in June 1998. From prior to 1998, Mr. Peco served as Vice President of European Operations for Mary Kay Cosmetics and President of Mary Kay Cosmetics — Iberia.

      Ademar Serodio joined the Company in January 2000 and currently serves as President of South America Operations. For more than the prior five years, Mr. Serodio was employed by Avon Products, Inc., holding several Country President roles in Avon’s South American markets.

      Beatriz Gutai has served as General Manager of the Hispanic Division of United States Operations since September of 2000. Prior to that time, Ms. Gutai served as Vice President of Sales for the Hispanic Division and in various positions in sales management, programs, and events since joining the Company in 1982.

      Dyan Lucero has served as General Manager of the General Division of United States Operations since September of 2000. Prior to that time, Ms. Lucero served as Vice President of Sales for the General Division and in various positions in sales management and business development since joining the Company in 1972.

      Donald J. Gogel has been a director of the Company since January 1998. Since 1998, Mr. Gogel has served as Chief Executive Officer of CD&R; since prior to 1997 he has served as President and a director of CD&R and since 1989 he has been a principal of CD&R. Mr. Gogel is also a limited partner of CD&R Associates V Limited Partnership (“Associates V”), the general partner of CD&R Fund V, and President and Chief Executive Officer and a shareholder and director of CD&R Investment Associates II, Inc. (“Investment Associates II”), a Cayman Islands exempted company that is the managing general partner of Associates V. Mr. Gogel is a director of Kinko’s, Inc., a corporation in which Fund V has an investment, and a director of Global Decisions Group, LLC, a limited liability company in which an investment fund managed by CD&R has an investment, and Turbochef, Inc. Mr. Gogel serves as a member of the compensation committee of the board of directors of Turbochef, Inc.

      Steven D. Goldstein has been a director of the Company since July 1998. Since February of 1998, Mr. Goldstein has served as President and Chief Executive Officer of Chaycon Inc. From November of 2000 to July of 2001, Mr. Goldstein served as Chairman and Chief Executive Officer of More Benefits, Corp. From December 1997 to November of 2000, Mr. Goldstein served as Chairman and Chief Executive Officer of Invenet, LLC. Prior to joining Invenet, LLC, Mr. Goldstein was employed as President, Credit of Sears, Roebuck & Co. Prior to 1997, Mr. Goldstein was employed by American Express Co., serving most recently as the Chairman and Chief Executive Officer of American Express Bank.

      Thomas E. Ireland has been a director of the Company since March 1998 and is a principal of CD&R, a limited partner of Associates V and a shareholder and a director of Investment Associates II. From prior to 1997 until joining CD&R in 1997, Mr. Ireland served as a senior managing director of Alvarez & Marsal, Inc. Mr. Ireland also serves on the board of directors of the Maine Coast Heritage Trust. Mr. Ireland is a director

110


Table of Contents

of Remington Arms Company, Inc. and its parent RACI Holding, Inc., a corporation in which an investment fund managed by CD&R has an investment.

      Siri Marshall has been a director of the Company since July 1999. Ms. Marshall has been employed by General Mills since prior to 1997 and currently serves as its Senior Vice President, Corporate Affairs and General Counsel and Secretary. She is also a director of Snack Ventures Europe, a joint venture between General Mills and PepsiCo.

      David A. Novak has been a director of the Company since January 1998. Mr. Novak is a principal of CD&R, a limited partner of Associates V, and a shareholder of Investment Associates II. Prior to joining CD&R in 1997, Mr. Novak worked in the Private Equity and Investment Banking Divisions of Morgan Stanley & Co. Incorporated and for the Central European Development Corporation. Mr. Novak also serves on the board of directors of Italtel Holdings.

      Ann Reese has been a director of the Company since July 1998. Ms. Reese has been the Executive Director of Center for Adoption Policy Studies since October 2000. From 1999 to December 2000, Ms. Reese was a professional employee of CD&R. From prior to 1997 to March 1998, Ms. Reese was Chief Financial Officer of ITT Corp., a company in the hotel and gaming businesses and previously in insurance and manufacturing.

      Edward H. Rensi has been a director of the Company since July 1998. For more than the prior five years, Mr. Rensi has been employed by McDonalds Corp. USA, serving most recently as President and Chief Executive Officer. Mr. Rensi also serves as a director of Snap-On Inc. and I.S.C. Corporation, and serves as a member of the compensation committee of the board of directors of Snap-On Inc. and I.S.C. Corporation.

      Kenneth D. Taylor has been a director of the Company since July 1998 and has been the Chairman of Global Public Affairs, Inc. since prior to 1997.

      At present, all directors will hold office until their successors are elected and qualified, or until their earlier removal or resignation.

111


Table of Contents

Item 11. Executive Compensation

Compensation Of Executive Officers

      The following table sets forth the compensation earned by Company’s Chief Executive Officer and the four additional most highly compensated executive officers of the Company for each (each, a “named executive officer”) of the last three fiscal years.

Summary Compensation Table

                                           
Long-Term
Compensation
Securities All Other
Underlying Compensation
Name and Principal Position Year Salary($) Bonus($) Options(#) ($)(1)






Ronald B. Clark
    2002     $ 674,848     $ 370,319             $ 53,184  
 
Chairman and Chief
    2001       648,729       391,872               43,691  
 
Executive Officer
    2000       626,218       227,610               56,811  
Gonzalo R. Rubio
    2002       562,358       308,591               44,446  
 
President and Chief
    2001       540,555       326,550               36,408  
 
Operating Officer
    2000       521,832       189,666               47,341  
Ralph S. Mason, III
    2002       506,148       277,746               6,616  
 
Vice Chairman, Executive
    2001       486,557       293,910               6,554  
 
Vice President and General Counsel
    2000       469,672       170,712               8,517  
Jaime Lopez Guirao
    2002       505,135       277,190               64,757  
 
President of Global Operations
    2001       484,202       293,322               56,434  
      2000       467,518       170,360               42,476  
Michael A. DiGregorio
    2002       337,465       185,182               35,714  
 
Senior Vice President and Chief
    2001       323,877       163,300               27,432  
 
Financial Officer
    2000       312,664       94,845       1,264       18,048  

(1)  Amounts shown in this column constitute the Company’s contributions under its 401(k) and Supplemental Savings Plan and automobile expense for Mr. Lopez Guirao and Mr. DiGregorio.

FISCAL YEAR-END OPTION VALUE TABLE

      The following table sets forth information for each Named Executive Officer with regard to the aggregate value of options held at December 31, 2002. No options were exercised by such executive officers during the year ended December 31, 2002.

                                 
Number of
Securities Underlying Value of Unexercised
Unexercised Options In-the-Money Options
at December 31, 2002(#) at December 31, 2002($)(1)


Name Exercisable Unexercisable Exercisable Unexercisable





Ronald B. Clark
    14,839       3,489     $ 3,412,970     $ 802,470  
Gonzalo R. Rubio
    14,839       3,489       3,412,970       802,470  
Ralph S. Mason, III
    11,769       2,767       2,706,870       636,410  
Jaime Lopez Guirao
    4,857       1,143       1,117,110       262,890  
Michael A. DiGregorio
    3,596       1,144       741,060       210,100  

(1)  Calculated based on a per share price of Parent Common Stock of $330, the estimated fair market value, less the per share exercise price.

Compensation Of Directors

      During 2002, each outside director of the Company received a retainer of $40,000 for serving on the Board of Directors of the Company and was reimbursed for his or her out-of-pocket expenses incurred in connection with attending board meetings. The Company pays no additional remuneration to officers of the Company or the principals or employees of CD&R for serving as directors.

112


Table of Contents

Employment Agreements

      The Company has employment agreements with each of the Named Executive Officers. The employment agreements of Messrs. Clark, Rubio and Mason have an initial term of three years that becomes a continuous “rolling” two year term as of the first anniversary of the closing of the Acquisition (the “Closing”). The employment agreements of Messrs. Guirao and DiGregorio have a continuous “rolling” term of two years, commencing as of June 1, 1998. Pursuant to their respective agreements, as of their 2002 anniversary dates, Messrs. Clark, Rubio, Mason, Guirao and DiGregorio receive annual base salaries of $686,000, $571,000, $514,000, $513,000 and $343,000, respectively. In addition, each of Messrs. Clark, Rubio, Mason and Guirao are eligible for a target annual bonus equal to 60%, and Mr. DiGregorio is eligible for a target annual bonus equal to 50%, of such Named Executive Officer’s annual base salary if the Company achieves the performance goals established under its annual incentive plan for executives and may receive a larger bonus if such goals are exceeded. The employment agreements further provide that, in the event of a termination of any such Named Executive Officer’s employment by the Company without “cause” (as defined in the employment agreement) or by such executive for “good reason” (as so defined), such Named Executive Officer will be entitled to continued payments of his base salary for the remaining term of his employment agreement and to payment of a pro rata annual bonus for the year of termination provided that the Company achieves the performance objectives applicable for such year and each year thereafter. Each of the employment agreements also contains covenants regarding nondisclosure of confidential information, noncompetition and nonsolicitation.

Compensation Committee Interlocks And Insider Participation

      The Board of Directors of the Company established a Compensation Committee to review all compensation arrangements for executive officers of the Company. During 2002, the individuals serving on the Compensation Committee were Mr. Taylor, Mr. Ireland and Ms. Marshall.

      Pursuant to a consulting agreement entered into following the Acquisition, CD&R receives a fee for advisory, management consulting and monitoring services to the Company. The annual fee received by CD&R was $400,000 for the year ended December 31, 2000. As of January 1, 2001, the annual fee was increased to $1,000,000 based on an amendment to the consulting agreement. The annual fee received by CD&R was $1,000,000 for the years ended December 31, 2001 and 2002. The amendment provides for an annual fee for ongoing services provided to the Company. As required by the terms of the Company’s lending arrangements, such fees were determined by arm’s-length negotiation and are believed by the Company to be reasonable. In addition, the amendment adds to CD&R’s services under the agreement financial advisory, investment banking and similar services with respect to future proposals for an acquisition, merger, recapitalization, or other similar transaction directly or indirectly involving the Company or any of its subsidiaries. The fee for such additional services in connection with future transactions would be an amount equal to 1% of the transaction value for the transaction to which such fee relates. Such transaction fees may be increased upon approval of a majority of the members of the Company’s Board of Directors who are not employees of the Company, CD&R or any affiliate of CD&R. The amendment also provides that if any employee of CD&R is appointed to an executive management position (or a position of comparable responsibility) in the Company or any of its subsidiaries, the annual fee will be increased by an amount to be determined by CD&R, the amount of such increase not to exceed 100% of the existing annual fee in effect at that time. Parent has also agreed to indemnify the members of the Board employed by CD&R and CD&R against liabilities incurred under securities laws, liabilities to third parties, and liabilities relating to the provision by CD&R of advisory management, consulting and monitoring services.

      The Company also engaged an entity, in which CD&R has an investment, to develop its e-commerce business. During 2000, the Company paid such entity fees of $1,798,000. The Company terminated this agreement and entered into a settlement and release agreement with such entity in 2000, pursuant to which such entity agreed to pay the Company $500,000 in quarterly installments, together with interest at 9.5% per annum through October 2005. At December 31, 2002, the balance was paid in full. See “Certain Relationships and Related Transactions.”

113


Table of Contents

 
Item 12. Security Ownership of Certain Beneficial Owners and Management

      Parent owns, indirectly, all of the outstanding capital stock of JCI and Jafra S.A. The table below sets forth, as of February 14, 2002, the owners of 5% or more of the Parent Common Stock and the ownership of Parent Common Stock by the directors and each Named Executive Officer, as well as by all directors and Named Executive Officers of the Company as a group.

                 
Number Percent
Name of Shares(1) of Class(2)



Clayton, Dubilier & Rice Fund V Limited Partnership(3)
    769,600       92.51  
Donald J. Gogel(4)
           
Steven D. Goldstein
    2,000       *  
Thomas E. Ireland(4)
           
Siri Marshall
    1,667       *  
David A. Novak(4)
           
Ann Reese
    2,500       *  
Edward H. Rensi
    2,500       *  
Kenneth D. Taylor
    500       *  
Ronald B. Clark(5)
    24,003       2.83  
Gonzalo R. Rubio(6)
    24,003       2.83  
Ralph S. Mason, III(7)
    19,037       2.26  
Jaime Lopez Guirao(8)
    7,857       *  
Michael A. DiGregorio(9)
    5,526       *  
All directors and Executive Officers as a group (14 persons)(10)
    115,715       12.85  

The symbol “*” denotes less than 1 percent.

(1)  Represents shares of common stock beneficially owned on December 31, 2002. Unless otherwise noted, each person has sole voting and investment power with respect to such shares.
 
(2)  Based upon 831,888 shares of common stock outstanding as of December 31, 2002.
 
(3)  Associates V is the general partner of CD&R Fund V and has the power to direct CD&R Fund V as to the voting and disposition of shares held by CD&R Fund V. Investment Associates II is the managing general partner of Associates V and has the power to direct Associates V as to its direction of CD&R Fund V’s voting and disposition of the shares held by CD&R Fund V. No person controls the voting and dispositive power of Investment Associates II with respect to the shares owned by CD&R Fund V. Each of Associates V and Investment Associates II expressly disclaims beneficial ownership of the shares owned by CD&R Fund V. The business address for each of CD&R Fund V, Associates V and Investment Associates II is c/o Investment Associates II, 1403 Foulk Road, Suite 106, Wilmington, Delaware 19803.
 
(4)  Does not include shares owned by CD&R Fund V.
 
(5)  Includes 14,839 shares as to which Mr. Clark has a right to acquire through the exercise of stock options.
 
(6)  Includes 14,839 shares as to which Mr. Rubio has a right to acquire through the exercise of stock options.
 
(7)  Includes 11,769 shares as to which Mr. Mason has a right to acquire through the exercise of stock options.
 
(8)  Includes 4,857 shares as to which Mr. Guirao has a right to acquire through the exercise of stock options.
 
(9)  Includes 3,596 shares as to which Mr. DiGregorio has a right to acquire through the exercise of stock options, and excludes 440 shares held by the trustee of subtrusts established for the benefit of Mr. DiGregorio’s children.

(10)  Includes 65,594 shares which the executive officers as a group have a right to acquire through the exercise of stock options and excludes 440 shares held by trustee of subtrusts established for the benefit of Mr. DiGregorio’s children. On July 11, 2000, a member of management purchased 316 shares of

114


Table of Contents

Common Stock; on July 27, 2000, a former member of management exercised 158 options to purchase Common Stock, and then sold a total of 632 shares of Common Stock back to the Company; on August 9, 2000, certain members of management purchased an aggregate of 4,108 shares of Common Stock, and on November 6, 2000, a former member of management sold 316 shares of the Common Stock back to the Company; on February 10, 2001, certain members of management purchased an aggregate of 474 shares of Common Stock; on June 14, 2001, a former member of management and a former director, sold an aggregate total of 2,563 shares of Common Stock back to the Company; on September 19, 2001, a former member of management exercised options to purchase 210 shares of Common Stock, and then sold a total of 526 shares of Common Stock back to the Company in transactions exempt from the registration requirements of the Securities Act. Shares owned by CD&R Fund V are not included herein. Mr. Gogel is an officer, director and shareholder of Investment Associates II, Mr. Ireland is a director and shareholder of Investment Associates II, and Mr. Novak is a shareholder of Investment Associates II.

115


Table of Contents

 
Item 13.  Certain Relationships and Related Transactions

      CD&R Fund V, which is Parent’s largest stockholder, is a private investment fund managed by CD&R. Amounts contributed to CD&R Fund V by its limited partners are invested at the discretion of the general partner in equity or equity-related securities of entities formed to effect leveraged buy-out transactions and in the equity of corporations where the infusion of capital, coupled with the provision of managerial assistance by CD&R, can be expected to generate returns on investments comparable to returns historically achieved in leveraged buyout transactions. The general partner of CD&R Fund V is Associates V, and the general partners of Associates V are Investment Associates II, CD&R Investment Associates, Inc. and CD&R Cayman Investment Associates, Inc., a Cayman Islands exempted company. Each of Mr. Gogel, who is President, Chief Executive Officer and a director of CD&R; President, Chief Executive Officer, and a shareholder and a director of Investment Associates II; and a limited partner of Associates V, Mr. Ireland, who is a principal of CD&R, a limited partner of Associates V and a shareholder and a director of Investment Associates II, and Mr. Novak, who is a principal of CD&R, a limited partner of Associates V, and a shareholder of Investment Associates II, is a director of Parent. See “Directors and Executive Officers of the Company.”

      CD&R is a private investment firm that is organized as a Delaware corporation. CD&R is the manager of a series of investment funds, including CD&R Fund V. CD&R generally assists in structuring, arranging financing for and negotiating the transactions in which the funds it manages invest. After the consummation of such transactions, CD&R generally provides advisory, management consulting and monitoring services to the companies in which its investment funds have invested during the period of such fund’s investment.

      Pursuant to a consulting agreement entered into at the closing of the Acquisition, until the tenth anniversary of the Acquisition or the date on which CD&R Fund V no longer has an investment in the Company or until the termination by either party with 30 days notice, CD&R will receive an annual fee (and reimbursement of out-of-pocket expenses) for providing advisory, management consulting and monitoring services to the Company. Effective January 1, 2000, the annual fee was $400,000. Such services include, among others, helping the Company to establish effective banking, legal and other business relationships and assisting management in developing and implementing strategies for improving the operational, marketing and financial performance of the Company. Based on an amendment to the consulting agreement, effective January 1, 2001, the annual fee was increased to $1,000,000, for ongoing services provided to the Company. As required by the terms of the Company’s lending arrangements, such fees were determined by arm’s-length negotiation and are believed by the Company to be reasonable.

      In addition, the amendment adds to CD&R’s services under the agreement financial advisory, investment banking and similar services with respect to future proposals for an acquisition, merger, recapitalization, or other similar transaction directly or indirectly involving the Company or any of its subsidiaries. The fee for such additional services in connection with future transactions would be an amount equal to 1% of the transaction value for the transaction to which such fee relates. Such transaction fees may be increased upon approval of a majority of the members of the Company’s Board of Directors who are not employees of the Company, CD&R or any affiliate of CD&R.

      The amendment also provides that if any employee of CD&R is appointed to an executive management position (or a position of comparable responsibility) in the Company or any of its subsidiaries, the annual fee will be increased by an amount to be determined by CD&R, the amount of such increase not to exceed 100% of the existing annual fee in effect at that time.

      CD&R, CD&R Fund V and Parent entered into an indemnification agreement, pursuant to which Parent has agreed to indemnify the members of its board of directors, as well as CD&R, CD&R Fund V, Associates V, Investment Associates II and certain of their members, partners, associates and affiliates (the “Indemnitees”) to the fullest extent allowable under applicable law and to indemnify the Indemnitees against any suits, claims, damages or expenses which may be made against or incurred by them under applicable securities laws in connection with offerings of securities of the Company, liabilities to third parties arising out of any action or failure to act by the Company, and, except in cases of gross negligence or intentional misconduct, the provision by CD&R of advisory, management consulting and monitoring services.

116


Table of Contents

      During 1999, the Company engaged Guidance Solutions Inc. (“Guidance”), a corporation in which an investment fund managed by CD&R has an investment, to develop its e-commerce business. Under the agreement entered into by both parties, the Company agreed to pay fees of approximately $2.0 million to Guidance in connection with the planning, defining, designing and consulting services performed related to the Company’s e-commerce initiative. During 2000, the Company paid fees to Guidance of $1,798,000. The Company terminated its agreement with Guidance and executed a settlement and mutual release agreement effective September 30, 2000. Upon execution of this settlement and mutual release agreement in October of 2000, Guidance paid the Company $25,000 and agreed to pay the Company an aggregate additional sum of $475,000, payable in quarterly installments, plus interest at 9.5% per annum, beginning in January 2001 through October 2005. At December 31, 2002, the balance was paid in full.

      The Company has entered into employment agreements with various members of management, including each of the Named Executive Officers. See “Executive Compensation — Employment Agreements.” The employment agreements of Messrs. Clark and Rubio provide that each will be a director of Parent during the term of his employment.

      Under certain circumstances, stockholders can require the Company to purchase their shares of Common Stock. Management stockholders are subject to a holding period of at least seven months from the date such shares were acquired. In June 2001, a former member of management and a director both requested that the Company purchase their entire balance of Common Stock, consisting of an aggregate of 2,563 shares. In September 2001, a former member of management exercised options to purchase 210 shares of Common Stock, and then requested that the Company purchase his entire balance of Common Stock, consisting of 526 shares. In July 2000, a former member of management exercised options to purchase 158 shares of Common Stock, and then requested that the Company purchase his entire balance of Common Stock, consisting of 632 shares. The Company repurchased the shares in 2001 at a total cost of $772,000, or $250 per share, which represented the respective estimated fair values at the time of the purchases.

      Certain members of management, including Named Executive Officers, financed a portion of the cash purchase price of the shares of Common Stock they acquired through loans from the Chase Manhattan Bank on market terms. In February 2001, certain members of management purchased an aggregate of 474 shares of the Common Stock at a purchase price of $210 per share, which represented the estimated fair value at the time of the purchase. In September 2001, a former member of management purchased 210 shares of Common Stock at a purchase price of $150 per share, which was below the estimated fair value at the time of the purchase of $250 per share. The Company recognized compensation expense of approximately $21,000 at the time of the purchase. During 2001, certain members of management were also granted options to purchase an aggregate of 948 shares of Common Stock. To help members of management obtain such terms for such financing, the Company fully and unconditionally guaranteed up to 75% of the purchase price for the shares of Common Stock purchased by each such member of management. The Company guaranteed loans for $687,300, $687,300, $545,100, $225,000 and $230,000 extended to Messrs. Clark, Rubio, Mason, Guirao, and DiGregorio, respectively, portions of which remain outstanding.

 
Item 14.  Controls and Procedures

      The Company’s principal executive officer and principal financial officer have evaluated the effectiveness of the Company’s “disclosure controls and procedures,” as such term is defined in Rule 13a-14(c) of the Securities Exchange Act of 1934, as amended, within 90 days of the filing date of this Annual Report on Form 10-K. Based upon their evaluation, the principal executive officer and principal financial officer concluded that the Company’s disclosure controls and procedures are effective.

      There have been no significant changes in the Company’s internal controls or in other factors that could significantly affect these controls subsequent to the date the Company performed the evaluation.

117


Table of Contents

PART IV

 
Item 15.  Exhibits, Financial Statement Schedules and Reports on Form 8-K

      (a)(1) Financial Statements. Reference is made to the Index to Financial Statements and Schedules of the Company on page 28 of this Annual Report on Form 10-K.

      (a)(2) Financial Statement Schedules. Reference is made to the Index to Financial Statements and Financial Statement Schedules of the Company on page 28 of this Annual Report on Form 10-K. See also the following financial statement schedules which should be read in conjunction with the financial statements included in Item 8 of this Annual Report on Form 10-K.

           
Pages in this
Annual Report
On Form 10-K

Jafra Cosmetics International, Inc.:
       
 
Independent Auditors’ Reports
    58  
 
Consolidated Balance Sheets as of December 31, 2002 and 2001
    59  
 
Consolidated Statements of Operations for the years ended December 31, 2002, 2001 and 2000
    60  
 
Consolidated Statements of Stockholder’s Equity for the years ended December 31, 2002, 2001 and 2000
    61  
 
Consolidated Statements of Cash Flows for the years ended December 31, 2002, 2001 and 2000
    62  
 
Notes to Consolidated Financial Statements
    63  
Jafra Cosmetics International, S.A. de C.V.:
       
 
Independent Auditors’ Reports
    80  
 
Consolidated Balance Sheets as of December 31, 2002 and 2001
    81  
 
Consolidated Statements of Operations for the years ended December 31, 2002, 2001 and 2000
    82  
 
Consolidated Statements of Stockholders’ Equity for the years ended December 31, 2002, 2001 and 2000
    83  
 
Consolidated Statements of Cash Flows for the years ended December 31, 2002, 2001 and 2000
    84  
 
Notes to Consolidated Financial Statements
    85  
 
Schedule II — Valuation and Qualifying Accounts
    99  

      (a)(3) Exhibits. The following documents are exhibits to this Annual Report on Form 10-K.

         
Exhibit
Number Description of Document


  3 .1   Articles of Association (Statuts Coordonnes) of CDRJ Investments (Lux) S.A., as restated on September 30, 1998; previously filed as Exhibit 3.1 to Amendment 2 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed December 23, 1998, and incorporated herein by reference.
  3 .2   Certificate of Incorporation of CDRJ Acquisition Corporation, dated March 31, 1998; previously filed as Exhibit 3.2 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed September 4, 1998, and incorporated herein by reference.
  3 .3   Certificate of Merger of Jafra Cosmetics International, Inc. into CDRJ Acquisition Corporation, dated April 30, 1998; previously filed as Exhibit 3.3 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed September 4, 1998, and incorporated herein by reference.

118


Table of Contents

         
Exhibit
Number Description of Document


  3 .4   Amended and Restated By-laws of Jafra Cosmetics International, Inc. (formerly CDRJ Acquisition Corporation), as adopted on July 21, 1998; previously filed as Exhibit 3.4 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed September 4, 1998, and incorporated herein by reference.
  3 .5   Deed of Incorporation (acta constitutiva), including all amendments thereto, and current by-laws (estatutos sociales) of Jafra Cosmetics International, S.A. de C.V., together with a unofficial summary thereof in English; previously filed as Exhibit 3.5 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed September 4, 1998, and incorporated herein by reference.
  3 .6   Deed of Incorporation (acta constitutiva), including all amendments thereto, and current by-laws (estatutos sociales) of Dirsamex, S.A. de C.V., together with a unofficial summary thereof in English; previously filed as Exhibit 3.7 to Amendment No. 1 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed October 27, 1998, and incorporated herein by reference.
  3 .7   Deed of Incorporation (acta constitutiva), including all amendments thereto, and current by-laws (estatutos sociales) of Jafra Cosmetics S.A. de C.V., formerly known as Jafra Cosmetics S. de R.L. de C.V., together with a unofficial summary thereof in English; previously filed as Exhibit 3.9 to Amendment No. 1 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed October 27, 1998, and incorporated herein by reference.
  3 .8   Deed of Incorporation (acta constitutiva), including all amendments thereto, and current by-laws (estatutos sociales) of Qualifax, S.A. de C.V., together with a unofficial summary thereof in English; previously filed as Exhibit 3.10 to Amendment No. 1 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed October 27, 1998, and incorporated herein by reference.
  3 .9   Deed of Incorporation (acta constitutiva), including all amendments thereto, and current by-laws (estatutos sociales) of Reday, S.A. de C.V., together with a unofficial summary thereof in English; previously filed as Exhibit 3.11 to Amendment No. 1 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed October 27, 1998, and incorporated herein by reference.
  3 .10   Deed of Incorporation (acta constitutiva), including all amendments thereto, and current by-laws (estatutos sociales) of Cosmeticos Y Fragrancias, S.A. de C.V., together with an unofficial summary thereof in English; previously filed as exhibit 3.10 to the Company’s Annual Report on Form 10-K for the fiscal year ended 2000, filed on April 2, 2001, and incorporated herein by reference.
  3 .11   Notarial Deed and Resolutions, together with an unofficial summary thereof in English, for the transformation of Jafra Cosmetics S. de R.L. de C.V. into Jafra Cosmetics S.A. de C.V.; previously filed as Exhibit 3.12 to the Company’s Annual Report on Form 10-K for the fiscal year ended 1999, filed on March 30, 2000, and incorporated herein by reference.
  3 .12   Approval, dated as of April 17, 2000, by the Public Registry of Commerce of the United Mexican States of the merger of Consultoria Jafra S.A. de C.V. and Distribuidora Venus, S.A. de C.V. with and into Reday, S.A. de C.V., together with supporting shareholders’ resolutions and the unofficial English translation thereof; previously filed as Exhibit 3.1 to the Company’s Quarterly Report on Form 10-Q for the second quarter ended June 30, 2000, filed on August 14, 2000, and incorporated herein by reference.
  3 .13   Notarial Deed and Resolutions, together with an unofficial summary thereof in English, for the changing of the corporate name from Reday, S.A. de C.V. to Distribuidora Venus, S.A. de C.V. as a consequence of the merger of Distribuidora Venus, S.A. de C.V. into Reday, S.A. de C.V.; previously filed as Exhibit 3.11 to the Company’s Annual Report on Form 10-K for the fiscal year ended 2000, filed on April 2, 2001, and incorporated herein by reference.

119


Table of Contents

         
Exhibit
Number Description of Document


  3 .14   Notarial Deed and Resolutions, together with an unofficial summary thereof in English, for the renaming of Qualifax, S.A. de C.V. as Serviday S.A. de C.V.; previously filed as Exhibit 3.1 to the Company’s Quarterly Report on Form 10-Q for the second quarter ended June 30, 2001, filed on August 14, 2001, and incorporated herein by reference.
  4 .1   Indenture, dated April 30, 1998, among CDRJ Acquisition Corporation, Jafra Cosmetics International, S.A. de C.V., CDRJ Investments (Lux) S.A., and State Street Bank and Trust Company; previously filed as Exhibit 4.1 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed September 4, 1998, and incorporated herein by reference.
  4 .2   First Supplemental Indenture, dated April 30, 1998, among Consultoria Jafra, S.A. de C.V., Distribuidora Venus, S.A. de C.V., Dirsamex, S.A. de C.V., Reday, S.A. de C.V., Qualifax S.A. de C.V., and Jafra Cosmetics S.R.L., CDRJ Acquisition Corporation and Jafra Cosmetics International, S.A. de C.V. and State Street Bank and Trust Company; previously filed as Exhibit 4.2 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed September 4, 1998, and incorporated herein by reference.
  4 .3   Purchase Agreement, dated April 28, 1998, between Credit Suisse First Boston Corporation, Chase Securities Inc., CDRJ Acquisition Corporation, Jafra Cosmetics International, S.A. de C.V., and CDRJ Investments (Lux) S.A.; previously filed as Exhibit 4.3 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed September 4, 1998, and incorporated herein by reference.
  4 .4   Purchase Agreement Amendment, dated April 30, 1998, executed on behalf of each of Reday, S.A. de C.V., Distribuidora Venus, S.A. de C.V., Dirsamex, S.A. de C.V., Qualifax, S.A. de C.V., Jafra Cosmetics, S.R.L., Consultoria Jafra, S.A. de C.V., Credit Suisse First Boston Corporation, and Chase Securities Inc.; previously filed as Exhibit 4.4 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed September 4, 1998, and incorporated herein by reference.
  4 .5   Registration Rights Agreement, dated April 30, 1998, among CDRJ Acquisition Corporation, Jafra Cosmetics International, Inc., Jafra Cosmetics International, S.A. de C.V., CDRJ Investments (Lux) S.A., Reday, S.A. de C.V., Distribuidora, S.A. de C.V., Dirsamex, S.A. de C.V., Qualifax, S.A. de C.V., Jafra Cosmetics, S.A. de C.V., Consultoria Jafra, S.A. de C.V., and Credit Suisse First Boston Corporation; previously filed as Exhibit 4.5 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed September 4, 1998, and incorporated herein by reference.
  4 .6   Credit Agreement, dated April 30, 1998, among CDRJ Acquisition Corporation, Jafra Cosmetics International, S.A. de C.V., CDRJ Investments (Lux) S.A., as Guarantor and Parent of the Borrowers, the Lenders named therein and Credit Suisse First Boston, as Administrative Agent; previously filed as Exhibit 4.6 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed September 4, 1998, and incorporated herein by reference.
  4 .7   Amendment No. 1 to the Credit Agreement, dated August 26, 1998; previously filed as Exhibit 4.7 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed September 4, 1998, and incorporated herein by reference.
  4 .8   Indemnity, Subrogation and Contribution Agreement, dated April 30, 1998, among Jafra Cosmetics International, S.A. de C.V. (“JCISA”), each Subsidiary of JCSI listed on Schedule I thereto and Credit Suisse First Boston; previously filed as Exhibit 4.8 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed September 4, 1998, and incorporated herein by reference.

120


Table of Contents

         
Exhibit
Number Description of Document


  4 .9   JCI Guarantee Agreement, dated April 30, 1998, between CDRJ Acquisition Corporation and Credit Suisse First Boston; previously filed as Exhibit 4.9 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed September 4, 1998, and incorporated herein by reference.
  4 .10   JCISA Guarantee Agreement, dated April 30, 1998, between Jafra Cosmetics International, S.A. de C.V. and Credit Suisse First Boston; previously filed as Exhibit 4.10 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed September 4, 1998, and incorporated herein by reference.
  4 .11   JCISA Subsidiary Guarantee Agreement, dated April 30, 1998, among each of the subsidiaries of Jafra Cosmetics International, S.A. de C.V. listed on Schedule I thereto, and Credit Suisse First Boston; previously filed as Exhibit 4.11 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed September 4, 1998, and incorporated herein by reference.
  4 .12   Parent Guarantee Agreement, dated April 30, 1998, between CDRJ Investments (Lux) S.A. and Credit Suisse First Boston; previously filed as Exhibit 4.12 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed September 4, 1998, and incorporated herein by reference.
  4 .13   Pledge Agreement, dated April 30, 1998 among CDRJ Investments (Lux) S.A., CDRJ North Atlantic Sarl, CDRJ Latin America Holding Company B.V., Latin Cosmetics Holdings B.V., Regional Cosmetics Holding B.V., Southern Cosmetics Holdings B.V., and CDRJ Mexico Holding Company B.V., CDRJ Acquisition Corporation, Jafra Cosmetics International, S.A. de C.V. and Credit Suisse First Boston; previously filed as Exhibit 4.13 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed September 4, 1998, and incorporated herein by reference.
  4 .14   Security Agreement, dated April 30, 1998, among CDRJ Acquisition Corporation (“JCI”), each subsidiary of JCI listed on Schedule I thereto and Credit Suisse First Boston; previously filed as Exhibit 4.14 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed September 4, 1998, and incorporated herein by reference.
  4 .15   Deed of Trust, with Assignment of Leases and Rents, Fixture Filing and Security Agreement, dated April 30, 1998, by Jafra Cosmetics International, Inc. to TitleServ Agency of New York City, Inc., as trustee for the Benefit of Credit Suisse First Boston; previously filed as Exhibit 4.15 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed September 4, 1998, and incorporated herein by reference.
  4 .16   Acknowledgment of Obligations and Mortgage, dated April 30, 1998, granted by Reday, S.A. de C.V. in favor of Credit Suisse First Boston, together with an unofficial English translation thereof; previously filed as Exhibit 4.16 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed September 4, 1998, and incorporated herein by reference.
  4 .17   Notarial Deed of Pledge, dated April 30, 1998, with respect to the pledge to Credit Suisse First Boston of (i) 24 ordinary shares of the capital stock of CDRJ Europe Holding Company B.V. by Jafra Cosmetics International, Inc., and (ii) 40 ordinary shares of the capital stock of CDRJ Latin America Holding B.V. by CDRJ North Atlantic (Lux) Sarl; previously filed as Exhibit 4.17 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed September 4, 1998, and incorporated herein by reference.

121


Table of Contents

         
Exhibit
Number Description of Document


  4 .18   Consent and Waiver, dated as of November 19, 1999, to the Credit Agreement dated as of April 30, 1998, as amended by Amendment No. 1 thereto dated as of August 26, 1998, among Jafra Cosmetics International Inc., Jafra Cosmetics International S.A. de C.V., CDRJ Investments (Lux) S.A., the several banks and financial institutions party to the Credit Agreement, the Issuing Bank and Credit Suisse First Boston, as Administrative Agent; previously filed as Exhibit 4.18 to the Company’s Annual Report on Form 10-K for the fiscal year ended 1999, filed on March 30, 2000, and incorporated herein by reference.
  4 .19   Substitution of Trustee and Partial Reconveyance of Deed of Trust, Assignment of Leases and Rents, Fixture Filing and Security Agreement, and Release of Financing Statement, dated November 29, 1999, which amends the Deed of Trust filed as Exhibit 4.15 above; previously filed as Exhibit 4.19 to the Company’s Annual Report on Form 10-K for the fiscal year ended 1999, filed on March 30, 2000, and incorporated herein by reference.
  4 .20   Partial Reconveyance of Deed of Trust, Assignment of Leases and Rents, Fixture Filing and Security Agreement and Release of Financing Statement, dated November 29, 1999, which amends the Deed of Trust filed as Exhibit 4.15 above; previously filed as Exhibit 4.20 to the Company’s Annual Report on Form 10-K for the fiscal year ended 1999, filed on March 30, 2000, and incorporated herein by reference.
  4 .21   Consent and Waiver, dated as of June 30, 2001, to the Credit Agreement dated as of April 30, 1998, as amended by Amendment No. 1 thereto dated as of August 26, 1998, among Jafra Cosmetics International Inc., Jafra Cosmetics International S.A. de C.V., CDRJ Investments (Lux) S.A., the several banks and financial institutions party to the Credit Agreement, the Issuing Bank and Credit Suisse First Boston, as Administrative Agent, previously filed as Exhibit 4.21 to the Company’s Annual Report of Form 10-K for the fiscal year ended 2001, filed on April 1, 2002, and incorporated herein by reference.
  10 .1   Indemnification Agreement, dated April 30, 1998, among CDRJ Investments (Lux) S.A., CDRJ Acquisition Corporation, Jafra Cosmetics International, S.A. de C.V., Clayton, Dubilier & Rice, Inc., Clayton, Dubilier & Rice Fund V Limited Partnership; previously filed as Exhibit 10.1 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed September 4, 1998, and incorporated herein by reference.
  10 .2   Consulting Agreement, dated April 30, 1998, by and among CDRJ Investments (Lux) S.A., Jafra Cosmetics International, Inc. and Jafra Cosmetics, S.A. de C.V., and Clayton, Dubilier & Rice, Inc.; previously filed as Exhibit 10.2 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed September 4, 1998, and incorporated herein by reference.
  10 .3   Form of Employment Agreement for Messrs. Clark, Rubio, Mason, Guirao and DiGregorio; previously filed as Exhibit 10.3 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed September 4, 1998, and incorporated herein by reference.
  10 .4   Amended and Restated Jafra Cosmetics International, Inc. Stock Incentive Plan, as adopted September 3, 1998; previously filed as Exhibit 10.4 to Amendment No. 1 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed October 27, 1998, and incorporated herein by reference.
  10 .5   CDRJ Investments (Lux) S.A. Form of Management Stock Option Agreement; previously filed as Exhibit 10.5 to Amendment No. 1 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed October 27, 1998, and incorporated herein by reference.
  10 .6   Amended and Restated Stock Purchase Warrant, dated September 30, 1998, by and between CDRJ Investments (Lux) S.A. and Jafra Cosmetics International, Inc.; previously filed as Exhibit 10.6 to Amendment No. 1 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed October 27, 1998, and incorporated herein by reference.

122


Table of Contents

         
Exhibit
Number Description of Document


  10 .7   Registration and Participation Agreement, dated April 30, 1998, among CDRJ Investments (Lux) S.A. and Clayton, Dubilier & Rice Fund V Limited Partnership and the other parties thereto; previously filed as Exhibit 10.7 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed September 4, 1998, and incorporated herein by reference.
  10 .8   CDRJ Investments (Lux) S.A. Form of Management Stock Subscription Agreement; previously filed as Exhibit 10.8 to Amendment No. 1 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed October 27, 1998, and incorporated herein by reference.
  10 .9   CDRJ Investments (Lux) S.A. Form of Individual Investor Stock Subscription Agreement; previously filed as Exhibit 10.9 to Amendment No. 1 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed October 27, 1998, and incorporated herein by reference.
  10 .10   Jafra Cosmetics International, Inc. Supplemental Savings Plan, dated October 27, 1998; previously filed as Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the first quarter ended March 31, 1999, filed May 17, 1999, and incorporated herein by reference.
  10 .11   Jafra Cosmetics International, Inc. Special Supplemental Savings Plan for Non-United States-Source Income, dated January 20, 1999; previously filed as Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q for the first quarter ended March 31, 1999, filed May 17, 1999, and incorporated herein by reference.
  10 .12   Asset Purchase Agreement, dated as of June 10, 1999, as amended by Amendment No. 1, dated as of June 10, 1999; by and between the Company and the Contractor, previously filed as Exhibit 10.1 to Form 8-K, filed on June 10, 1999, and incorporated herein by reference (portions of which were filed under a confidentiality request).
  10 .13   Amendment No. 1 to Asset Purchase Agreement, dated as of June 10, 1999; previously filed as Exhibit 10.2 to Form 8-K, filed on June 10, 1999, and incorporated herein by reference (portions of which were filed under a confidentiality request).
  10 .14   Manufacturing Agreement, dated as of June 10, 1999, by and between the Company and the Contractor, as amended by Amendment No. 1, dated as of June 22, 1999; previously filed as Exhibit 10.3 to Form 8-K, filed on June 10, 1999, and incorporated herein by reference (portions of which were filed under a confidentiality request).
  10 .15   Form of Amendment No. 1 to Manufacturing Agreement, dated as of June 10, 1999; previously filed as Exhibit 10.4 to Form 8-K, filed on June 10, 1999 and incorporated herein by reference (portions of which were filed under a confidentiality request).
  10 .16   Form of Secured Note for the Assets, dated June 10, 1999, made by the Contractor in favor of the Company; previously filed as Exhibit 10.5 to Form 8-K, filed on June 10, 1999 and incorporated herein by reference (portions of which were filed under a confidentiality request).
  10 .17   Form of Secured Note for the Inventory, dated June 10, 1999, made by the Contractor in favor of the Company; previously filed as Exhibit 10.6 to Form 8-K, filed on June 10, 1999 and incorporated herein by reference (portions of which were filed under a confidentiality request).
  10 .18   Trust Agreement dated May 20, 1999 by and between Jafra Cosmetics International, Inc. and Scudder Trust Company; previously filed as Exhibit 10.20 to the Company’s Annual Report on Form 10-K for the fiscal year ended 1999, filed on March 30, 2000, and incorporated herein by reference.
  10 .19   Amendment No. 1 to Consulting Agreement, dated as of March 15, 2000, by and among CDRJ Investments (Lux) S.A., Jafra Cosmetics International, Inc., Jafra Cosmetics International, S.A. de C.V., and Clayton, Dubilier & Rice, Inc.; previously filed as Exhibit 10.21 to the Company’s Annual Report on Form 10-K for the fiscal year ended 1999, filed on March 30, 2000, and incorporated herein by reference.

123


Table of Contents

         
Exhibit
Number Description of Document


  10 .20   First Amendment to Amended and Restated Jafra Cosmetics International, Inc. Stock Incentive Plan; previously filed as exhibit 10.22 to the Company’s Annual Report on Form 10-K for the fiscal year ended 2000, filed on April 2, 2001, and incorporated herein by reference.
  10 .21   CDRJ Investments (Lux) S.A. Form of Management Stock Subscription Agreement, as amended; previously filed as exhibit 3.10 to the Company’s Annual Report on Form 10-K for the fiscal year ended 2000, filed on April 2, 2001, and incorporated herein by reference.
  10 .22   Amended and Restated Consulting Agreement, dated as of January 1, 2001, by and among CDRJ Investments (Lux) S.A., Jafra Cosmetics International, Inc., Jafra Cosmetics International, S.A. de C.V., and Clayton, Dubilier & Rice, Inc; previously filed as Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the first quarter ended March 31, 2001, filed May 15, 2001, and incorporated herein by reference.
  21 .1   Subsidiaries of the registrant.

  (b)  Reports on Form 8-K

      On November 13, 2002, the Company filed a Current Report on form 8-K, dated November 13, 2002, with the Securities and Exchange Commission regarding fair disclosure, which information was reported under Item 7, “Financial Statements and Exhibits” and Item 9, “Regulation FD Disclosure”.

124


Table of Contents

SIGNATURES

      Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

  CDRJ Investments (Lux) S.A.

  By:  /s/ RONALD B. CLARK
 
  Name: Ronald B. Clark
  Title:  Chief Executive Officer of the Advisory
  Committee and Director

Date March 18, 2003

      Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of Registrant and in the capacities and on the dates indicated.

         
Signature Title Date



/s/ RONALD B. CLARK

Ronald B. Clark
  Chief Executive Officer of the
Advisory Committee and Director
(Principal executive officer)
  March 18, 2003
 
/s/ MICHAEL A. DIGREGORIO

Michael A. DiGregorio
  Senior Vice President and Chief Financial
Officer of the Advisory Committee
(Principal financial officer, Principal
accounting officer)
  March 18, 2003
 
/s/ RALPH S. MASON, III

Ralph S. Mason, III
  Secretary and Executive Vice President
of the Advisory Committee
(Representative in the U.S.)
  March 18, 2003
 
/s/ DONALD J. GOGEL

Donald J. Gogel
  Director   March 18, 2003
 
/s/ STEVEN D. GOLDSTEIN

Steven D. Goldstein
  Director   March 18, 2003
 
/s/ THOMAS E. IRELAND

Thomas E. Ireland
  Director   March 18, 2003
 
/s/ SIRI MARSHALL

Siri Marshall
  Director   March 18, 2003
 
/s/ DAVID A. NOVAK

David A. Novak
  Director   March 18, 2003
 
/s/ ANN REESE

Ann Reese
  Director   March 18, 2003
 
/s/ EDWARD H. RENSI

Edward H. Rensi
  Director   March 18, 2003
 
/s/ GONZALO RUBIO

Gonzalo Rubio
  Director   March 18, 2003
 
/s/ KENNETH D. TAYLOR

Kenneth D. Taylor
  Director   March 18, 2003

125


Table of Contents

CERTIFICATIONS

I, Ronald B. Clark, certify that:

      1.     I have reviewed this annual report on Form 10-K of CDRJ Investments (Lux) S.A.;

      2.     Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report;

      3.     Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report:

      4.     The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and have:

        a) designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared;
 
        b) evaluated the effectiveness of the registrant’s disclosure controls and procedures as of a date within 90 days prior to the filing date of this annual report (the “Evaluation Date”); and
 
        c) presented in this annual report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;

      5.     The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

        a) all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant’s ability to record, process, summarize and report financial data and have identified for the registrant’s auditors any material weaknesses in internal controls; and
 
        b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls; and

      6.     The registrant’s other certifying officers and I have indicated in this annual report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

  /s/ RONALD B. CLARK

  Ronald B. Clark
  Chief Executive Officer of the Advisory Committee and Director

Date March 18, 2003

126


Table of Contents

I, Michael A. DiGregorio, certify that:

      1.     I have reviewed this annual report on Form 10-k of CDRJ Investments (Lux) S.A.;

      2.     Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report;

      3.     Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report:

      4.     The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and have:

        a) designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared;
 
        b) evaluated the effectiveness of the registrant’s disclosure controls and procedures as of a date within 90 days prior to the filing date of this annual report (the “Evaluation Date”); and
 
        c) presented in this annual report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;

      5.     The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

        a) all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant’s ability to record, process, summarize and report financial data and have identified for the registrant’s auditors any material weaknesses in internal controls; and
 
        b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls; and

      6.     The registrant’s other certifying officers and I have indicated in this annual report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

  /s/ MICHAEL A. DIGREGORIO
_______________________________________
Michael A. DiGregorio
  Senior Vice President and Chief Financial Officer of the Advisory Committee (Principal Financial Officer)

Date March 18, 2003

127


Table of Contents

      Supplemental Information to be Furnished with Reports Filed Pursuant to Section 15(d) of the Act by Registrants Which Have Not Registered Securities Pursuant to Section 12 of the Act.

      No annual report or proxy material has been sent to security holders.

128


Table of Contents

EXHIBIT INDEX

         
Exhibit
Number Description of Document


  3.1     Articles of Association (Statuts Coordonnes) of CDRJ Investments (Lux) S.A., as restated on September 30, 1998; previously filed as Exhibit 3.1 to Amendment 2 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed December 23, 1998, and incorporated herein by reference.
  3.2     Certificate of Incorporation of CDRJ Acquisition Corporation, dated March 31, 1998; previously filed as Exhibit 3.2 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed September 4, 1998, and incorporated herein by reference.
  3.3     Certificate of Merger of Jafra Cosmetics International, Inc. into CDRJ Acquisition Corporation, dated April 30, 1998; previously filed as Exhibit 3.3 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed September 4, 1998, and incorporated herein by reference.
  3.4     Amended and Restated By-laws of Jafra Cosmetics International, Inc. (formerly CDRJ Acquisition Corporation), as adopted on July 21, 1998; previously filed as Exhibit 3.4 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed September 4, 1998, and incorporated herein by reference.
  3.5     Deed of Incorporation (acta constitutiva), including all amendments thereto, and current by-laws (estatutos sociales) of Jafra Cosmetics International, S.A. de C.V., together with a unofficial summary thereof in English; previously filed as Exhibit 3.5 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed September 4, 1998, and incorporated herein by reference.
  3.6     Deed of Incorporation (acta constitutiva), including all amendments thereto, and current by-laws (estatutos sociales) of Dirsamex, S.A. de C.V., together with a unofficial summary thereof in English; previously filed as Exhibit 3.7 to Amendment No. 1 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed October 27, 1998, and incorporated herein by reference.
  3.7     Deed of Incorporation (acta constitutiva), including all amendments thereto, and current by-laws (estatutos sociales) of Jafra Cosmetics S.A. de C.V., formerly known as Jafra Cosmetics S. de R.L. de C.V., together with a unofficial summary thereof in English; previously filed as Exhibit 3.9 to Amendment No. 1 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed October 27, 1998, and incorporated herein by reference.
  3.8     Deed of Incorporation (acta constitutiva), including all amendments thereto, and current by-laws (estatutos sociales) of Qualifax, S.A. de C.V., together with a unofficial summary thereof in English; previously filed as Exhibit 3.10 to Amendment No. 1 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed October 27, 1998, and incorporated herein by reference.
  3.9     Deed of Incorporation (acta constitutiva), including all amendments thereto, and current by-laws (estatutos sociales) of Reday, S.A. de C.V., together with a unofficial summary thereof in English; previously filed as Exhibit 3.11 to Amendment No. 1 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed October 27, 1998, and incorporated herein by reference.
  3.10     Deed of Incorporation (acta constitutiva), including all amendments thereto, and current by-laws (estatutos sociales) of Cosmeticos Y Fragrancias, S.A. de C.V., together with an unofficial summary thereof in English; previously filed as exhibit 3.10 to the Company’s Annual Report on Form 10-K for the fiscal year ended 2000, filed on April 2, 2001, and incorporated herein by reference.

129


Table of Contents

         
Exhibit
Number Description of Document


  3.11     Notarial Deed and Resolutions, together with an unofficial summary thereof in English, for the transformation of Jafra Cosmetics S. de R.L. de C.V. into Jafra Cosmetics S.A. de C.V.; previously filed as Exhibit 3.12 to the Company’s Annual Report on Form 10-K for the fiscal year ended 1999, filed on March 30, 2000, and incorporated herein by reference.
  3.12     Approval, dated as of April 17, 2000, by the Public Registry of Commerce of the United Mexican States of the merger of Consultoria Jafra S.A. de C.V. and Distribuidora Venus, S.A. de C.V. with and into Reday, S.A. de C.V., together with supporting shareholders’ resolutions and the unofficial English translation thereof; previously filed as Exhibit 3.1 to the Company’s Quarterly Report on Form 10-Q for the second quarter ended June 30, 2000, filed on August 14, 2000, and incorporated herein by reference.
  3.13     Notarial Deed and Resolutions, together with an unofficial summary thereof in English, for the changing of the corporate name from Reday, S.A. de C.V. to Distribuidora Venus, S.A. de C.V. as a consequence of the merger of Distribuidora Venus, S.A. de C.V. into Reday, S.A. de C.V.; previously filed as Exhibit 3.11 to the Company’s Annual Report on Form 10-K for the fiscal year ended 2000, filed on April 2, 2001, and incorporated herein by reference.
  3.14     Notarial Deed and Resolutions, together with an unofficial summary thereof in English, for the renaming of Qualifax, S.A. de C.V. as Serviday S.A. de C.V.; previously filed as Exhibit 3.1 to the Company’s Quarterly Report on Form 10-Q for the second quarter ended June, 30, 2001, filed on August 14, 2001, and incorporated herein by reference.
  4.1     Indenture, dated April 30, 1998, among CDRJ Acquisition Corporation, Jafra Cosmetics International, S.A. de C.V., CDRJ Investments (Lux) S.A., and State Street Bank and Trust Company; previously filed as Exhibit 4.1 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed September 4, 1998, and incorporated herein by reference.
  4.2     First Supplemental Indenture, dated April 30, 1998, among Consultoria Jafra, S.A. de C.V., Distribuidora Venus, S.A. de C.V., Dirsamex, S.A. de C.V., Reday, S.A. de C.V., Qualifax S.A. de C.V., and Jafra Cosmetics S.R.L., CDRJ Acquisition Corporation and Jafra Cosmetics International, S.A. de C.V. and State Street Bank and Trust Company; previously filed as Exhibit 4.2 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed September 4, 1998, and incorporated herein by reference.
  4.3     Purchase Agreement, dated April 28, 1998, between Credit Suisse First Boston Corporation, Chase Securities Inc., CDRJ Acquisition Corporation, Jafra Cosmetics International, S.A. de C.V., and CDRJ Investments (Lux) S.A.; previously filed as Exhibit 4.3 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed September 4, 1998, and incorporated herein by reference.
  4.4     Purchase Agreement Amendment, dated April 30, 1998, executed on behalf of each of Reday, S.A. de C.V., Distribuidora Venus, S.A. de C.V., Dirsamex, S.A. de C.V., Qualifax, S.A. de C.V., Jafra Cosmetics, S.R.L., Consultoria Jafra, S.A. de C.V., Credit Suisse First Boston Corporation, and Chase Securities Inc.; previously filed as Exhibit 4.4 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed September 4, 1998, and incorporated herein by reference.
  4.5     Registration Rights Agreement, dated April 30, 1998, among CDRJ Acquisition Corporation, Jafra Cosmetics International, Inc., Jafra Cosmetics International, S.A. de C.V., CDRJ Investments (Lux) S.A., Reday, S.A. de C.V., Distribuidora, S.A. de C.V., Dirsamex, S.A. de C.V., Qualifax, S.A. de C.V., Jafra Cosmetics, S.A. de C.V., Consultoria Jafra, S.A. de C.V., and Credit Suisse First Boston Corporation; previously filed as Exhibit 4.5 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed September 4, 1998, and incorporated herein by reference.

130


Table of Contents

         
Exhibit
Number Description of Document


  4.6     Credit Agreement, dated April 30, 1998, among CDRJ Acquisition Corporation, Jafra Cosmetics International, S.A. de C.V., CDRJ Investments (Lux) S.A., as Guarantor and Parent of the Borrowers, the Lenders named therein and Credit Suisse First Boston, as Administrative Agent; previously filed as Exhibit 4.6 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed September 4, 1998, and incorporated herein by reference.
  4.7     Amendment No. 1 to the Credit Agreement, dated August 26, 1998; previously filed as Exhibit 4.7 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed September 4, 1998, and incorporated herein by reference.
  4.8     Indemnity, Subrogation and Contribution Agreement, dated April 30, 1998, among Jafra Cosmetics International, S.A. de C.V. (“JCISA”), each Subsidiary of JCSI listed on Schedule I thereto and Credit Suisse First Boston; previously filed as Exhibit 4.8 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed September 4, 1998, and incorporated herein by reference.
  4.9     JCI Guarantee Agreement, dated April 30, 1998, between CDRJ Acquisition Corporation and Credit Suisse First Boston; previously filed as Exhibit 4.9 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed September 4, 1998, and incorporated herein by reference.
  4.10     JCISA Guarantee Agreement, dated April 30, 1998, between Jafra Cosmetics International, S.A. de C.V. and Credit Suisse First Boston; previously filed as Exhibit 4.10 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed September 4, 1998, and incorporated herein by reference.
  4.11     JCISA Subsidiary Guarantee Agreement, dated April 30, 1998, among each of the subsidiaries of Jafra Cosmetics International, S.A. de C.V. listed on Schedule I thereto, and Credit Suisse First Boston; previously filed as Exhibit 4.11 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed September 4, 1998, and incorporated herein by reference.
  4.12     Parent Guarantee Agreement, dated April 30, 1998, between CDRJ Investments (Lux) S.A. and Credit Suisse First Boston; previously filed as Exhibit 4.12 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed September 4, 1998, and incorporated herein by reference.
  4.13     Pledge Agreement, dated April 30, 1998 among CDRJ Investments (Lux) S.A., CDRJ North Atlantic Sarl, CDRJ Latin America Holding Company B.V., Latin Cosmetics Holdings B.V., Regional Cosmetics Holding B.V., Southern Cosmetics Holdings B.V., and CDRJ Mexico Holding Company B.V., CDRJ Acquisition Corporation, Jafra Cosmetics International, S.A. de C.V. and Credit Suisse First Boston; previously filed as Exhibit 4.13 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed September 4, 1998, and incorporated herein by reference.
  4.14     Security Agreement, dated April 30, 1998, among CDRJ Acquisition Corporation (“JCI”), each subsidiary of JCI listed on Schedule I thereto and Credit Suisse First Boston; previously filed as Exhibit 4.14 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed September 4, 1998, and incorporated herein by reference.
  4.15     Deed of Trust, with Assignment of Leases and Rents, Fixture Filing and Security Agreement, dated April 30, 1998, by Jafra Cosmetics International, Inc. to TitleServ Agency of New York City, Inc., as trustee for the Benefit of Credit Suisse First Boston; previously filed as Exhibit 4.15 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed September 4, 1998, and incorporated herein by reference.

131


Table of Contents

         
Exhibit
Number Description of Document


  4.16     Acknowledgment of Obligations and Mortgage, dated April 30, 1998, granted by Reday, S.A. de C.V. in favor of Credit Suisse First Boston, together with an unofficial English translation thereof; previously filed as Exhibit 4.16 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed September 4, 1998, and incorporated herein by reference.
  4.17     Notarial Deed of Pledge, dated April 30, 1998, with respect to the pledge to Credit Suisse First Boston of (i) 24 ordinary shares of the capital stock of CDRJ Europe Holding Company B.V. by Jafra Cosmetics International, Inc., and (ii) 40 ordinary shares of the capital stock of CDRJ Latin America Holding B.V. by CDRJ North Atlantic (Lux) Sarl; previously filed as Exhibit 4.17 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed September 4, 1998, and incorporated herein by reference.
  4.18     Consent and Waiver, dated as of November 19, 1999, to the Credit Agreement dated as of April 30, 1998, as amended by Amendment No. 1 thereto dated as of August 26, 1998, among Jafra Cosmetics International Inc., Jafra Cosmetics International S.A. de C.V., CDRJ Investments (Lux) S.A., the several banks and financial institutions party to the Credit Agreement, the Issuing Bank and Credit Suisse First Boston, as Administrative Agent; previously filed as Exhibit 4.18 to the Company’s Annual Report on Form 10-K for the fiscal year ended 1999, filed on March 30, 2000, and incorporated herein by reference.
  4.19     Substitution of Trustee and Partial Reconveyance of Deed of Trust, Assignment of Leases and Rents, Fixture Filing and Security Agreement, and Release of Financing Statement, dated November 29, 1999, which amends the Deed of Trust filed as Exhibit 4.15 above; previously filed as Exhibit 4.19 to the Company’s Annual Report on Form 10-K for the fiscal year ended 1999, filed on March 30, 2000, and incorporated herein by reference.
  4.20     Partial Reconveyance of Deed of Trust, Assignment of Leases and Rents, Fixture Filing and Security Agreement and Release of Financing Statement, dated November 29, 1999, which amends the Deed of Trust filed as Exhibit 4.15 above; previously filed as Exhibit 4.20 to the Company’s Annual Report on Form 10-K for the fiscal year ended 1999, filed on March 30, 2000, and incorporated herein by reference.
  4.21     Consent and Waiver, dated as of June 30, 2001, to the Credit Agreement dated as of April 30, 1998, as amended by Amendment No. 1 thereto dated as of August 26, 1998, among Jafra Cosmetics International Inc., Jafra Cosmetics International S.A. de C.V., CDRJ Investments (Lux) S.A., the several banks and financial institutions party to the Credit Agreement, the Issuing Bank and Credit Suisse First Boston, as Administrative Agent, previously filed as Exhibit 4.21 to the Company’s Annual Report of Form 10-K for the fiscal year ended 2001, filed on April 1, 2002, and incorporated herein by reference.
  10.1     Indemnification Agreement, dated April 30, 1998, among CDRJ Investments (Lux) S.A., CDRJ Acquisition Corporation, Jafra Cosmetics International, S.A. de C.V., Clayton, Dubilier & Rice, Inc., Clayton, Dubilier & Rice Fund V Limited Partnership; previously filed as Exhibit 10.1 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed September 4, 1998, and incorporated herein by reference.
  10.2     Consulting Agreement, dated April 30, 1998, by and among CDRJ Investments (Lux) S.A., Jafra Cosmetics International, Inc. and Jafra Cosmetics, S.A. de C.V., and Clayton, Dubilier & Rice, Inc.; previously filed as Exhibit 10.2 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed September 4, 1998, and incorporated herein by reference.
  10.3     Form of Employment Agreement for Messrs. Clark, Rubio, Mason, Guirao and DiGregorio; previously filed as Exhibit 10.3 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed September 4, 1998, and incorporated herein by reference.

132


Table of Contents

         
Exhibit
Number Description of Document


  10.4     Amended and Restated Jafra Cosmetics International, Inc. Stock Incentive Plan, as adopted September 3, 1998; previously filed as Exhibit 10.4 to Amendment No. 1 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed October 27, 1998, and incorporated herein by reference.
  10.5     CDRJ Investments (Lux) S.A. Form of Management Stock Option Agreement; previously filed as Exhibit 10.5 to Amendment No. 1 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed October 27, 1998, and incorporated herein by reference.
  10.6     Amended and Restated Stock Purchase Warrant, dated September 30, 1998, by and between CDRJ Investments (Lux) S.A. and Jafra Cosmetics International, Inc.; previously filed as Exhibit 10.6 to Amendment No. 1 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed October 27, 1998, and incorporated herein by reference.
  10.7     Registration and Participation Agreement, dated April 30, 1998, among CDRJ Investments (Lux) S.A. and Clayton, Dubilier & Rice Fund V Limited Partnership and the other parties thereto; previously filed as Exhibit 10.7 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed September 4, 1998, and incorporated herein by reference.
  10.8     CDRJ Investments (Lux) S.A. Form of Management Stock Subscription Agreement; previously filed as Exhibit 10.8 to Amendment No. 1 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed October 27, 1998, and incorporated herein by reference.
  10.9     CDRJ Investments (Lux) S.A. Form of Individual Investor Stock Subscription Agreement; previously filed as Exhibit 10.9 to Amendment No. 1 to Registration Statement No. 333-62989 under the Securities Act of 1933, as amended, filed October 27, 1998, and incorporated herein by reference.
  10.10     Jafra Cosmetics International, Inc. Supplemental Savings Plan, dated October 27, 1998; previously filed as Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the first quarter ended March 31, 1999, filed May 17, 1999, and incorporated herein by reference.
  10.11     Jafra Cosmetics International, Inc. Special Supplemental Savings Plan for Non-United States-Source Income, dated January 20, 1999; previously filed as Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q for the first quarter ended March 31, 1999, filed May 17, 1999, and incorporated herein by reference.
  10.12     Asset Purchase Agreement, dated as of June 10, 1999, as amended by Amendment No. 1, dated as of June 10, 1999; by and between the Company and the Contractor, previously filed as Exhibit 10.1 to Form 8-K, filed on June 10, 1999, and incorporated herein by reference (portions of which were filed under a confidentiality request).
  10.13     Amendment No. 1 to Asset Purchase Agreement, dated as of June 10, 1999; previously filed as Exhibit 10.2 to Form 8-K, filed on June 10, 1999, and incorporated herein by reference (portions of which were filed under a confidentiality request).
  10.14     Manufacturing Agreement, dated as of June 10, 1999, by and between the Company and the Contractor, as amended by Amendment No. 1, dated as of June 22, 1999; previously filed as Exhibit 10.3 to Form 8-K, filed on June 10, 1999, and incorporated herein by reference (portions of which were filed under a confidentiality request).
  10.15     Form of Amendment No. 1 to Manufacturing Agreement, dated as of June 10, 1999; previously filed as Exhibit 10.4 to Form 8-K, filed on June 10, 1999 and incorporated herein by reference (portions of which were filed under a confidentiality request).

133


Table of Contents

         
Exhibit
Number Description of Document


  10.16     Form of Secured Note for the Assets, dated June 10, 1999, made by the Contractor in favor of the Company; previously filed as Exhibit 10.5 to Form 8-K, filed on June 10, 1999 and incorporated herein by reference (portions of which were filed under a confidentiality request).
  10.17     Form of Secured Note for the Inventory, dated June 10, 1999, made by the Contractor in favor of the Company; previously filed as Exhibit 10.6 to Form 8-K, filed on June 10, 1999 and incorporated herein by reference (portions of which were filed under a confidentiality request).
  10.18     Trust Agreement dated May 20, 1999 by and between Jafra Cosmetics International, Inc. and Scudder Trust Company; previously filed as Exhibit 10.20 to the Company’s Annual Report on Form 10-K for the fiscal year ended 1999, filed on March 30, 2000, and incorporated herein by reference.
  10.19     Amendment No. 1 to Consulting Agreement, dated as of March 15, 2000, by and among CDRJ Investments (Lux) S.A., Jafra Cosmetics International, Inc., Jafra Cosmetics International, S.A. de C.V., and Clayton, Dubilier & Rice, Inc.; previously filed as Exhibit 10.21 to the Company’s Annual Report on Form 10-K for the fiscal year ended 1999, filed on March 30, 2000, and incorporated herein by reference.
  10.20     First Amendment to Amended and Restated Jafra Cosmetics International, Inc. Stock Incentive Plan; previously filed as exhibit 10.22 to the Company’s Annual Report on Form 10-K for the fiscal year ended 2000, filed on April 2, 2001, and incorporated herein by reference.
  10.21     CDRJ Investments (Lux) S.A. Form of Management Stock Subscription Agreement, as amended; previously filed as exhibit 3.10 to the Company’s Annual Report on Form 10-K for the fiscal year ended 2000, filed on April 2, 2001, and incorporated herein by reference.
  10.22     Amended and Restated Consulting Agreement, dated as of January 1, 2001, by and among CDRJ Investments (Lux) S.A., Jafra Cosmetics International, Inc., Jafra Cosmetics International, S.A. de C.V., and Clayton, Dubilier & Rice, Inc; previously filed as Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the first quarter ended March 31, 2001, filed May 15, 2001, and incorporated herein by reference.
  21.1     Subsidiaries of the registrant.

134